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IC50 50% Inhibitory Concentration 




iNOS Inducible Nitric Oxide Synthase 
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LBP LPS-Binding Protein 
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LFA(s) Lymphocyte Function-Associated Antigen(s) 
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MTX Methotrexate 
M.W. Molecular Weight 
NK Natural Killer 
nm Nanometer 
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RNase Ribonuclease 
rmIL-3 Murine Recombinant IL-3 
rmIL-2 Murine Recombinant IL-2 
RNI Reactive Nitrogen Intermediates 
R〇I Reactive Oxygen Intermediates 
rpm Revolutions Per Minute 
RPMI1640 Roswell Park Memorial Institute Tissue 
Culture Medium 1640 
r.t. Room Temperature 
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S.I. Stimulation Index 
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Bacterial capsular polysaccharide antigens are a diverse range of biologically 
important molecules with high molecular weights and contain repeating 
oligosaccharide units. These characteristic features of capsular polysaccharide 
antigen make them immunogenic in nature. However, research in the past had 
concentrated on studying the vaccine potential of capsular polysaccharide antigens 
against bacterial infections, and the immunomodulatory and anti-tumour activities 
of capsular polysaccharide antigens are far from being understood. Since large 
quantity of highly purified capsular polysaccharides can be obtained from Klebsiella 
pneumoniae serotype 7 by relatively simple extraction and purification method, 
Klebsiella pneumoniae serotype 7 capsular antigen (K7 antigen) becomes an 
appropriate candidate on which its therapeutic advantages can be studied. 
Therefore, in this thesis project, attempts have been made to study the 
immunomodulatory and anti-tumour activities of K7 antigen. 
In the present study, K7 antigen was firstly extracted from Klebsiella 
pneumoniae serotype 7 and purified by Cetavlon precipitation. The purified capsular 
antigen was characterized to contain mainly carbohydrate with a high uronic acid 
content, and trace amounts of protein and nucleic acid. In addition, K7 antigen was 
demonstrated to be non-toxic in nature by the brine shrimp assay and exhibited 
little, if any, cytotoxicity to murine splenocytes. 
Our results show that K7 antigen alone was capable of stimulating the 
proliferation and differentiation of murine bone marrow cells. On the other hand, it 
significantly suppressed the proliferation and colony forming ability of rmIL-3-
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stimulated bone marrow cells, In addition to its hematopoietic activity, K7 antigen 
was found to exhibit potent mitogenic activity in vitro and in vivo. Moreover, the in 
Vitro mitogenic activity of K7 antigen was further found to be T cell- and 
macrophage- independent and K7 antigen mainly acted on B lymphocytes. 
K7 antigen also exhibited a stimulatory effect on the murine peritoneal 
macrophages, the non-specific effector cells of the immune system. In vitro study 
demonstrated that K7 antigen not only augmented the nitric oxide (NO) and tumour 
necrosis factor (TNF) production and cytostatic activity of thioglycollate (TG)-
elicited macrophages, but also significantly enhanced the phagocytic activity of 
resident macrophages. Moreover, K7 antigen not only enhanced the functional 
activities of macrophages but could also induce the in vivo migration of 
macrophages. Using RT-PCR technique, K7 antigen was shown to enhance the 
expression of inducible nitric oxide synthase (iNOS) gene and certain pro-
inflammatory cytokine genes, including tumour necrosis factor-a (TNF-a), 
interleukin-la (IL-la), interleukin-lp (IL-ip), interleukin-6 (IL-6) and transforming 
growth factor-p (TGF-P). 
Finally, K7 antigen was found to exhibit potent anti-proliferative activity on 
certain tumour cell lines in vitro such as the murine myeloid leukemia Ml and 
WEHI-3B JCS cells. Although K7 antigen exerted no inhibitory effect on the growth 
of EAT cells in vitro, it exhibited a significant anti-tumour activity against EAT cells 
in vivo. The present findings also show that K7 antigen enhanced the NK cell and 
LAK cell activity of splenocytes in vivo. Interestingly enough, K7 antigen not only 
suppressed the proliferation of WEHI-3B JCS leukemia cells, but could also induce 
the differentiation of the cells into mature cells with the characteristics of 
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macrophages, including expression of macrophage differentiation antigens (Mac-1 & 
F4/80 antigens), and exhibition of non-specific esterase and phagocytic activities. 
Taken together, the results indicate that K7 antigen may exert its anti-tumour 
activity, at least in part, via host-mediated mechanisms. 
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Neoplasia is a process by which the normal controlling mechanisms that 
regulate cell growth and differentiation are impaired, resulting in progressive, 
uncontrolled growth of abnormal cells. Cancer cells or malignant tumour cells refer 
to the neoplastic cells with a specific capacity to invade surrounding tissues and 
eventually disseminate from the primary tumour site through the circulatory system 
to other locations in the body. 
Cancers may arise in any tissue. Carcinogenesis is a result of malignant 
transformation of a normal cell. It is generally accepted that malignant 
transformation is a multi-step process. It involves multiple, cumulative alterations of 
the cell's DNA leading to genetic damage. Carcinogens, such as chemical 
carcinogens, ionizing radiation and oncogenic viruses, are the agents capable of 
initiating carcinogenesis (Alberts et al., 1994). Recently, the role of oncogenes and 
tumour suppressor genes in tumour initiation are the focus of many investigations. 
Oncogenes are genes within the cell that may initiate the cell's transformation from 
normal to malignancy. Interestingly, examples of positively acting oncogenes are 
quite rare in human tumours. So-called tumour suppressor genes probably play a 
more important role. Well known tumour suppressor genes include the P53 gene 
and the retinoblastoma gene. These genes are involved in controlling the cell-cycle. It 
is believed that the gene product of P53 (p53) acts by preventing cells with DNA 
damage from dividing or causing them to die by apoptosis and therefore, suppresses 
potential tumours. However, if a mutation occurs in the P53 gene, then its function 
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may be impaired and cells with genetic damage may replicate. As a result, malignant 
transformation may occur (Levine et al., 1991). 
Cancer cells sometimes grow large enough at the primary site to interfere 
with function at the involved organ or to compress nearby organs and structures. 
Cancers cause morbidity through local growth, the spreading of cancer cells from 
primary tumour site to distant organs (i.e. metastasis), and their systemic effects. 
Approximately one in five people in Western societies will die from cancer. In the 
United States, it is estimated that cancers affect three out of four families. Since 
cancers cause substantial mortality and morbidity, scientists are still trying to put 
much of their effort to look for new anti-cancer treatments which are effective, safe 
for the patients, and especially those with fewer side effects. 
In this early century, the concept of immune surveillance was originally 
articulated by Paul Ehrlich and was later expanded by Macfarlane Burnet and Lewis 
Thomas in the 1950s and 1960s (Burnet, 1970). This concept states that our immune 
system could recognize and destroy neoplastic clones of cells, arising as a result of 
spontaneous mutation or the action of carcinogens, before they grow into tumours.、 
Although there is still no direct evidence that immune surveillance actually protects 
individuals from tumours, certain observations support the validity of the concept. 
For example, immunodeficient individuals are more likely to develop certain types 
of tumours than normal individuals. Moreover, the ability of our immune system 
specially to prevent the growth of malignant tumours are clearly demonstrated in 
many animal models. In such models, the host is able to resist a tumour challenge 
following previous exposure to the same tumour or its cell membrane extracts. 
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For the malignant cells and tumours to stimulate an immune response, they 
must express tumour antigens that are recognized as foreign by the tumour-bearing 
host. Two types of tumour antigens may be found on tumour cell surface: (1) 
tumour-specific antigens (TSA), which are unique to particular tumours; and (2) 
tumour-associated antigens (TAA), such as oncofetal and histocompatibility (class I 
and II) antigens, which can be found on both tumour and non-malignant cells. 
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1.2 E F F E C T O R C E L L S MEDIATING ANTI -TUMOUR 
IMMUNITY 
Cytotoxic effector cells should meet two basic requirements: (1) they are 
capable of producing effector molecules that mediate cytotoxicity, and (2) they 
should express receptors capable of triggering activation or releasing of effector 
molecules following ligand binding. Different host mechanisms for meeting these 
requirements have evolved, resulting in a diverse collection of cytotoxic cells with 
numerous mechanisms capable of reacting against a wide variety of foreign cells and 
organisms. 
Major sources of cytotoxic effector cells are cytotoxic T lymphocytes (CTLs), 
natural killer (NK) cells, macrophages (M(t>), lymphokine-activated killer (LAK) cells, 
and tumour-infiltrating lymphocytes (TILs). The cell-mediated immune responses to 
tumour antigens have been demonstrated in vivo, and many immunologic effector 
mechanisms mediated by different effector cells have been shown to kill tumour 
cells in vitro. The most important killer cells towards tumours are cytotoxic T 
lymphocytes. Other effector cells suth as NK cells, TILs, LAK cells, as well as 
activated M(|) are also effective in the lysis of certain tumour targets. Although the 
above effector cells are involved in immune surveillance mechanisms, tumour cells 
often do escape from being destroyed. The failure of immune surveillance may be 
due to the antigenic heterogeneity of the original tumour, the shedding of tumour 
antigens, and host-mediated immunosuppression. The aims of tumour immunology 
research therefore include the elucidation of the mechanism(s) of tumour cell 
destruction by cytotoxic effector cells, its regulation, and the development of 
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methods for increasing cellular immunity to tumours suitable for clinical application 
(Hillmanet al.f 1992). 
1.2.1 Cytotoxic T Lymphocytes (CTLs) 
Cytotoxic T lymphocytes (CTLs) are a subpopulation of T cells with 
immunological specificity for antigens expressed by virus-infected cells, tumour cells 
or even parasites (Kupfer and Singer, 1989). All CTLs express the T cell receptor 
(TCR)/CD3 complex, with most CTLs using TCRaP for antigen recognition. The 
class of major histocompatibility complex (MHC) molecule with which the target-cell 
antigen is associated, correlates with whether the CTL is CD4+ or CD8+: CD8+ CTLs 
primarily recognize MHC class I associated antigens, and CD4
+
 CTLs recognize 
primarily MHC class II associated antigens. The cytolytic activity of CTLs is 
normally initiated by their binding to target cells and forming cell conjugates. The 
process involves a cooperative effort of ligand binding by TCRs and adhesion 
molecules expressed on the surface of T cells, as neither alone is usually sufficient for 
conjugate formation with naturally derived cells. The adhesion molecules, such as 
lymphocyte function-associated antigens (LFAs), various intercellular adhesion 
molecules (ICAMs), including CD2, CD28, CD43, CD4, and CD8, act as receptors for 
ligands that are naturally expressed on the surface of target cells (Shimizu and Shaw, 
1990 & Martz, 1993). Thus, cytolysis initiated by TCR recognition of target cells is 
normally target cell specific, both in vitro and in vivo. 
The two major pathways for CTL-mediated cytolysis are (1) granule 
exocytosis and (2) Fas-induced apoptosis, both of which result in the lysis of target 
cells with DNA fragmentation (Berke, 1997). Granule exocytosis is a mechanism that 
is associated with cytolytic substances isolated from cytoplasmic granules in 
activated CTLs. CTLs secrete the contents of cytoplasmic granules into the area of 
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contact between GTLs and target cells. Cytoplasmic granules contain a series of 
serine proteases, known as granzymes, and also a pore-forming protein called 
cytolysin (perforin). The cytolysin (perforin) causes a channel or ring-like hole to be 
introduced into the target cell membrane. In the presence of granzymes, the 
likelihood of target cell lysis and triggering apoptosis is enhanced. In this case, the 
CTLs are not damaged as a result of attacking target cells; they detach from lysed 
cells and recycle to attack again. Fas-induced apoptosis is another mechanism 
associated with the target cell-surface molecule (Fas) which is a member of the 
family of receptors for tumour necrosis factor (TNF) and nerve growth factor (Suda 
et al., 1993). Cross-linking of this receptor can trigger apoptotic cell death of target 
cells with lysis in a fashion that is independent of Ca
2+
 and does not involve pore 
formation in the tiarget cell membrane (Rouvier et al., 1993). 
1.2.2 Natural Killer (NK) Cells 
Natural killer (NK) cells are predominantly large granular lymphocytes 
lacking both CD3 antigen and T cell receptor chain (a, (3, y, or 8) expression. They 
commonly express certain cell surface markers in humans (CD16 & CD56) and in 
mice (NK-1.1 / NK-1.2). However, the precise lineage of NK cells is unknown. They 
mediate cytolytic reactions that do not require expression of class I or class II MHC 
molecules on the target cells (Fitzgerald-Bocarsly et al., 1989). 
Natural cytotoxicity, mediated by NK cells, is important in the immune 
surveillance against cancer. In animal studies, animals with low levels of NK cell 
activity, such as beige, cyclophosphamide, or anti-asialo GM1 serum-treated mice, 
have been shown to develop an increasing number of spontaneous and experimental 
tumour metastases (Talmadge et al, 1980 & Gorelick et al, 1982). Despite convincing 
evidence from animal studies, the role of NK cells in the immunologic surveillance 
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against cancer in humans is poorly defined. Circumstantial evidence for the 
importance of natural cytotoxicity in humans is provided by studying NK deficiency 
states of patients. Patients who have Chediak-Higashi syndrome (Roder et al" 1980), 
X-linked lymphoproliferative syndrome (Sullivan et al., 1980), or who have had renal 
transplants (Gui et al., 1983) and are pharmacologically immunosuppressed, all have 
reduced NK cell activity and increased incidence of cancer. 
NK cells can lyse, in vitro, allogeneic tumour cell lines and virus-infected 
cells, without prior sensitization. In general, untreated NK cells are unable to lyse 
freshly isolated autologous tumour cells (Trincheri, 1989). NK cell-mediated lysis can 
be considered to occur in four stages: (1) target cell binding (adhesion); (2) effector 
cell activation (recognition / signal transduction); (3) delivery of the lethal signal to 
the target cell (i.e. lethal hit); and (4) effector cell detachment and recycling (Ortaldo 
and Hiserodt, 1989). Recent studies suggest that recognition of susceptible targets 
and activation of NK cells appear to be mediated by a NK cell receptor (NKR-P1) 
that binds to a lectin-like molecule (Yokoyama, 1995). Granule exocytosis, cytolysin 
(perforin) and granzymes also have well-established roles in cytotoxicity mediated 
by NK cells. Granule exocytosis results in target cell lysis with apoptosis, and NK 
cell detaches from the target cell. Because of the expression of the well-characterized 
receptors (FcyRIII or CD16), NK cells can kill the target cells via antibody-dependent 
cellular cytotoxicity (ADCC). Besides, NK cells are able to mediate lysis by the 
release of soluble factors, which are mainly cytokines (Pertussia, 1991). 
NK cell activity can be affected by various cytokines. Interleukin-12 (IL-12), 
originally termed NK cell stimulating factor, is itself a potent inducer of cytokine 
production by NK cells (Chehimi et al, 1993). Interleukin-2 (IL-2) (Rabinowich et al,, 
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1993) and Interferon-a (IFN-a) (Trincheri, 1989) are also potent enhancers of NK cell 
activity. 
1.2.3 Lymphokine-Activated Killer (LAK) Cells 
Lymphokine-activated killer (LAK) cells refer to the killer cells with potent 
cytotoxicity in vitro and in vivo after short-term culture of lymphoid cells with IL-2. 
Initially, LAK cells were separated from peripheral blood lymphocytes, but 
subsequent studies have shown that they can also be isolated from thymus, spleen, 
lymph node, bone marrow and from thoracic duct cells (Vujanovic et al., 1988). The 
precursors of murine LAK cells can be divided into two major subsets: NK-like 
(CD8一, NK1.1+, asialo GM1+) and T cell-like (CD8+, NK1.1。asialo GM1+). LAK cells 
have generally been characterized as being either CD8
+
 or NK1.1+ (Ballas and 
Rasmussen, 1990). 
LAK cells can kill a wide panel of autologous, allogeneic and xenogeneic 
tumour cells both in vivo and in vitro (Grimm and Rosenberg, 1984). Unlike NK cells, 
the LAK cells can also lyse fresh non-cultured tumour cells of different origins. 
Several established tumour cell lines, such as DAUDI cells, which are usually NK-
resistant, are highly susceptible to LAK cell-mediated killing. In addition, normal 
cultured cells such as fibroblasts and mitogen-activated lymphoblasts are also the 
targets of LAK cells. However, fresh normal tissue cells are resistant to LAK lysis. 
Clinical in vivo studies using LAK cells administered together with IL-2 for 
adoptive immunotherapy of advanced cancer patients had revealed a number of 
complete or partial responses, mainly in patients with melanoma and renal 
carcinoma. Unfortunately, this course of treatment was again not free of unpleasant 
side effects, and in a few cases, the side-effects were fatal (Rosenberg, 1990). Since 
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then, a number of groups have reported varying levels of success with slight 
modifications of the dose and duration of the IL-2 infusion regimen (Sznol and Urba, 
1993). However, the reasons for most solid tumours being relatively unresponsive 
have yet to be elucidated, and toxicity remains to be a problem and is the limiting 
factor. 
Interestingly, a recent study has shown that IL-2-induced LAK activity of 
human peripheral blood lymphocytes can be significantly increased by 1 hr in vitro 
incubation with low dose of granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Baxevanis et al.,1995). Pilot studies are currently underway to assess the 
potential benefits of GM-CSF-pulsed cells with LAK activity. 
1.2.4 Macrophages 
Macrophages constitute a cell lineage which is derived from the 
hematopoietic stem cells and play an important role in non-specific defense 
mechanisms of the immune system (Seljelid and Eskeland, 1993). Activation of 
macrophages to the tumouricidal state is a multistep pathway in which the 
responsive macrophages sequentially become primed and triggered by a variety of 
stimuli (Uhing and Adams, 1989). IFN-y, Poly I:C ,and the microbial agents 
lipopolysaccharides (LPS), Corynebacterium -parvum, and Listeria monocytogenes are all 
putative macrophage-activating agents for tumouricidal effector function (Seljelid 
and Eskeland, 1993). Moreover, macrophages can be activated to tumouricidal state 
through contact with tumour cells (Fauve, 1993). Activated macrophages can 
mediate the destruction of tumour cells or inhibition of their growth by a variety of 
mechanisms (Duerksen-Hughes and Gooding, 1993). These include antigen non-
specific cytotoxicity, killing by anti-tumour antibodies via ADCC, inhibition of DNA 
synthesis (Keller, 1976) or mitochondrial respiration (Granger et al., 1980), release of 
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iron (Hibbs et al, 1984) and neutral protease (Fidler and Ichinose, 1989), inhibition of 
tricarboxylic acid cycle enzyme aconitase (Drapier and Hibbs, 1986), and the 
production of reactive oxygen intermediates (ROT) such as superoxide (O2一）and 
hydrogen peroxide (H2O2) (Adams and Hamilton, 1984), reactive nitrogen 
intermediates (RNI) such as nitric oxide (NO) (Keller and Keist, 1989), and cytostatic 
and cytolytic cytokines such as interleukin-1 (IL-1) and TNF-a (Fidler and Ichinose, 
1989). 
Activated macrophages mediated tumour cytotoxicity differs in several 
aspects from that triggered by other cytotoxic cells as follows (Adams and Somers, 
1985): (1) Only malignant, but not non-malignant cells are recognized and destroyed 
by activated macrophages; (2) Macrophage killing proceeds slowly and it requires 
usually hours or even days for complete manifestation of cytolysis; (3) In the initial 
phase a transient intimate contact, but no firm persistent binding is essential for the 
mediation of target cell lysis; (4) Activated macrophages do not contain pore forming 
proteins and do not primarily destroy the target cell membranes. 
Macrophages can be deactivated by several factors, including members of 
transforming growth factors (3 family and interleukin-10 (IL-10) (Bogdan and 
Nathan, 1993). 
As discussed previously, activated macrophages often display potent 
cytostatic and cytotoxic activity towards tumour cells, therefore, efforts are presently 
directed towards exploiting the anti-tumour potential of activated macrophages in 
cancer therapy. Recently, adoptive transfer of activated macrophages locally to 
patients with tumours in the peritoneal cavity has been attempted (Andreesen, 
1993). 
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1.2.5 Tumour-Infiltrating Lymphocytes (TILs) 
Tumour-infiltrating lymphocytes (TILs) are the mononuclear cells, mostly 
macrophages and lymphocytes, derived from the inflammatory infiltrate in solid 
tumours, which can be grown in vitro under the influence of IL-2 (Whiteside et al., 
1992). The great majority of TILs are CD3+ T lymphocytes. NK cells and B 
lymphocytes are usually very few in the context of neoplastic tissues. Freshly 
isolated TILs usually have a very low, or no NK activity. In addition, TILs showed 
specificity against the autologous tumour but not the allogeneic tumour cell lines 
(Shimizu et al" 1991). Moreover, the culture of TILs in IL-2 will result in proliferation 
and increased cytotoxicity of cells against the autologous tumour (Whiteside et al., 
1992). 
Evidence demonstrating the in vivo anti-tumour effects of adoptively 
transferred murine TILs have been accumulated (Cohen et al" 1996). Results from 
these experiments have shown that TILs expanded in vitro are 50 to 100 times more 
efficacious than LAK cells in reducing the metastatic burden. In models of advanced 
pulmonary or hepatic macrometastatic disease, TILs are capable of prolonging the 
survival of tumour-bearing hosts, sometimes resulting in long-term cures (survival > 
100 days). In comparison with TILs, LAK cells are ineffective against such advanced 
disease. 
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1 .3 C U R R E N T MODALITIES F O R C A N C E R T R E A T M E N T 
Most current cancer treatments aim to combat uncontrollable growth, tissue 
invasion and metastasis. Traditionally, three approaches are used in cancer 
treatment, including surgery, radiotherapy and chemotherapy. Nowadays, 
biological therapies have joined the three traditional approaches of cancer therapy, 
and represent a fourth approach to cancer treatment that is based on the ability of 
immune system to mount an attack against cancer. In the rest of this section, the four 
approaches of cancer treatment will be discussed. 
1.3.1 Surgery 
Surgery is the earliest therapy established for cancer and nowadays it is still 
the most widely used approach in cancer treatment. Surgical excision of a tumour is 
both quick and effective, and it accounts for the largest number of cures. Surgery is 
also the only method of therapy that offers the opportunity for the pathologist to 
confirm that a tumour has been fully excised. 
Unfortunately, this form of treatment has several critical shortcomings. 
Firstly, removal of the tumour mass visible to the surgeon does not in itself 
guarantee elimination of the microscopic extensions that so often characterize cancer. 
Secondly, in most cases, a large amount of healthy tissue is forced to be cut out to 
ensure that the complete invasive edge around a tumour is included and in doing so 
may severely damage the patient's organ functions or appearance. Finally, the most 
crucial limitation of surgery is that it cannot treat cancer that has metastasized 
widely throughout the body. 
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1.3.2 Radiation Therapy 
Radiation therapy is preferable to surgery in many instances. With this 
method, powerful X-rays or gamma (y) rays irradiate the region of the patient's 
tumour. Radiation treatment acts either by inflicting genetic damage sufficient to kill 
cells directly or by inducing programmed cell death (i.e. apoptosis) of cancer cells. 
The advantages of radiation therapy over surgery are that (1) it can preserve the 
anatomical structures that surround a cancerous mass and retain the patient's ability 
to function normally since healthy tissues can recover from radiation exposure more 
readily than cancerous cells; (2) it can also destroy microscopic extensions of 
cancerous tissue around a tumour that surgical excision may miss; and (3) it is a safer 
option for older, frailer patients who might have difficulty in recovering from 
surgery. Cancer of the uterine cervix and the larynx, and the early stages of both 
prostate cancer and Hodgkin's disease are well treated with radiation therapy. 
Despite these many attractive attributes, radiation therapy cannot treat widespread 
metastases. 
1.3.3 Chemotherapy 
Chemotherapy refers to the treatment of cancer achieved by the systemic 
administration of anti-cancer drugs or medications that travel throughout the body 
via the blood circulatory system. Nowadays, chemotherapeutic drugs in use can be 
divided into several families including anti-metabolites, topoisomerase inhibitors, 
alkylating agents and plant alkaloids. Chemotherapeutic drugs typically operate by-
preventing cells from multiplication by interfering with their ability to replicate 
DNA. In some cases, anti-cancer drugs appear to induce apoptosis in cancerous cells. 
Many malignancies such as leukemias, lymphomas and testicular cancer are now 
successfully treated by combination chemotherapy. 
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The available chemotherapeutic drugs often fail because they kill many 
healthy cells and thus bring serious side effects that limit the doses physicians can 
administer. The major side effects of chemotherapy include anemia, loss of ability to 
fight infection and a propensity for internal bleeding, which are resulted from the 
damage to the rapidly growing cells of the bone marrow by chemotherapeutic drugs. 
The critical limitation of chemotherapy is that some tumours are found to be able to 
survive anti-cancer drugs used to treat them. Certain tumours have proven to be 
drug resistant from the outset, whereas others develop a resistance with repeated 
treatment. The problem of drug resistance in chemotherapy is particularly serious 
because tumours can develop a resistance to multiple drugs after only one drug has 
been administered to the patient (Kartner and Ling, 1989). 
1.3.4 Biologic Therapy 
The treatment of cancer through biologic approach, which has variously been 
called biologic therapy, biotherapy, or biomodulation, refers to any therapeutic 
alteration of the host-tumour relationship that improves the ability of a tumour-
bearing host to reject the tumour (Mitchell, 1992). Because of this broad definition, 
biologic therapy can encompass a number of different approaches to therapy 
including the direct effects against the tumour, modulation of the host immune 
system, inhibition of metastases, inhibition of angiogenesis and interruption of 
autocrine/ paracrine growth factor loops (Wagstaff, 1995). Immunotherapeutic 
approach of biologic therapy is usually termed immunotherapy, in which the 
benefits from the modulation of host immune system are focused. The agents or 
approaches that used in biologic therapy are termed biological response modifiers 
(BRMs) or biomodulators. Immunotherapy is particularly appealing because it can 
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attack cancer that has metastased. With the concept of immune surveillance, 
immunotherapy can be designed to be more specific than chemotherapy. 
In the past decade, adoptive cellular therapy or adoptive immunotherapy 
became one of the hot approaches in immunotherapy to the cancer treatment, which 
can be defined as the transfer to the tumour-bearing host of immunological reagents, 
such as immune cells that have anti-tumour reactivity, and can mediate, either 
directly or indirectly, anti-tumour effects (Rosenberg, 1991). The immune cell types 
that have been used in clinical trials including LAK cells (Koretz et al., 1991 & 
Rosenberg et al" 1993) and TILs (Rosenberg et al., 1988 & Aoki et al； 1991). 
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1 .4 B IOLOGICAL R E S P O N S E M O D I F I E R S A S C A N C E R 
T H E R A P E U T I C S 
Biological Response Modifiers (BRMs) are defined as "agents or approaches 
that will modify the relationship between tumour and host by modifying the host's 
biologic response to tumour cells, with resultant therapeutic benefit" (Mihich and 
Fefer, 1983). The majority of BRMs in use nowadays are iirimunotherapeutic 
materials. Immunotherapy is still one of the major categories in biologic therapy, in 
which many researches are conducting. BRMs can act in the following ways 
(Oldham, 1991): 
(1) augment the host's defenses through the administration of cells, natural 
biologicals, or the synthetic derivatives thereof as effectors or mediators 
(direct or indirect) of an anti-tumour response; 
(2) increase the individual's anti-tumour responses through augmentation or 
restoration of effector mechanisms, or decrease a component of the host's 
reaction that is deleterious; 
(3) augment the individual's responses using modified tumour cells or vaccines 
to stimulate a greater response, or increase tumour cell sensitivity to an 
existing biological response; 
(4) decrease transformation and/or increase differentiation or maturation of 
tumour cells; 
(5) interfere with the growth-promoting factors produced by tumour cells; 
(6) decrease or arrest the tendency of tumour cells to metastasize to other sites; 
(7) increase the ability of the host to tolerate damage by cytotoxic modalities of 
cancer treatment; 
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(8) use biological molecules to target and bind to cancer cells and induce more 
effective cytostatic or cytocidal anti-tumour activity. 
BRMs can be classified into various groups, according to their nature or origins 
(Table 1.1). 
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Table 1.1: Examples of Biological Response Modifiers 
Type of BRMs Examples 




Synthetic molecules Pyran copolymer 
Malic anhydride-divinyl ether 
Poly I : C 
Pyrimidines 






Tumour necrosis factor-a (TNF-a) 
Hematopoietic growth factors 
Hormones Thymosin ai 
Thymostimulin 
Thymopoietin 
Antigens Tumour-associated, antigens 
Vaccines 
Monoclonal antibodies MAbs to growth-promoting factors 
(MAbs) Anti-T cell antibody 
Anti-T suppressor cell antibody 
Anti-tumour antibody-
Effector cells Macrophages 
NK cells 
Cytotoxic T cells 
Helper T cells 
LAK cells 
TILs 
(Modified from Oldham, 1991 & Clark, 1993) 
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1.4.1 Monoclonal Antibodies 
In monoclonal antibody therapy, monoclonal antibodies are expected to bind 
to target tumour cells, and trigger an immune attack that destroyed the target cells 
but ignored normal cells lacking the tumour antigens. In addition, the antibodies 
would be expected to make more deadly to tumours by coupling with toxic 
chemicals or toxins to tumours. The toxic chemicals coupled to the antibodies 
include chemotherapeutic drugs, such as doxorubicin, methotrexate or vinca 
alkaloid (LoBuglio and Saleh, 1992), radionuclides such as iodine 131 (Zalutsky et al., 
1989) and yttrium 99 (LoBuglio and Saleh, 1992), and toxins including the plant 
toxins, such as ricin and abrin, and bacterial toxins, such as Pseudomonas exotoxin 
and diphtheria toxin (Dillman et al., 1988), and recombinant toxins. The advantages 
of using different immunoconjugates in monoclonal antibody therapy are 
summarized in Table 1.2. 
Table 1.2 : Advantages of Different Immunoconjugates 
Type of Conjugates Advantages 
Radioisotope-MAb Large variety with widely varied 
characteristics 
Most isotopes radiate beyond a single cell 
Most isotopes will not require internalization 
Toxin-MAb Extremely potent 
Well defined chemistry 
Drug-MAb Proven "track record" in cancer therapy 
Toxicity well defined 
Maximal tolerated doses known 
New and more potent drugs may be useful as 
immunoconjugates 
(Modified from Foon, 1989) 
Research studies are currently underway using monoclonal antibodies for a 
variety of cancers including T cell lymphoma, chronic and acute lymphocytic 
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leukemia, melanoma, colorectal cancer, and neuroblastoma. In the case of clinical 
trials on metastatic melanoma, monoclonal antibodies, GD2 and GD3, directed 
towards gangliosides are utilized. These antibodies confer toxicity through eliciting 
complement mediated cell lysis. Other antibodies have used a ricin chain attached to 
the Fc portion to confer cytotoxicity. The overall response rate of trials involving 
monoclonal antibodies is less than 10%, but individual study sizes are small 
(Bridgewater and Gore, 1995). 
There are several limitations on this therapy and make it clinically not so 
effective as expected (Foon, 1989). (1) It has been difficult to define tumour-
associated antigens which are both sufficiently specific and present in sufficient 
concentrations on malignant cells to allow significant antibody binding; (2) Rapid 
modulation of cell surface antigens off the malignant cells frequently occurs, 
effectively removing the available monoclonal antibody (especially in leukemias 
and lymphomas); (3) Neutralizing antibodies generated from the body react with the 
available monoclonal antibodies before any therapeutic effect occurs; (4) Side effects 
of monoclonal antibodies include dyspnea and mild wheezing, fever, chills, 
headache, rash, nausea, vomiting, tachycardia, and allergic reactions; and (5) One 
side effect of toxin, the vascular leak syndrome, is the result of nonspecific toxicity of 
the toxin moiety to the body. 
1.4.2 Differentiating Agents 
Cancer can be viewed as a disorder resulting from an uncoupling of gene 
expression that controls cellular proliferation and differentiation (Sachs, 1986). This 
concept does not necessarily imply that the maturation block is irreversible, and 
much attention has been paid to neoplastic cell line models, which can be induced to 
terminal differentiation following exposure in vitro to a variety of chemicals or 
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chemotherapeutic agents (Bloch, 1984). The concept of differentiation therapy of 
malignant diseases is thus based on the demonstration that the phenotype of cancer 
cells can be suppressed or reversed by induction of differentiation or by restoration 
of responses to normal growth control mechanisms (Lotan et al" 1990). 
Differentiation therapy is now receiving increasing attention in the treatment 
of hematopoietic tumours, such as acute myeloid leukemia and acute promyclocytic 
leukemia (Martin, 1996). Studies have been conducted that strongly support true 
differentiation of malignant cells (Warrell et al" 1991 & Elliot et al, 1992). 
Interestingly, in the study of HL-60 cell model, which is a human acute 
promyelocytic leukemic cell line, it was found that apoptosis may be the final 
mechanism by which the leukemic clone is extinguished (Martin et al" 1990). Many 
quite different compounds have been shown to induce differentiation of various 
leukemia cells, both in vitro and in vivo (Table 1.3). 
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Table 1.3: Some Common Inducers of Tumour Cell Differentiation 
Types of compound Inducers 











Tumour necrosis factor (TNF) 
Hormones Glucocorticoids 
Dexamethasone 
Vitamins Retinoic acid 
1,25-dihydroxyvitamin D3 
Polar-planar compounds Dimethyl sulfoxide 
Hexamethylene blsacetamide 
Immunopotent ia tors Mycobacterium bovis BCG 
Lipopolysaccharides 















cis-diammiriedichloroplantinum II “ 
Triterpenes 
Chloroqtiine 
(Hozumi, 1983; Gabrilove, 1986; Lotan et al, 1990; Komiyama and Funayama, 1992; & 
MichaeliefaZ., 1993) 
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1.4.3 Cytokines 
Cytokines are low molecular weight (10-50 kDa) proteins or glycoproteins 
released by cells of immune system. They are produced locally by a variety of 
diverse cell types and act in an autocrine or paracrine manner (Balkwill and Burke, 
1989). Cytokines produced by lymphocytes are called lymphokines; those produced 
by mononuclear phagocytes are called monokines. They bind with extreme 
specificity and great affinity to receptors on target cells and regulate their 
proliferation, differentiation and functional activation (Hill et al., 1992). However, 
different cytokines display considerable overlap in their biological activities. The 
development of recombinant DNA technology has enabled the production of large 
quantities of recombinant cytokines for use in the treatment of cancer (Guillou, 
1987). 
The cytokines that have been shown to have therapeutic potential in the 
treatment of cancer including the interleukins, the interferons, tumour necrosis 
factor and the colony-stimulating factors (De Vita et al., 1995). 
Interferons 
The interferons (IFNs) are a family of glycoproteins that are produced in 
response to viral infections, double-stranded RNA, endotoxin (lipopolysaccharide) 
and a variety of mitogenic and antigenic stimuli. There are three types of interferon : 
(1) Interferon-alpha (IFN-a), (2) Interferon-beta (IFN-P), (3) Interferon-gamma (IFN-
Y). IFN-a, which is produced by leucocytes, and IFN-p, which is produced by 
fibroblasts, are very similar, but IFN-y is structurally distinct. IFN-a and IFN-P not 
only are similar in their structure, but they also share the same receptors on the 
target cells (Hill et al" 1992). 
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Among the cytokines, IFNs were the first used for cancer treatment. IFN-a 
has been most widely used in last several years in the treatment of cancer. IFNs have 
been shown to have several possible therapeutic effects in cancer: (1) They slow 
down cell replication by inhibiting protein synthesis and DNA production in cancer 




-oligoadenylate synthetase (Revel et al, 
1980), and by prolonging the cell cycle. The most noticeable effect is on the G1 and 
GO phase, often characterized by the arrest of cells at GO phase (Creasey et al., 1980). 
In other words, IFNs are tumouristatic, as opposed to tumonricidal; (2) They may 
also stimulate a host response to the tumour by enhancing NK activity and may 
modulate the cytotoxicity of T cells, macrophages and neutrophils. (3) IFNs also 
initiate the secretion of several other cytokines, such as tumour necrosis factor, a 
major mediator of macrophage cytotoxicity. (4) They can enhance the presentation of 
molecules on the surface of tumour cells, leading to their recognition by the immune 
system (Weir and Stewart, 1993). 
IFN-a has currently been used in the treatment of hairy-cell leukemia, 
chronic myelogenous leukemia, multiple myeloma, certain non-Hodgkin's 
lymphomas, AIDS-associated Kaposi's sarcoma, renal cell carcinoma, and malignant 
melanoma. IFN-a has had its greatest impact in the treatment of certain 
hematological malignancies (Bezwoda et al" 1987). Overall, approximately 90% of 
the patients will benefit symptomatically from IFN-a therapy (Foon et al； 1986). In 
the case of solid tumour, the combination of IFN-a with IL-2 had resulted in an 
encouraging effect on renal cell carcinoma and malignant melanoma. Increasing the 
dose of both IFN-a and IL-2 induced a higher response rate, with maximum rates of 
38 and 43% for renal cell carcinoma and malignant melanoma respectively 
(Rosenberg et al, 1989). 
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Tumour Necrosis Factor 
Tumour necrosis factor (TNF) is a pro-inflammatory cytokine that derives its 
name from its ability to induce necrosis in experimental animal tumours (Balkwill, 
1989). It is identical to 'cachectin' and was initially isolated during studies aimed at 
defining the underlying mechanisms of cancer cachexia (Carswell et al., 1975). There 
are two forms of TNF, one of which (TNF-a or cachectin) is a cytotoxic factor with a 
molecular weight of 17 kDa and is released by macrophages following their 
activation by bacterial endotoxin (lipopolysaccharide) (Carswell et al" 1975). TNF-P 
(also known as lymphotoxin'), another form of TNF, has a molecular weight of 18 
kDa and is released from stimulated lymphocytes (Devlin et al., 1984). TNF-a was 
found to play a role in tumour necrosis and cell mediated killing of bacteria, 
parasites, and neoplastic cells, and TNF-P was also demonstrated to have the 
capacity to lyse tumour cells (Beutler and Cerami, 1988). 
Two forms of TNF have been produced by the recombinant DNA technology. 
The recombinant TNFs appear to have anti-proliferative, cytostatic arid cytolytic 
effects against human tumour cells either in vitro (Ruggiero et al" 1987) or when 
injected into nude mice (Chun and Hoffman, 1987). 
It has been estimated that approximately 40% of tumour cell lines are growth 
inhibited or lysed by TNF in vitro (Goeddel et al., 1986). Studies have shown that 
TNF can induce either apoptotic or necrotic forms of cell death in different tumour 
cell lines (Laster et al., 1988). This indicates that TNF has different modes of action or 
that the effect of TNF is related to the biological characteristics of different cell 
populations (Malik and Balkwill., 1992). The cytotoxic effect of TNF to tumour cells 
may be related to (1) the involvement of arachidonic acid metabolism (Suffys et al., 
1987); (2) the involvement of free radical generation (Yamauchi et al., 1989); (3) the 
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activation of lysosomal enzymes, endonucleases, proteases (Baglioni et al, 1987) and 
ADP ribosylation (Aggarwal et al., 1988). 
Preliminary reports on the clinical administration of recombinant TNF-a did 
not indicate significant therapeutic effects (Aulitzky et al., 1991) and considerable 
toxicity such as thrombosis, hypotension and shock had been described (Schiller et 
al., 1991). Any future use of TNF-a will be limited to low-dose schedules involving 
the co-administration of other cytokines, such as IL-2. Currently, the gene encoding 
TNF is also being inserted into tumour cells in the hope that it will exert potent 
activity locally. 
Interleukins 
Interleukin-1 (IL-1) was originally described in the 1940s as 'endogenous 
pyrogen' because of its ability to produce fever when injected into experimental 
animals (Dinarello, 1996). Two polypeptide forms are now recognized: IL-la and IL-
1(3. IL-la, which is synthesized predominantly by mononuclear phagocytes, but can 
also be derived from a variety of other cells (Dinarello, 1996), is thought to be 
involved in antigen presentation (Stephan et al., 1987). IL-lp is the predominant form 
and is readily secreted from macrophages. Although they have only limited amino 
acid sequence identity, both IL-la and IL-ip recognize the same receptor and share 
the same biological properties. 
The effects of IL-1 are diverse and it is involved in immunomodulation, 
inflammation, wound healing, hematopoiesis, metabolism and the endocrine system 
(Dinarello, 1996). IL-1 also has a number of properties useful in fighting tumours, 
including direct anti-proliferative activity against certain human tumour cell lines 
and several murine tumours (Onozaki et al., 1985 & Nakamura et al., 1986); it can 
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activate effector cells in vitro (Herman et al" 1985; Yamashita and Shirakawa, 1987 & 
Crump et al, 1989); it can inhibit tumour angiogenesis (Curti and Smith, 1995); and 
it can induce secondary cytokines that may have direct anti-proliferative or 
immunostimulatory activities (Philip and Epstein, 1986 & Dinarello, 1996). Studies 
have shown that a number of murine tumours regress in vivo in response to IL-1 
(North et al" 1988). Phase I trials of both IL-la and IL-1 (3 in patients with advanced 
cancer had been carried out. However, several side effects, including hypotension, 
fever, chills, myalgia and vomiting, were observed (Curti and Smith, 1995). Phase II 
trials of IL-1 in cancer therapy are currently in progress (Curti and Smith, 1995). 
IL-2 was first characterized by Morgan et al. (1976), who reported the 
discovery of a protein, produced by normal peripheral blood lymphocytes, that 
induced proliferation of stimulated T lymphocytes. It is the pivotal molecule in the 
maintenance of an intact immune system and stimulates both T and B cell immunity. 
IL-2 is also a vital cofactor in the development of cytotoxic T lymphocyte activity 
against tumours (Hill et al., 1992). In addition to its T cell growth-promoting effects, 
IL-2 participates in tumouricidal activity through stimulating the growth of NK cells 
(Henney et al" 1981) and LAK cells (Grimm et al., 1983). IL-2 also augments B cell 
growth and immunoglobulin production (Doi et al., 1989), and enhances IFN-y 
production (Ortaldo et aL, 1984). 
A number of studies using recombinant IL-2 in experimental animals and 
humans have shown that it has some activity against a variety of cancers 
(Rosenberg, 1988). In addition, clinical trials have shown that a more potent anti-
tumour response can be obtained by using IL-2 in combination with LAK cells 
(Rosenberg et al., 1987). Recently, clinical trials have demonstrated that the use of 
tumour-infiltrating lymphocytes and IL-2 together can mediate substantial tumour 
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regression in some patients with advanced malignant melanoma (Rosenberg et al, 
1988). 
The most significant anti-tumour responses associated with IL-2 therapy 
have been identified in the treatment of malignant melanoma (Parkinson et al., 1990) 
and renal cell carcinoma (Robertson et al, 1990). Other tumours, including gliomas, 
bladder, ovarian, lung, breast, lymphoma and colon, have also been treated with IL-
2(HinetflZ., 1992). 
IL-2 therapy is associated with significant side-effects, including pronounced 
fluid retention, anemia, thrombocytopenia and hypotension (Rosenberg et al" 1987), 
which have limited its significant clinical use. The usage of IL-2 will expand with the 
further development of adoptive immunotherapy using LAK cells and TILs as well 
as in combination with other cytokines. 
Colony Stimulating Factors 
The colony-stimulating factors are a group of glycoproteins with ability to 
control the proliferation and differentiation of granulocytes, mononuclear 
phagocytes and certain related hematopoietic cells. They include IL-3 (multi-colony-
stimulating factor), macrophage colony-stimulating factor (M-CSF), granulocyte 
colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). 
Today, the main use of CSFs in cancer treatment has been to rescue the bone 
marrow from the toxic effects of chemotherapy. They have therefore been used in a 
supportive role rather than as primary treatment. However, the anti-tumour effect of 
GM-CSF should not be ignored. GM-CSF, which is secreted by activated T cells, 
endothelial cells, fibroblasts and macrophages, can provide effective proliferative 
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stimulus in human marrow cultures to granulocyte, macrophage and eosinophil 
colonies. It is also capable of stimulating the antibody-dependent cytolysis of tumour 
cells by mature human neutrophils and eosinophils (Metcalf et al., 1986). Another 
important pathway in anti-tumour defence may be provided by GM-CSF as it 
induces macrophage tumouricidal activity (Grabstein et al., 1986). Similarly, GM-CSF 
appears to have anti-immunosuppressive activity on macrophages (Bilyk and Holt, 
1993). In addition, in vivo administration of GM-CSF decreases tumour growth in a 
murine Lewis lung carcinoma model (Hill et al" 1993). In 1991, both G-CSF and GM-
CSF were approved by the Food and Drug Administration to be used clinically, and 
a direct action on lymphoma cells has been suggested by a recent clinical trial 
(GerhartzefflZ., 1993). 
1.4.4 Bioactive Plant Polysaccharides 
As far as the class of low molecular weight compounds is concerned, at 
present no structure-activity relationships can be recognized in terms of their anti-
tumour and immunomodulatory activities. Therefore, there has been an increasing 
interest in the development of useful immunostimxilatory drugs in the class of high 
molecular weight compounds, especially polysaccharides of a particular structural 
type (Wagner and Poksch, 1985). Since traditional cancer treatments, especially 
radiotherapy and /or chemotherapy, often have many undesirable side effects in 
which the normal immune system of patients is severely compromised, the isolation 
and characterization of potent immunomodulatory and anti-tumour polysaccharides 
from plant sources may help to restore the compromised immune system of patients 
or may open the way for more effective treatment of cancer. In the past, extensive 
studies had been made on non-cytotoxic and host-mediated anti-tumour 
polysaccharides extracted from different botanical sources (i.e. higher plants, algae 
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and fungi) (Franz, 1989; Lien, 1990 & Lien and Gao, 1990). The use of 
polysaccharides in the treatment of cancer have the advantages that (1) they are 
readily soluble in water and thus easily administered; (2) none of the 
polysaccharides have been found to be mutagenic or carcinogenic to animals; (3) 
they are readily biodegradable (Wagner and Poksch, 1985). Polysaccharides may 
therefore be promising agents for future immunomodulatory and anti-tumour 
medications. 
It has been reported that polysaccharides isolated from lower plants, such as 
yeast, lichen and algae, exhibit potent anti-tumour activities. The composition, 
structure and molecular weight of anti-tumour polysaccharides isolated from yeast, 
lichen and fungi are summarized in Table 1.4. Zymosan, isolated from the yeast cell 
wall, roughly contains equal amount of (3-(l->3)-D-glucan and a-mannan, was 
reported to be active against solid tumours such as Sarcoma 37 and Sarcoma 180 in 
mice (Whistler et aL, 1976), whereas ascitic tumours were not responsive. Moreover, 
both D-mannan and D-glucan isolated from the yeast Saccharomyces cerevisiae were 
found to be capable of inhibiting the growth of mouse tumours transplanted 
subcutaneously into allogeneic mice (Suzuki et al., 1969). Pustulan, lichenan, and 
isolichenan are the glucans isolated from lichens with potent anti-tumour effect 
against implanted Sarcoma 180 in mice (Whistler et al, 1976). Interestingly, Itoh et al 
(1993) have reported that fucoidan, a sulfate polysaccharide isolated from a marine 
algae (Sargassum thunbergii) and typified by the presence of L-fucose, markedly 
suppressed the growth of Ehrlich ascites Tumour (EAT) with no sign of toxicity in 
mice and its anti-tumour effect was suggested to be due to the stimulation of the 
immune system by fucoidan. In addition, Itoh et al (1995) further reported that this 
fucoidan could significantly inhibit the lung metastases induced by Lewis lung 
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carcinoma in mice. Similarly, Ren et al (1995) demonstrated that funoran, a sulfated 
polysaccharide, isolated from a red algae (Gloiopeltis fenax), possessed potent anti-
tumour activities against both solid and ascites tumours and the anti-tumour effect 
of funoran was due to the augmentation of T-helper, T-cytotoxic, and NK cells. 
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Table 1.4: The Composition, Structure and Molecular Weight of Anti-Tumour 
Polysaccharides Isolated from Lichen, Yeast and Fungi. 
Polysaccharides Source Type Linkages M.W. 
Lichen Pustulan Gyrophera Glucan (l-»6)-(3-D 100,000 - 500,000 
esculenta 
Lichenan Cetraria Glucan (1—3)- 100,000 - 500,000 
islandica (l-^4)-P-D 
IsoUchenan Cetraria Glucan (1—3)-, 100,000 - 500,000 
islandica (l->4)-a-D 
Yeast Zymosan Saccharomyces Glucan (l-»3)-P-D 50,000 -120,000 
cerevisiae 
Marmozyme Saccharomyces Marrnan (l->3)-P-D; 5,000 - 20,000 
cerevisiae (l-^3)-,(1^4)-P-D 50,000-65,000 
Mannan Candida Mannan N.D. N . D , 
albicans 
Glucomannan Candida Mannan N.D. N.D. 
albicans & Glucan 
Fungi Lentinan Lentinus Glucan (l->3)-P-D 〜500,000 -1,000,000 
edodes 
SchizophyHan Schizophyllum Glucan (l->3)-, 〜400,000 
commune 
Pachymaran Poria cocos Glucan (1->3)~P-D 180,000 
Scleroglucan Sclerotium Glucan (l->3)-, N.D. 
glucanicum (l->6)-(3-D 
SSG Sclerotinia 、 G l u c a n (l->3)-p-D >5,000,000 
sclerotiorum 
Krestin Coriolus Glucan (1—4)-, 50,000 -100,000 
(PSK) versicolor (l-^6)-P-D 
OL-2 Omphalia Glucan (l->3)-p-D N.D. 
lapidescens 
SPR-901 Rice bran Glucan (l->6)-a-D 〜10,000,000 
(RON) 
* N.D. = Not determined. 
(Whistler et al； 1976; Wagner and Proksch, 1985; Kado et al, 1991; Ohno et al, 1992 & Sakurai 
et al, 1992a) 
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The fungi are remarkable for the variety of polysaccharide structures that 
they produce. Interestingly, most anti-tumour polysaccharides from fungi are P-
glucans composed of P-(l->3) or p-(l->4)-glucosidic linkages (Morrison, 1988). 
Crude polysaccharides composed mainly of p-D-(l->3)-linked D-glucose have been 
isolated from mycelia of Grifola frondosa (grifolan NMF-5N), from culture filtrates of 
Sclerotinia sclerotiorum (SSG) and Schizophyllum commune (Schizophyllan) and from 
the fruit bodies of Lentinus edodes (Lentinan). Such polysaccharides have shown 
activity against solid tumours (Suga et al” 1984; Sugawara et al., 1984; Suzuki et al, 
1987 & Suzuki et al" 1988). Clinically, two kinds of (l->3)-p-D-glucans, lentinan and 
schizophyllan, have been applied as BRMs in Japan for several years (Chihara et al., 
1987 & Lien, 1990). Recently, a glucan composed of (3-(1->3), (l->4) glucosidic 
linkages has been isolated from the fruit bodies of Ganoderma applanatum (Gao and 
Yang, 1991). It has shown to have anti-tumour effect against implanted sarcoma 180 
in mice with no signs of toxicity (Gao and Yang, 1991). 
In higher plants, polysaccharides from different parts of the same plant may 
differ from one another in monosaccharide compositions and structural aspects. 
Most polysaccharides from higher plants are heteroglycans which are composed of 
many kinds of monosaccharides. There are many possibilities for inter-
monosaccharide linkages, even when they are composed of only one kind of 
monosaccharide, they can have different secondary and tertiary structures (Lien and 
Gao, 1990). Most higher plant polysaccharides contain galactose, arabinose and 
glucose. Some are acidic and most belong to plant mucilages (Morrison, 1988). Most 
higher plant polysaccharides have complex structures characterized by many branch 
chains at tached to ma in chains. Polysaccharides isolated f r om different higher plants 
have been shown to possess anti-tumour activities against different types of tumours 
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(Lien and Gao, 1990). For example, polysaccharides isolated from Rumex acetosa, 
Kureha (?S-K)f Grifola umbellata (GU-P), Broncasma berna (BB), and pine cone were 
found to exhibit anti-tumour effect against implanted Sarcoma 180 in ICR mice. In 
addition, polysaccharide isolated from Actinidia chinensis can suppress the growth of 
EAT cells in vivo (Lien and Gao, 1990). Recently, Lycium barbarum polysaccharides 
(LP) isolated from Lycium barbarum have been used in the treatment of 79 advanced 
cancer patients in combination with LAK/IL-2 therapy in a clinical trial in China 
(Cao et al, 1994). The initial results of the treatment from 75 evaluable patients 
indicated that objective regression of cancer was achieved in patients with malignant 
melanoma, renal cell carcinoma, colorectal carcinoma, lung cancer, nasopharyngeal 
carcinoma, and malignant hydrothorax. The response rate of patients treated with 
LAK/IL-2 plus LP was 40.9% while that of patients with LAK/IL-2 was only 16.1% 
(Cao et al., 1994). Therefore, this study opens the way for the utilization of bioactive 
polysaccharides as BRMs in the biotherapy of cancer. 
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f 1.5 BACTERIAL POLYSACCHARIDES AS POTENTIAL 
IMMUNOMODULATORS AND ANTI-TUMOUR AGENTS 
1.5.1 General Properties of Bacterial Polysaccharides 
Bacterial polysaccharides make up a group of polymers in which the unusual 
sugars are often components of these polymers (Kenne and Lindberg, 1983). In 
addition, the structural variation of these polymers is almost unlimited because the 
monosaccharides within the polymers may join in a number of configurations as a 
consequence of the multiple hydroxy! groups within each monosaccharide unit that 
may be involved in the formation of a glycosidic bond. As a result, bacterial 
polysaccharides are an incredibly diverse range of molecules that may differ not 
only by monosaccharide units but also in how these units are joined together. 
Moreover, the induction of branches into the polysaccharide chain yield an 
additional structural complexity of bacterial polysaccharides (Isaac, 1985). 
The majority of bacterial polysaccharides show high immunological 
specificity and are produced by only one type, one species, or one group of bacteria. 
These polysaccharides are generally composed of oligosaccharide repeating units. 
The repeating units are consistently small, a decasaccharide being the largest 
definitely established (Aman et al., 1982). Generally, only the "chemical" repeating 
unit has been determined, and the biological repeating unit may be any cyclic 
permutation of that structure. Other bacterial polysaccharides that do not show this 
specificity but may be elaborated by bacteria belonging to different groups or 
families. They often have a less regular structure, and only average structures can be 
obtained for these polymers, many of which are homoglycans (Kenne and Lindberg, 
1983). 
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1.5.2 Structure and Function of Bacterial Polysaccharides 
Bacteria can produce four major types of carbohydrate polymer: (1) 
exopolysaccharide (EPS), (2) teichoic acid, (3) peptidoglycan ( P G ) , ⑷ 
lipopolysaccharide (LPS). EPS are defined as any polysaccharide polymer that is 
found outside the wall of the Gram-positive or outside the outer membrane of the 
Gram-negative bacteria (Poxton and Blackwell, 1986). One group of EPS, known as 
the capsular polysaccharides, are linked to the cell surface of the bacterium via 
covalent attachment to either phospholipid or lipid-A molecules (Whitfield and 
Valvano, 1993), forming a capsule, whereas others appear to be released onto the cell 
surface with no visible means of attachment and are often sloughed off to form slime 
(Roberts, 1996). EPS are very hydrated polymers with 99% of their wet weight 
comprised of water (Sutherland, 1982). Generally, EPS are, but not always acidic. 
The acidic component is most often an uronic acid, a pyruvic acid acetal, or a 
phosphoric diester grouping (Kenne and Lindberg, 1983). A great diversity of 
structural difference is present in EPS. Even within the same species, the 
monosaccharide contents and the way of these monosaccharides joined are also 
different from serotype to serotype. Thus, EPS always show considerable 
heterogeneity, from the simple a,l-4 linked, unbranched glucose polymers (i.e. 
homopolysaccharide) called dextrans, to the highly complex, branched, and 
substituted heteropolysaccharides made up of oligosaccharide repeating subunits 
(i.e. heteropolysaccharides) such as xanthan and colanic acid (Sutherland, 1982 & 
Christensen et al； 1985). Bacterial cellulose and levans are examples of extracellular 
homopolysaccharides whereas capsular polysaccharides of Gram-negative bacteria 
such as Escherichia coli, Klebsiella pneumoniae, and Haemophilus influenzae, and 
extracellular polysaccharides from Streptococcus pneumoniae, some species of 
Pseudomonas and Azotobacter are examples of extracellular heteropolysaccharides 
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(Sutherland, 1982). Furthermore, EPS can also be substituted, normally ester or N-
linked, with pyruvate, acetate, formate, sulfate, phosphate and other side groups 
(Jann and Westphal, 1975) ‘ The functions of EPS are (a) as a physical protective 
barrier; (b) as a response to environmental stress; (c) in cell/ cell recognition and 
interaction; and (d) in biofilm formation/ adhesion (Weiner et al" 1995). 
Teichoic acids (also teichuronic acids and other secondary cell wall polymers 
of Gram-positive bacteria) are defined as the carbohydrates that are covalently 
linked to the peptidoglycan of the Gram-positive cell wall. The teichoic acids are 
complex structures of polyglycerol or polyribitol phosphate with glycosyl or alanyl 
residues attached variably at some of the polyol hydroxyl groups. They may also 
exist as copolymers of glycosyl units with glycerol or ribitol phosphate (Kenne and 
Lindberg, 1983). The teichoic acids are highly antigenic (Henderson and Wilson, 
1996) and have been shown to be the phage receptor of certain species (Burger, 
1966). Teichoic acids bind magnesium ions, and there is some evidence that they 
help to protect bacteria from thermal injury by providing an accessible pool of these 
cations for stabilization of the cytoplasmic membrane (Pelczar et al., 1986). 
PG is an insoluble, porous, cross-linked polymer of enormous strength and 
rigidity. Thus, this polymer is an important and major cell wall constituent of all 
bacteria which plays a role in maintaining the shape of bacteria (Schleifer and 
Kandler, 1972). PG differs somewhat in composition and structure from one species 
to another, but it is basically a polymer of N-acetylglucosamine, N-acetylmuramic 
acid, L-alanine, D-alanine, D-glutamate, and a diamino acid (LL- or meso-
diamiaopimelic acid, L-lysine, L-ornithine, or L-diaminobutyric acid) (Pelczar et al, 
1986). This polymer is cross-linked by short peptides. 
General Introduction Page 38 
LPS are unique and characteristic components of the cell envelope of Gram-
negative bacteria. The architecture of LPS is built up of three separate "building 
block": (I) lipid A, (ii) an inner core region, and (iii) the O-specific side chain. The 
lipid A molecules from different bacteria can differ in terms of the sugar residues; 
the chain length, the number and location of acyl residues; the degree of 
phosphorylation; and the nature of the substituents on phosphate groups (Rietschel 
et al" 1992). The inner core region of LPS is characterized by the presence of the 
unusual sugars such as heptose and 2-keto-3-deoxyoctonic acid, and these have been 
reported to exert an effect on the biological activities of lipid A, including its capacity 
to induce cytokine synthesis (Cavaillon and Haeffner-Cavaillon, 1990). More 
detailed information about LPS can be found in a review article published by Raetz 
(1990). 
1.5.3 Immunomodulatory and Anti-Tumour Activities of Bacterial 
Polysaccharides 
Bacterial polysaccharides have been considered to be thymus-independent 
(TI) antigens as they can directly stimulate B-cell division and antibody production 
without the help of T cells because their long repetitive structures can directly 
interact with and activate B cells (Sood et al, 1996). Thus, a number of bacterial 
polysaccharides could induce mitogenic and polyclonal B cell responses. These 
bacterial polysaccharides include PG (Rasanen and Arviloirnni, 1981), LPS 
(Andersson et al., 1972), capsular polysaccharides from Hemophilus influenzae type b 
(Lucas and Asser, 1986), Streptococcus mutans carbohydrate antigens (Torii et al., 
1981) as well as mucoid exopolysaccharide of Pseudomonas aeruginosa (Daley et al" 
1985). 
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In addition, a variety of bacterial polysaccharides are found to possess 
cytokine-inducing ability. LPS is a well known bacterial product that can induce the 
production of different cytokines such as IL-1, IL-6 and IL-8 (Rietschel et al, 1994). 
Recently, accumulated evidence has demonstrated that other bacterial 
polysaccharides, apart from their ability to bind to monocytes and to promote 
engulfment and killing of bacteria by lectinophagocytosis, share many 
immunomodulating activities with LPS from Gram-negative bacteria (Weidemann et 
al, 1994 & Soell et al" 1995b). A number of reports have also shown that EPS or cell 
surface polysaccharides can stimulate cytokine production. For example, a capsular-
like, serotype b-specific polysaccharide antigen from Actinobacillus 
actinomycetemcomitans was found to stimulate human monocytes to release IL-1, IL-6 
and TNF (Yamaguchi et al" 1996). On the other hand, Soell et al (1995b) recently 
reported that rhamnose-glucose polymers from Streptococcus mutans were capable of 
stimulating the production of TNF-a from human monocytes in a dose dependent 
manner. In addition, capsular polysaccharides from two serotypes (serotype 5 and 8) 
of Staphylococcus aureus have shown to stimulate the release of IL-1 p, IL-6, IL-8 and 
TNF-a from human peripheral blood mononuclear cells (Soell et al., 1995a). 
Moreover, it has been reported that lipoteichoic acid from different types of 
bacteria can modulate the cytokine production from mononuclear cells, including 
TNF (Tsutsui et al., 1991), IL-1 (Riesenfeld-Orn et al, 1989), IL-8 (Standiford et aL, 
1994) and IL-6 (Heumann et al" 1994), as well as induction of NO production of 
macrophages (Keller et al" 1992). -
Like EPSs and teichoic acids, some PGs were also found to be capable of 
modulating the immune system. Timeerman et al (1993) reported that PG prepared 
from Staphylococci species can induce the production of TNF from human monocytes. 
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In addition, a soluble PG obtained from the culture supernatant of Staphylococcus 
aureus, grown in the presence of penicillin, was able to induce the release of IL-1 and 
IL-6 from human mononuclear cells (Weidemann et al., 1994) • 
In addition to the immunomodulatory effect, bacterial polysaccharides were 
also shown to have anti-tumour effect in vivo. Usami et al. (1988) reported that 
lipoteichoic acids extracted from Streptococcus pyogenes can suppress the growth of 
both solid- and ascites-type of Meth A fibrosarcoma. Besides, a lipoarabinomannan 
extracted from Mycobacterium tuberculosis strain Aoyama B (SSM) can prolong the 
survival time of mice implanted either with EAT cells or RL1 leukemia cells (Suzuki 
et al, 1986). More recently, Wang et al (1995) have reported that PS1 A l fraction, a 
glucan isolated from Mycobacterium bovis BCG vaccine and has a molecular weight of 
approximately 70 kDa and a dextran-like structure with 1 ^ 4 a-glucose side chains, 
showed potent anti-tumour activity against Sarcoma 180 implanted mice. 
1.5.4 General Properties of Klebsiella K7 Capsular Antigen 
Klebsiella K7 capsular antigen is defined as the antigenic capsular 
polysaccharide, termed K- or capsular antigen, isolated from Klebsiella pneumoniae 
serotype 7. Klebsiella is a member of the family Enterobacteriaceae. Klebsiella species 
are Gram-negative, encapsulated non-motile bacilli (0rskov and 0rskov, 1984). 
Klebsiella species often cause urinary tract, wound, soft tissue, respiratory tract 
infections and bacteremia (Lee, 1996). Infections due to Klebsiella species are a major 
cause of morbidity and mortality in compromised patients (Graybill et al" 1973). 
Klebsiella pneumoniae is the most commonly isolated member of the genus Klebsiella 
and it causes pneumonia in humans (Lee, 1996). 
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Capsular antigens or K-antigens are important for the serological 
classification of Klebsiella species. Approximately 82 different serotypes of Klebsiella 
species have been recognized on the basis of immunochemical tests (0rskov and 
0rskov, 1984). Interestingly, most clinical isolates of Klebsiella possess a well-
developed polysaccharide capsule, which appears to be a critical factor in the 
virulence of these bacteria. The amount of capsular polysaccharide produced has 
been correlated with pathogenicity (Cryz et al, 1984). Klebsiella capsular 
polysaccharide was also found to be anti-phagocytic (Cooper et al" 1983). 
Serotype-specific anti-capsular antibody has been shown to provide a 
substantial degree of protection against the live challenge with Klebsiella pneumoniae 
in experimental animal models (Riottot et al., 1981 & Cryz et al" 1984). Thus, in the 
past, researchers had devoted much of their efforts in the development of vaccines 
using capsular polysaccharide antigens against Klebsiella infection. 
Among the various Klebsiella strains, the K7-encapsulated isolate is 
significantly less toxic (Podschun and Ullmann, 1992). K7 capsular polysaccharide is 
an acidic and negatively charged molecule (Dutton et al" 1974). The partial structure 
of K7 capsular polysaccharide has been reported previously (Dutton et al, 1974). 
More recently, the complete structure of K7 capsular polysaccharide has been 
elucidated (Kjellberg et al" 1995). The K7 capsular polysaccharide is composed of 
hexasaccharide repeating units. Each unit contains mannose, galactose, glucose, 
glucuronic acid (2:1:2:1), and has an additional moiety of pyruvic acid. 
There are a few reports concerning the immunomodulatory activities 
of Klebsiella capsular polysaccharide. For example, Cryz et al. (1984) has reported that 
the K7 capsular antigen purified by Cetavlon precipitation was found to have potent 
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antigenicity in triggering antibody response in vivo. On the other hand, capsular 
polysaccharide isolated from Klebsiella pneumonia type 1 Kasuya strain (CPS-K) could 
induce the production of interferon and cytotoxic factor in mice (Kato et al" 1975 & 
1979) and increase the phagocytic capacity of murine macrophages in vitro (Yokochi 
et al" 1977). Furthermore, Wang et al. (1994) found that whole Klebsiella bacteria can 
induce thymic atrophy in both LPS-responder (C3H/HeN) and LPS-non-responder 
(C3H/HeJ) mice via the production of TNF-a. These findings imply that LPS in 
Klebsiella is not the essential component for the release of endogenous TNF in mice. 
Podschun et al (1992) also showed that Klebsiella pneumoniae serotype 7 bacteria 
could stimulate the human polymorphonuclear leucocytes in vitro. Whether the 
Klebsiella capsular polysaccharide can display similar immunomodu la to ry effects 
have no t yet been investigated. 
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1 .6 AIMS AND S C O P E S O F THE INVESTIGATION 
In the past, polysaccharides isolated from different natural sources, such as 
fungi (Lien, 1990) and higher plants (Lien and Gao, 1991 & Wong et al., 1994a), were 
found to possess immunomodulatory and anti-tumour activities. However, these 
polysaccharides are rather heterogeneous in structure, which made the extraction 
and purification method become complicated and tedious. Previous works of our 
laboratory have shown that polysaccharide fractions isolated from Pseudostellaria 
heterophylla contain high uronic acid contents and possess significant anti-tumour 
and immunomodulatory activities (Wong et al" 1994b; 1994c & 1994d). In another 
study, Sakagami et al (1987) suggested that uronic acid content of acidic 
polysaccharide fractions extracted from pine cones would be the essential 
determinant of their anti-tumour effect. Since the Klebsiella pneumoniae serotype 7 
capsular (K7) antigen was known to contain a considerable amount of glucuronic 
acid (Dutton, 1974) and exhibited potent antigenicity in triggering antibody response 
in vivo (Cryz et al" 1985), therefore, it represents a good candidate to be studied for 
its anti-tumour activities. 
In this thesis project, the K7 antigen will be extracted and purified by 
Cetavlon precipitation from Klebsiella pneumoniae serotype 7. Its purity will be 
assessed by gel filtration chromatography and its chemical composition will be 
determined by different biochemical methods. Afterwards, the bio-toxicity and 
cellular cytotoxicity of K7 antigen will be examined, using the brine shrimp assay 
and trypan blue dye exclusion method respectively. 
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Since a number of polysaccharides have been reported to affect 
hematopoiesis (Wong et al., 1994c & Egger et al., 1996) and exhibit mitogenicity on 
lymphocytes (Lucas and Asser, 1986 & Wong et al., 1992), therefore, the 
hematopoietic and mitogenic activities of K7 antigen will be first investigated. The 
modulatory effects of K7 antigen on the proliferation and differentiation of bone 
marrow cells and IL-3-stimulated bone marrow cells will be studied. In addition, the 
mitogenic effect of K7 antigen on murine lymphocytes will be studied, both in vitro 
a n d in vivo. 
On the other hand, the modulatory effects of K7 antigen on the activation and 
function of the murine peritoneal macrophages will be assessed. Parameters studied 
include measuring the effects of K7 antigen on the phagocytic and cytostatic 
activities of macrophages, as well as the production of NO and TNF by macrophages 
in vitro. Moreove r / t he effect of K7 antigen on the in vivo migra t ion of macrophages 
will be studied. Furthermore, the RT-PCR technique will be used to study the effect 
of K7 antigen on the differential expression of various cytokine genes in vitro. 
Finally, the anti-proliferative effect of K7 antigen on a variety of established 
tumour cell lines will be studied in vitro. In addition, the in vivo anti-tumour effect of 
K7 antigen against the EAT carcinoma in mice will be examined. Since bioactive 
polysaccharides have been reported to exert their anti-tumour activity through 
modulation of the host immune system (Wong et al., 1994b), the effect of K7 antigen 
on the activity of different cytotoxic effector cells such as NK and LAK cells will be 
studied. In addition, the differentiation-inducing ability of K7 antigen on a murine 
myelomonocytic leukemia (WEHI-3B JCS) will also be determined. 
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CHAPTER 2 
MATERIALS & METHODS 
2.1 MATERIALS 
2.1.1 Animals 
Inbred female BALB/c (H-2d), C57BL/6J (H-2” and outbred male ICR mice 
aged 6-8 weeks were bred at the University Animal House of The Chinese 
University of Hong Kong under pathogen-free condition. They were fed with animal 
diet (Chow 5001, Rodent Laboratory) and tap water ad libitum. 
2.1.2 Klebsiella pneumoniae Serotype 7 
Klebsiella pneumoniae serotype 7 strain 4140 was purchased from Dr. I. 
0rskov, the International Escherichia coli and Klebsiella Center, Statens 
Seruminstitiute, Copenhagen, Denmark. The culture was obtained as stab culture. 
2.1.3 Agar Medium for Cultivation of Klebsiella pneumoniae Serotype 7 
The agar medium used for cultivation of Klebsiella pneumoniae serotype 7 was 
prepared by dissolving Bacto agar (15 g), Bacto yeast extract (2 g), sucrose (30 g), 
NaCl (2 g), MgS0 4 • 7H 2 0 (0.25 g) and CaC0 3 (0.5 g) in one litre of double distilled 
water. It was sterilized by autoclaving at 121°C for 20 min before use. 
2.1.4 Cell Lines 
Various cell lines used in the study were as follows: 
(a) Lymphoid Tumours : 
(i) MBL-2, a T cell lymphoma induced by Moloney leukemia virus from 
C57BL/6J mouse, was obtained from the Department of Pathology, 
University of Cambridge, U.K.. 
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(ii) YAC-1, a T cell lymphoma induced by Moloney leukemia virus from 
A/Sn mouse, was purchased from American Type Culture Collection 
(ATCC). It is sensitive to the cytotoxic activity of natural killer (NK) cells 
in mice. Therefore, YAC-1 cells are often used as target cells in NK 
assays. 
(b) Myeloid Tumours: 
(i) Ml , a murine myelomonoblastic leukemic cell line, was a spontaneous 
myeloid leukemia derived from the highly leukemic STL strain mice 
(Ichikawa, 1969). It was kindly obtained from the Experimental 
Hematology Group, the John Curtin School of Medical Research, 
Canberra, Australia. 
(ii) WEHI-3B (D-), a murine myelomonocytic leukemic cell line, was 
originally obtained from Dr. D. Metcalf (Walter and Eliza Hall Institute 
for Medical Research, Melbourne, Australia.) and subsequently sub-
cloned at the John Curtin School of Medical Research, Canberra, 
Australia. One of the subclones derived from the D- line was designated 
as WEHI-3B (JCS) (Mak et al, 1993). 
(iii) HL-60, a human promyelocytic leukemic cell line, was established from 
the leukemic blood cell population of a 36-year-old female with acute 
promyelocytic leukemia, (Collins et al., 1977). It was purchased from 
ATCC. 
(c) Fibroblast-like Tumours: 
(i) L929, a transformed fibroblast cell line derived from C3H mice, was 
purchased from ATCC. 
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(ii) WEHI-164, a methylcholanthrene-induced fibrosarcoma derived from 
BALB/c mice, was purchased from ATCC. 
(iii) SC180 (Sarcoma 180), a sarcoma was derived from Swiss Webster 
Sarcoma 180 ascites, was purchased from ATCC. 
(d) Other Tumours: 
(i) P388Di is a methylcholanthrene-induced macrophage-like tumour 
derived from DBA/2 mice. It was purchased from ATCC. 
(ii) EAT (Ehrlich Ascites Tumour) is an ascites derivative of a spontaneous 
murine mammary adenocarcinoma (tetraploid subline My Klein Strain). 
It was a generous gift from Professor K.P. Fung, Department of 
Biochemistry, The Chinese University of Hong Kong. 
All the cell lines mentioned above were maintained as continuous cultures in 
RPMI1640 medium supplemented with 10% FCS, 100 uni ts /ml penicillin G sodium, 
100 jug/ml streptomycin sulphate and 0.25 fig/ml of amphotericin B (GIBCO BRL). 
Cell stock was stored iri liquid nitrogen in 10% dimethylsulphoxide (DMSO) and 
50% fetal calf serum (FCS). 
2.1.5 Buffers, Culture Medium and Other Reagents 
(a) Dulbecco's Phosphate-Buffered-Saline (PBS) 
PBS (Sigma Chemical Co.) was prepared by dissolving the powdered salt (8 g 
sodium chloride, 0.2 g potassium chloride, 0.2 g monobasic potassium phosphate 
and 1.15 g anhydrous dibasic sodium phosphate) in one litre of double distilled 
water. The pH of the solution was adjusted to 7.4 before use. It was sterilized by 
autoclaving at 121°C for 15 min. 
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(b) Hank's Balanced Salt Solution (HBSS) 
HBSS without phenol red (Sigma Chemical Co.) was prepared by dissolving 
0.4 g KC1, 0.06 g K H 2 P O 4 , 8 g NaCl, 0.35 g NaHCOs • 0 . 1 2 g Na 2 HP0 4 • 12H 2 0 ,1 g D-
glucose in one litre of double distilled water and buffered with 25 mM sodium 
bicarbonate ( N a H C 〇 3 ) according to the manufacturer's specification. The solution 
was adjusted to pH 7.2 and sterilized by filtration through a 0.22 \im membrane 
filter. 
(c) Culture Medium 
RPMI 1640 medium, supplemented with 25 mM N-2-hydroxy-
ethylpiperazine-N
/
-2-ethane-sulfonic acid (HEPES) and 2 mM L-glutamine, was 
purchased from GIBCO BRL Life Technologies, Inc.. The powdered medium was 
dissolved in double distilled water and buffered with 25 mM sodium bicarbonate 
( N a H C 〇 3 ) according to the manufacturer's specification. The pH of the solution was 
adjusted to 7.2. It was then sterilized by filtration through a 0.22 \im membrane filter. 
The medium was stored at 4°C and used within one month. 
For routine cell passages or general cell culture experiments, unless indicated, 
otherwise, the medium was supplemented with 100 uni ts /ml penicillin G sodium, 
100 | ig /ml streptomycin sulfate and 0.25 }ig/ml amphotericin B as PSF (GIBCO BRL) 
and 10 % fetal calf serum (RPMI complete medium). 
(d) Fetal Calf Serum (FCS) 
FCS was purchased from GIBCO BRL Life Technologies Inc. and was stored 
at -20°C as 20 ml aliquots. Heat-inactivated fetal calf serum (HI-FCS) was prepared 
by heating 10 ml aliquots at 56°C for 30 min. 
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(e) Antibiotic-Antimycotic (xlOO) solution (PSF) 
PSF was purchased from GIBCO BRL Life Technologies Inc. containing 
10,000 uni t s /ml of penicillin G sodium, 10,000 |Lig/ml streptomycin sulfate and 25 
jLig/ml of amphotericin B . It was stored at -20°C as 5 ml aliquots. 
(f) Normal Saline 
Normal saline was prepared by dissolving 9 g sodium chloride (NaCl) in one 
litre double distilled water and sterilized by autoclaving at 121°C for 15 min. 
(g) 2-Mercaptoethanol (2-ME) Solution 
A 0.1 M stock solution of 2-mercaptoethanol (Sigma Chemical Co.) was 
prepared in sterilized double distilled water and stored at -20°C until use. 
(h) Scintillation Fluid 
Triton X-toluene scintillation fluid was prepared by mixing 12 g 2,5-
diphenyloxazole (PPO) (Sigma Chemical Co.), 1.2 g 2,2
/
-p-phenylene-bis-[5-
phenyloxazole] (POPOP) (Sigma Chemical Co.), two litres toluene and one litre 
triton X-100. The suspension was stirred overnight until all the POPOP and PPO 
were completely dissolved. 
(i) Dye Solutions 
V 
Neutral Red Solution : 
0.5 g neutral red powder (Sigma Chemical Co.) was dissolved in 100 ml 
normal saline. The insoluble dye was filtered through Whatman No. 1 filter paper. 
Crystal Violet Solution : 
0.5 g crystal violet powder (Sigma Chemical Co.) was dissolved in 100 ml 
PBS. The insoluble dye was filtered through Whatman No. 1 filter paper. 
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Trypan Blue Solution : 
0.4% trypan blue solution was purchased from Sigma Chemical Co.. 
Modified Wright-Giemsa Stain : 
0.4% Modified Wright Giemsa stain was purchased from Sigma Chemical 
Co.. 
Hematoxylin Solution: 
Hematoxylin solution (Gill No. 3) was purchased from Sigma Chemical Co.. 
(j) Complement 
The lyophilized powder of Low-Tox®-M rabbit complement was purchased 
from Cedarlane Laboratories Ltd. and stored at -20°C until use. The lyophilized 
complement was reconstituted with 1 ml sterilized cold double distilled water. The 
complement solution was then diluted 5 fold with cold plain RPMI medium and 
sterilized by filtration through a 0.22 \im membrane filter. The toxicity of the 
complement was reduced by incubating the complement solution with BALB/c 
spleen cells at 4°C for 15 min with occasional shaking. 
(k) Citrate-Acetone-Formaldehyde (CAF) Solution 
Citrate-Acetone-Formaldehyde (CAF) solution was prepared by adding 8 ml 
of 37% formaldehyde and 65 ml acetone to 25 ml citrate solution. The solution was 
placed in a glass bottle and cap tightly. It was stored at 4°C before use. 
(1) Citrate Solution 
Citrate solution was prepared to contain 18 mM citric acid, 9 mM sodium 
citrate and 12 mM sodium chloride. The solution was stored at 4°C before use. 
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(m) Trypsin-EDTA (xl) Solution 
Trypsin-EDTA solution was purchased from GIBCO BRL Life Technologies 




. It was stored at -20°C as 2 or 3 ml aliquots until use. 
(n) Thioglycollate (TG) Broth 
3% TG broth was prepared by suspending 3 g of dehydrated thioglycollate 
powder (Difco Lab.) in 100 ml double distilled water. It was then heated to boil to 
dissolve the powder completely and sterilized by autoclaving at 121°C for 15 min. It 
was stored at room temperature (r.t.) in the dark for at least one month before use. 
(o) Protease Peptone (PP) solution 
10% PP solution was prepared by dissolving 10 g of protease peptone (Difco 
Lab.) in 100 ml PBS and sterilized by autoclaving at 121°C for 15 min. It was stored at 
4°C before use. 
(p) Wright's Stain Buffer 
Wright's stain buffer was prepared by dissolving 3.5 g KH2PO4 and 5.72 g 
Na2HP〇4 • I2H2O in one litre double distilled water. The solution was adjusted to 
pH 7.2 before use. 
(q) Polymyxin B Sulphate (PB) 
PB (Sigma Chemical Co.) was dissolved in RPMI medium as a stock solution 
of 500 jag/ml. It was then stored at -20°C as 0.5 ml aliquots until use. 
(r) Lipopolysaccharide (LPS) 
LPS (E. coli serotype 026:B6, Sigma Chemical Co.) was dissolved in RPMI 
medium at 500 |iig/ml. It was then stored as 250 jil aliquot at -20°C until use. 
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(s) Concanavalin A (Con A) 
Con A (from Canavalia ensiformis, Sigma Chemical Co.) was dissolved in 
RPMI medium at 500 |Lig/inl. It was then stored as 50 jul aliquots at -20°C until use. 
(t) FITC-conjugated latex beads 
Fluoresbrite™ plain YG 2 \xm microsphere latex beads were purchased from 
Polyscience, Inc. and stored in the dark at 4°C until use. 
(u) Actinomycin D 
Actinomycin D (Sigma Chemical Co.) was dissolved in sterilized double 
distilled water as a stock solution of 500 jxg/ml and stored as 100 |iil aliquots at -20°C 
until use. 
2.1.6 Antibodies 
(a) Fluorescein isothiocyanate (FITC) conjugated goat anti-rat IgG antibody 
was purchased from Southern Biotechnology Associates Inc. The 
purified antibody reacts specifically with rat IgG and does not react 
with other heavy chain isotypes. It was stored at 4°C. 
(b) Fluorescein isothiocyanate (FITC) conjugated mouse anti-rat IgM 
antibody (clone G53-238, mouse IgGi isotype) was purchased from 
Pharmingen. The purified antibody reacts specifically with rat IgM and 
does not react with other heavy chain isotypes. It was stored at 4°C. 
(c) Monoclonal rat anti-mouse B cell-antigen antibody (LR-1, clone 
LR6.2B6D6.C9, rat IgM isotype) was purchased from Serotec Ltd. It was 
stored at a dilution of 1 : 50 in PBS supplemented with 2% HI-FCS at 
-20°C until use. 
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(d) Monoclonal rat anti-mouse Thy-1.2 antibody (clone F7D5, rat IgM 
isotype) was purchased from Serotec Ltd. It was stored at a dilution of 
1:20 in PBS supplemented with 2% HI-FCS at -20。C until use. 
(e) Monoclonal rat anti-mouse CDl l b (Mac-1) antibody (clone Ml /70 , rat 
IgG2b isotype) was obtained from the culture supernatant of the 
hybridoma cell line Ml /70 (ATCC). It was stored at -20。C until use. 
(f) Monoclonal rat anti-mouse F4/80 (macrophage differentiation antigen) 
antibody (clone C1.A3-1, rat IgG2b isotype) was obtained from the 
culture supernatant of the hybridoma cell line F4/80 (ATCC). It was 
stored at -20°C until use. 
(g) Monoclonal rat anti-mouse CD3 antibody (clone #29B, rat IgG2b isotype) 






H]-TdR) in sterilized saline solution with 




(b) Sodium chromate (Na
51
Cr〇4) in sterilized saline solution with specific 
activity of 200-500 mCi /mg chromium was purchased from Amersham. 
It was then diluted to a concentration of 5 mCi /ml with plain RPMI 
medium supplemented with 1% PSF, and stored at 4°C before use. 
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2.1.8 Recombinant Cytokines 
(a) Recombinant Murine Interleukin-3 (rmIL-3) 
rmIL-3 was obtained from Pharmingen. It was Escherichia coli derived and 
had a specific activity of 1 x 10
7
 uni ts /mg. The diluted aliquots were stored at -20°C 
until use. One unit of rmIL-3 is defined as the amount of rmIL-3 that is required to 
support half-maximal stimulation of cell proliferation with the mouse IL-3 
dependent cell line MC-9. 
(b) Recombinant Murine Tumour Necrosis Factor-alpha (rmTNF-a) 
rmTNF-a was purchased from Boehringer Mannheim. It was produced in 
Escherichia coli and had a specific activity of 6 x 10
7
 uni ts /mg, as measured by a cell 
lytic assay using the mouse transformed fibroblast cell line L929 and/or mouse 
fibrosarcoma cell line WEHI164 in the presence of actinomycin Ci (Aggarwal, 1985). 
(c) Recombinant Murine Interleukin-2 (rmIL-2) 
rmIL-2 was purchased from Boehringer Mannheim. It was produced in 
Escherichia coli and had a specific activity of 2 x 10
6
 uni ts /mg. The diluted aliquots 
were stored at -20°C until use. One unit of rmIL-2 is defined as the amount of rmIL-2 
that is required to support half-maximal stimulation of cell proliferation with 
CTLL-2 cells. 
All recombinant cytokines were prepared in sterile PBS containing 2% HI-
FCS. Stock solutions were prepared as small-volume aliquots, which were stored at 
-20°C and thawed only once. The working solutions were then kept at 4°C and used 
within one month. 
2.1.9 Oligonucleotide Primers and Internal Probes 
For every gene of interest, a specific pair of oligonucleotide primers was 
designed according to the published sequence of its cloned cDNA. They were 
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designed to prime on the sense and the antisense sequence of the corresponding 
cDNA respectively (Table 2.1). Whenever possible, primers were selected from 
different exons which may span an intron so as to permit discrimination between 
amplification of mRNA from contaminating genomic DNA. 
In order to verify the specificity of the PCR products with dot blot 
hybridization, an oligonucleotide probe which is specific for the gene of interest was 
synthesized and labelled at the 3' end with digoxigenin (DIG) (Table 2.1) (DIG 
oligonucleotide 3' end labelling kit, Boehringer Mannheim). 
All oligonucleotides used in the gene expression study were kindly provided 
by Prof. M.C. Fung, Department of Biology, The Chinese University of Hong Kong, 
Hong Kong. 
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Table 2.1: Summary of the Nucleotide Sequence of Primers and Internal Probes 
Used in RT-PCR and Hybridization Studies 
~ S i z e of 
predicted 
PCR 
Gene Sequence product 
(bp) 
u p p e r p r i m e r 5 , -ACC ACA GTC CAT GCC ATC A C - 3 ' 
咖 加 l o w e r p r i m e r 5 ' - T C C ACC ACC C T 6 TTG CTG T A - 3 ' 4 5 2 
u p p e r p r i m e r 5' -TCC CCA AAG GGA TGA GAA GTT C - 3 ' ""“ 
T N F - a l o w e r p r i m e r 5 ' - T C A TAC CAG GGT TTG A6C TCA G - 3 ' 4 1 1 
i n t e r n a l p r o b e 5 ' -CAC ACT CAG ATC ATC TTC TC-3' 
u p p e r p r i m e r 5 ' -ACA GTA TCA GCA ACG TCA AGC A A - 3 ' “ 
I L - l a l o w e r p r i m e r 5 ' -CCG ACT TTG TTC TTT GGT GGC A - 3 ' 5 4 6 
i n t e r n a l p r o b e 5 ' -GGC AAC TCC TTC AGC AAC A C G - 3 ' 
u p p e r p r i m e r 5 ' -GAG CTT CAG GCA GGC AGT A T C - 3 ' 
I L _ 1 | 3 l o w e r p r i m e r 5 ' - G T A TAG ATT CTT TCC TTT GAG G C - 3 ' 3 8 2 
i n t e r n a l p r o b e 5, -CAC TTG TTG GTT GAT ATT CTG T C - 3 ' 
u p p e r p r i m e r 5 ' - T G A GAA AAG AGT TGT GCA ATG G C - 3 ' ~ 
I L - 6 l o w e r p r i m e r 5 ' -GAA TGT CCA CAA ACT GAT ATG C T T - 3 ' 4 7 9 
i n t e r n a l p r o b e 5 ' - G T T AGG AGA GCA TTG GAA ATT G G - 3 ' 
u p p e r p r i m e r 5 ' -CCG GCA AAC CCA AGG TCT A C - 3 ' 
i N O S l o w e r p r i m e r 5 ' ~CTC ACC ATT ATC TTT ACT CAG T G - 3 ' 3 5 4 
i n t e r n a l p r o b e 5 ' -GCC CCA TAG GAA AAG ACT G C A - 3 ' 
u p p e r p r i m e r 5 ' - C A T GGA GCT GGT GAA ACG GAA GCG C A T - 3 ' 
T G F - p l o w e r p r i m e r 5 ' - C T C CAG TGA CGT CAA AAG ACA GCC ACT C - 3 '
 4 9 7 
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2.1.10 Reagents and Solutions for Gene Expression Analysis 
(i) Double Distilled Water 
The double distilled water used was treated with 0.1% diethyl pyrocarbonate 
(DEPC) (Sigma Chemical Co.), and shaken thoroughly to disperse the DEPC through 
the entire solution. The solution was then autoclaved at 121°C for 15 min to remove 
the remaining DEPC. 
(ii) Tris-HCl Buffer (pH 7.5) 
Tris [hydroxymethyl] amino methane (Tris, Sigma Chemical Co.) was 
prepared as a 1 M stock solution in DEPC-treated double distilled water. The buffer 
was then adjusted to p H 7.5 with hydrochloric acid (HC1) and autoclaved at 121。C 
for 15 min. 
(iii) Guanidine Thiocyanate (GT) Solution 
Guanidine thiocyanate (Sigma Chemical Co.) was prepared as a 4 M solution 
in DEPC-treated double distilled water and buffered with 0.1 M Tris-HCl (pH 7.5). It 
was then autoclaved and stored at r.t.. Before use, 0.1 M 2-ME (Sigma Chemical Co.) 
was added to the solution. 
(iv) rRNasin Ribonuclease Inhibitor 
The E. coli-dehved recombinant RNasin ribonuclease inhibitor was 
purchased from Promega Corporation. The inhibitor was supplied in a storage 
buffer of 20 mM HEPES-potassium hydroxide (HEPES-KOH, pH 7.6), 50 mM 
potassium chloride (KC1), 8 mM dithiothreitol (DTT) and 50% (v/v) glycerol. One 
unit is defined as the amount of rRNasin ribonuclease inhibitor that is required to 
inhibit 50% activity of 5 ng RNase A as measured by the inhibition of hydrolysis of 
cytidine 11,3'-cyclic monophosphate. 
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(v) TioEo.i Buffer 
The T10E0.1 buffer contains 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA. 
(vi) Ultrapure dNTP Set, 2'-Deoxynucleoside 5。Triphosphate, Sodium Salt 
The deoxynucleoside triphosphate (dNTP) set was purchased from 
Pharmacia Biotech., with each nucleotide supplied as 100 mM solution in distilled 
water (pH 7.5). Stock solution containing 10 mM of each dNTP was prepared in 1 
mM Tris-HCl (pH 7.5) and was stored at -20°C. 
(vii) 01igo-dTi2-i8, Sodium Salt 
Oligo-dTu-is was purchased from Promega Corporation. Stock solution of 1 
|ig/|xl was prepared in TioEo.i buffer and stored at -20°C. 
(viii) Moloney Murine Leukemia Virus (M-MLV) Reverse Transcriptase 
The M-MLV reverse transcriptase was isolated from Escherichia coli and 
purchased from GIBCO BRL Life Technologies Inc. The enzyme was supplied in a 
storage buffer of 20 mM Tris-HCl (pH 7.5), 1 mM DTT, 0.01% (v/v) NP-40, 0.1 mM 
disodium EDTA (Na2EDTA), 0.1 M sodium chloride (NaCl) and 50% (v/v) glycerol. 
One unit of M-MLV reverse transcriptase is defined as the amount of enzyme that 
incorporates 1 nmole deoxythymidine triphosphate (dTTP) into acid-precipitable 
material in 10 min at 37°C, using poly(A) and oligo-dTi2-i8 as template and primer 
respectively (Houts et al., 1979). 
(ix) First Strand Buffer 
The first strand buffer (GIBCO BRL Life Technologies Inc.) was obtained as a 
5x solution of 250 mM Tris-HCl (pH 8.3), 375 mM KC1 and 15 mM magnesium 
chloride (MgCl2). 
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(x) Reaction Buffer IV 
The reaction buffer IV (Advanced Biotechnologies Ltd.) was obtained as a lOx 
solution of 200 mM ammonium sulphate ([NH^SC^), 750 mM Tris-HCl (pH 9.0) and 
0.1% (w/v) Tween®. 
(xi) Thermoprime
p l u s
 DNA Polymerase 
Thermoprime
p l u s
 DNA Polymerase (Advanced Biotechnologies Ltd.) was 
isolated from Thermus icelandicus, which was characterized to have a 5' to 3' 
polymerization-dependent exonuclease replacement activity but lacked the 3' to 5' 
exonuclease activity. The enzyme was supplied in a storage buffer of 50% (v/v) 
glycerol, 10 mM potassium phosphate (pH 7.0), 100 mM NaCl, 0.1 mM EDTA, 2 mM 
DTT and stabilizers. One unit of enzyme is defined as the amount of enzyme that 
incorporates 10 nmoles of dNTPs into acid insoluble material in 30 min at 74°C 
under the described analysis conditions: 25 mM Tris-[hydroxymethyl]-methyl-
amino-propane-sulfonic acid, sodium salt (TAPS, pH 9.3 at 25。C), 50 mM KC1, 2 mM 
MgCl 2 ,1 mM 2-ME, 250 \xU of deoxycytidine triphosphate (dCTP), deoxyguanosine 
triphosphate (dGTP), deoxythymidine triphosphate (dTTP), 250 |iM pH]-deoxy-
adenosine triphosphate (pH]-dATP, specific activity of 0.05 Ci/mmole), 1.25 
activated salmon sperm DNA in a total volume of 50 jil. 
(xii) Gel Loading Solution 
The gel loading solution (Sigma Chemical Co.) was supplied as a 5x solution 
of 0.05% (w/v) bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8.0) and 
0.5% (w/v) sodium dodecyl sulfate (SDS). The solution is suitable for non-
denaturing agarose gel electrophoresis of nucleic acids. 
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(xiii) Tris-Borate-EDTA (TBE) Electrophoresis Buffer 
The TBE electrophoresis buffer contains 90 mM Tris-borate and 2 mM EDTA 
(pH 8.0). 
(xiv)Digoxigenin (DIG) Oligonucleotide 3。End Labelling Kit 
The DIG oligonucleotide 3'-end labelling kit was purchased from Boehringer 
Mannheim and contains the following components: 
(a) 5x Reaction Buffer: 1 M potassium cacodylate, 0.125 M Tris-HCl, 1.25 mg /ml 
bovine serum albumin (BSA, pH 6.6 at 25°C). 
(b) Cobalt Chloride Solution (CoCl2,25 mM). 
(c) DIG-ll-ddUTP solution: 1 mM DIG-ll-ddUTP (Digoxigenin-3>Osuccinyl-s-
aminocaproyl-�5-(3-aminoall)d)-2',3'-dideoxy-uridine-5'-triphosphate] 
tetralithium salt). 
(d) Terminal Transferase: 50 units/jil terminal transferase in 0.2 M potassium 
cacodylate, 1 mM EDTA, 200 mM KC1, 200 mM KC1, 0.2 m g / m l BSA (pH 6.5 at 
25°C) and 50% (v/v) glycerol. 
(e) Glycogen Solution (20 mg/ml). 
(xv) Standard Saline Citrate (SSC) 
Standard saline citrate (SSC) was prepared as a 20x stock solution of 3 M 
NaCl and 0.3 M trisodium citrate. The pH of the solution was adjusted with NaOH 
to 7.0. It was then sterilized by autoclaving and was stored at r.t.. 
(xvi) Hybridization Buffer 
The hybridization buffer contains 5x SSC, 1% (w/v) blocking agent (DIG 
Luminescent Detection Kit, Boehringer Mannheim), 0.1% (w/v) N-lauroyl-sarkosine 
(Sigma Chemical Co.) and 0.02% (w/v) SDS (Sigma Chemical Co.). 
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(xvii) Maleic Acid Buffer 
Maleic acid buffer (pH 7.5) contains 0.1 M maleic acid (Fluka Chemika) and 
0.15MNaCl. 
(xviii) DIG Luminescent Detection Kit 
The DIG luminescent detection kit was purchased from Boehringer 
Mannheim and contains the following components: 
(a) Blocking Reagent 
(b) CSPD®: D i s o d m m 3 - { 4 - m e t h o x y s p i r o [ l , 2 - d i o x e n t a n e - 3 / 2 , - ( 5 , - c h l o r o ) tricyclo 
(3.3.1.1) decan]-4-yl}phenyl phosphate. 
(c) Anti-DIG-AP: 75 units/jil alkaline phosphatase (AP) conjugated sheep anti-DIG 
polyclonal antibody (Fab fragment, IgM isotype) in 50 mM 
triethanolamine buffer, 3 mM NaCl, 1 mM M g d 0.1 mM zinc 
chloride (ZnCl2) and 1% (w/v) BSA (pH 7.6). 
(xvix) Detection Buffer 
The detection buffer (pH 9.5) contains 0.1 M Tris-HCl, 0.1 M NaCl and 50 
mM MgCl2. 
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2 .2 M E T H O D S 
2.2.1 Extraction, Purification and Characterization of Klebsiella K7 
Capsular Antigen 
2.2.1.1 Extraction and Purification of K7 Capsular Antigen 
The procedure for extraction and purification of Klebsiella K7 capsular antigen 
was shown in Fig.2.1. The Klebsiella pneumoniae serotype 7 was cultured on agar 
plates and grew at 37。C for 2 days. The bacteria in mucoid form were harvested and 
killed with 1% phenol in normal saline. The bacteria was centrifuged at 19,000 x g for 
3 hr at 4°C and the cell-free supernatant was then dialysed against double-distilled 
water overnight using dialysis tubings with membrane pore size of 3,500 
(Spectra/POR 4). The sample was then lyophilized for 3 days. The lyophilized 
powder, which was designed as the crude extract, was subjected to Cetavlon 
precipitation. Briefly, the crude extract was dissolved in double distilled water (1% 
w / v ) and 5% Cetavlon ( N - c e t y l - N , N , N - t r i m e t h y l - a n u r i o n i u m bromide, CwH^BrN, 
Merck) was added slowly to the dissolved crude extract in 1:1 (w/w) ratio. After 
centrifugation at 3000 x g for 15 min, the precipitate of the extract could be obtained 
and the supernatant was discarded. Minimum volume of 4 M NaCl solution was 
then added to dissolve the pellet of crude extract with continuous stirring. The 
dissolved extract was then slowly added to large volume of absolute ethanol with 
continuous stirring using a glass rod. Silk-like product could be obtained around the 
glass rod and the NaCl was precipitated out. The silk-like product was blotted dry 
and redissolved in 4 M NaCl, and added slowly to absolute ethanol for further 
extraction of K7 capsular polysaccharide. The silk-like product was then blotted dry 
again and dissolved in double distilled water, followed by dialysis against double 
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distilled water using dialysis tubings with membrane pore size of 3,500 
(Spectra/POR 4) at 4°C for at least 3 days. The sample was then lyophilized for 3 
days and was designated as Klebsiella K7 capsular antigen. 
2.2.1.2 Gel Filtration of K7 Capsular Antigen 
K7 antigen was applied onto a Sepharose CL-2B (Pharmacia Fine Chemicals) 
column (2.6 x 57 cm) and eluted with 0.15 M NaCl. Fractions of 4.4 ml were collected 
at a flow rate of 17.6 ml /hr . The relative amount of carbohydrate in each fraction 
was determined by phenol sulfuric acid method (O.D. 490nm) (Dubois et al., 1956). 
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Culture of Klebsiella pneumoniae serotype 7 on agar medium 
at 37°C for 2 days 
I . • D 
Harvest and kill the Klebsiella mucoid colonies with 
1 % phenol in normal saline 
I II 
Centrifuge at 19,000 x g for 3 hr at 4。C 
u 
Lyophilize for 3 days to obtain the crude extract 
u 
Dissolve the crude extract in double distilled water (1% w / v) 
I • u 
Dialyse the cell-free supernatant against 
double distilled water overnight 
l i 
Add 5% Cetavlon in 1:1 (w/w) ratio 
u 
Centrifuge at 3000 x g for 15 min to obtain a pellet 
II 
Dissolve the pellet in 4 M NaCl with continuous stirring 
l i 
Slowly pour the dissolved extract into absolute ethanol 
& obtain the silk-like product by 
stirring with a glass rod 
U 
Blot the silk-like product dry & redissolve it in 4 M NaCl with 
continuous stirring, add slowly to absolute ethanol 
u 
Blot the silk-like product dry & 
dissolve it in double distilled water 
u 
Dialyse against double distilled water at 4°C for at least 3 days 
U 
Lyophilize for 3 days 
Obtain purified Klebsiella K7 capsular antigen 
Figure 2.1: A flow chart showing the extraction and purification procedures of K7 
capsular antigen from Klebsiella pneumoniae serotype 7. 
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2.2.1.3 Characterization of K7 Capsular antigen 
Protein content was determined by the Bradford method using bovine 
serum albumin (BSA) as a standard (Bradford, 1976). Nucleic acid content were 
quantitated by measuring the absorbance at 260 nm of 1 mg /m l polysaccharide 
solution in double distilled water by using the conversion formula, 50 |xg/ml of 
nucleic acid yields an absorbance value of 1.0 in 1 cm cuvette (Wong et al" 1977). 
Carbohydrate content was determined by the phenol sulfuric acid method (Dubois et 
ah, 1956) while uronic acid content was determined by the carbazole method (Bitter 
and Muir, 1962). Results were expressed as mean 土 standard error (S.E.) of triplicate 
determinations. 
2.2.1.4 Determination of the Bio-toxicity of K7 Capsular Antigen 
The bio-toxicity of K7 antigen was determined by the brine shrimp assay 
(Meyer et al” 1982). 
(a) Hatching the Shrimp 
Brine shrimp eggs were hatched in a shallow rectangular hatching 
tank filled with artificial sea water which was prepared by dissolving 3.8 g 
sea salt in 100 ml double distilled water. A plastic divider with small space 
away from the bottom was used to make two unequal compartments. The 
- eggs were sprinkled into the larger compartment which was darkened, while 
the small compartment was illuminated. After 48 hr the phototropic nauplii 
were collected by pipette from the illuminated side, having been separated 
by the divider from their shells. 
(b) Bioassay 
Each sample was tested in triplicate. Individual sample at 1000, 100, 
10 (ig/ml was mixed with 10 brine shrimps (Artemia salina LEACH) and the 
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volume of solution was then adjusted to 5 ml/vial with artificial sea water. 
The vials were maintained under illumination. The number of survivors was 
counted two days later, which was then analyzed by a computer software 
called Finney for determination of L C 5 0 value. LC50 is defined as the 
concentration of sample (|Lig/ml) which causes 50% of the total shrimps death 
in the brine medium. Hippuric acid was used as the positive control. 
2.2.1.5 In Vitro Cytotoxicity of K7 Capsular Antigen on Splenocytes 
Splenocytes (5 x 10
5
/well) were cultured with different concentrations of K7 
antigen in 96-well flat-bottomed microtiter plates (Nunc) in a final volume of 0.2 ml. 
The cytotoxicity of K7 antigen on splenocytes was determined after 6 hr and 24 hr 
incubation by counting the number of dead cells in 200 cells using the trypan blue 
exclusion method (Philip, 1973). Results were expressed as arithmetic mean 土 S.E. of 
triplicate cultures. 
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2.2.2 Assay for the Hematopoietic and Mitogenic Activities of Klebsiella 
K7 Capsular Antigen 
2.2.2.1 Isolation and Preparation of Cells 
(a) Murine spleen lymphocytes 
BALB/c mice were sacrificed by cervical dislocation, and the spleens were 
aseptically excised. Splenocytes were obtained by cutting the spleens into small 
pieces and gently pressing the tissue through a 200-gauge stainless steel sieve, and 
washed once with plain RPMI medium. Viable lymphocytes were obtained by Ficoll-
isopaque (Pharmacia Fine Chemicals) gradient centrifugation (1300 x g, 20 min) of 
spleen cell suspension. The lymphocytes were then washed twice with plain RPMI 
medium and resuspended in complete RPMI medium. 
(b) Murine thymocytes 
BALB/c mice were sacrificed by cervical dislocation, and the thymuses were 
aseptically excised. Thymocytes were obtained by cutting the thymuses into small 
pieces and gently pressing the tissue through a 200-gauge stainless steel sieve, and 
washed once with plain RPMI medium. Viable cells were obtained by Ficoll-
isopaque gradient centrifugation (1300 x g, 20 min) of thymocyte suspension. The 
thymocytes were then washed twice with RPMI medium and resuspended in 
complete RPMI medium. 
(c) Bone marrow cells 
BALB/c mice were sacrificed by cervical dislocation. The femurs were 
excised and put into a 60 mm culture dish (Corning) containing cold RPMI complete 
medium. Using a 1 ml syringe fitted with a 25-gauge needle, the marrow plugs were 
flushed into complete RPMI medium and then washed once with plain RPMI 
medium. Red blood cells and dead cells of the bone marrow cell suspension were 
removed by Ficoll-isopaque gradient centrifugation (1300 x g, 20 min). The bone 
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marrow cells were then washed twice with plain RPMI medium and resuspended in 
complete RPMI medium. 
2.2.2.2 In Vitro Lymphocyte Transformation Assay 
Proliferative response was determined by incubating murine spleen 
lymphocytes with appropriate dilution of samples in 96-well flat-bottomed 
microliter plates at a cell density of 5 x 10
5
 cells/well in a total volume of 0.2 ml. 
Microliter plates were incubated at 37°C in a humidified atmosphere containing 5% 
C02-95% air for 48 hr. The cells were then pulsed with 0.5 imcrocurie (jiiCi) tritiated 
methyl-thymidine ([
3
H]-TdR) (Specific activity = 2 Ci/mmole, Amersham 
International) in a volume of 20 \xl for each well for 6 hr. Cultures were harvested 
onto a Whatman GF/C glass microfibre filter (Whatman International Ltd.) and the 
radioactivity in counts per minute (cpm) was measured using a Beckman liquid 
scintillation counter (model LS-1801). Results were expressed as the arithmetic mean 
stimulation index (S.I.) 土 S.E. of quadruplicate cultures (S.I. = counts in test cultures 
divided by counts in control cultures). 
2.2.2.3 In Vitro Assay of Thymocyte Proliferation 
The proliferative response of murine thymocytes was determined by 
incubating cells with appropriate dilution of samples in 96-well flat-bottomed 
microliter plates at a cell density of 5 x 10
5
 cells/well in a total volume of 0.2 ml. 
Microliter plates were incubated at 37°C in a humidified atmosphere containing 5% 
COi-95% air for 48 hr. The cells were then pulsed with 0.5 |iCi [3H]-TdR in a volume 
of 20 pi for each well for 6 hr. Cultures were harvested onto a Whatman GF/C glass 
microfibre filter and the radioactivity in cpm was measured using a Beckman liquid 
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scintillation counter. Results were expressed as the arithmetic mean S.I. 土 S.E. of 
quadruplicate cultures. 
2.2.2.4 Depleting Mouse T Cells by Anti-Thy-1.2 Antibody Plus 
Complement Treatment 
Monoclonal anti-Thy-1.2 antibody (40 was added to 2 ml spleen cell 
suspension (2 x 10
7
 cells/ml) at a final antibody dilution of 1:1000. The mixture was 
then incubated at r.t. for 30 min. The cells were spun down and resuspended in 2 ml 
Low-Toxi®-M rabbit complement (diluted 1:4 with plain RPMI medium) for 1 hr at 
37°C to lyse the T cells. The viability of the remaining cells was measured by the 
trypan blue dye exclusion method. The cells were then washed two times with RPMI 
plain medium and resuspended to 5 x 10
6
 cells/ml in RPMI complete medium. 
2.2.2.5 Depleting Mouse B Cells by Anti-mouse B Cell Antibody Plus 
Complement Treatment 
Monoclonal anti-mouse B cell-antigen antibody (10 |al) was added to 2 ml 
spleen cell suspension (2 x 10
7
 cells/ml) at a final antibody dilution of 1:10,000. The 
mixture was then incubated at r.t. for 30 min. The cells were spun down and 
resuspended in 2 ml Low-Toxi®-M rabbit complement (diluted 1:4 with RPMI plain 
medium) for 1 hr at 37°C to lyse B cells. The viability of the remaining cells was 
measured by the trypan blue dye exclusion method. The cells were then washed two 
times with RPMI plain medium and resuspended to 5 x 10
6
 cells/ml in RPMI 
complete medium. 
2.2.2.6 Depleting Macrophages from Spleen Cell Suspension 
3 x 10
7
 spleen cells were added onto a 60 mm culture dish (Corning) and 
incubated at 37°C for at least 3 hr. The non-adherent cells were then washed out with 
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warm plain RPMI medium, collected and spun down (250 x g, 5 min). The cell pellet 
was then resuspended to 5 x 10
6
 cells/ml in RPMI complete medium. 
2.2.2.7 Flow Cytometric Analysis of Different Cell Populations from 
Splenocytes 
Splenocytes were washed once with FACS washing buffer (PBS containing 
2% HI-FCS and 0.05% sodium azide) in order to inhibit the internalization of 
membrane components or antigen-antibody complexes. In order to alleviate the 
problem of non-specific binding through Fc receptors, the cells (2 x 10
5
) were first 
incubated with mouse IgG and rat IgG blocking antibodies (10 |ig/ml, Sigma 
Chemical Co.) at 4°C for 30 min. They were then washed once with FACS washing 
buffer and incubated with 1 jag monoclonal antibody against CD3 antigen or 1:10,000 
dilution of monoclonal antibody against LR-1 antigen in a total volume of 100 pi for 
another 30 min at 4°C. Unbound antibodies were removed by washing the cells 
twice with FACS washing buffer. Afterwards, the cells were stained in dark with 1 
lag FITC-conjugated goat anti-rat IgG antibody or FITC-conjugated mouse anti-rat 
IgM antibody. After 30 min of incubation at 4°C, the mixtures were washed three 
times with FACS washing buffer and fixed with 1% paraformaldehyde (w/v) in 
0.85% saline solution.(Lanier and Warner, 1981). 
Stained cells (1 x 10
4
) were then analyzed for fluorescence intensity using 
the FACSort flow cytometer (Becton Dickinson) equipped with an argon laser and 
set at an excitation wavelength of 488 nm. The instrument was calibrated with 2.5 
|om fluorescent plastic beads (CaliBRITE beads, Becton Dickinson Immunocytometry 
Systems). Data acquisition and data analysis were performed with the Lysys II 
software (Leung et al., 1994). 
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2.2.2.8 In Vitro Assay of rmIL-3-Stimulated Proliferation of Murine Bone 
Marrow Cells 
Murine bone marrow cells were co-cultured with different concentrations of 
K7 antigen and in the presence of appropriately diluted rmIL-3 in 96-well flat-
bottomed microtiter plates at a cell density of 1 x 10
5
 cells/well in a total volume of 
0.2 ml. Microtiter plates were incubated at 37°C in a humidified atmosphere 
containing 5% C02-95% air for 72 hr. The cells were then pulsed with 0.5 |iiCi [
3
H]-
TdR in 20 fol volume for further 18 hr. Cultures were harvested onto Whatman GF/C 
glass microfibre filters. Incorporation of [
3
H]-TdR into cells was determined by a 
Beckman liquid scintillation counter. Results were expressed as the arithmetic mean 
S.I. 土 S.E. of quadruplicate cultures. 
2.2.2.9 In Vitro Cytotoxicity of K7 Capsular Antigen on Bone Marrow 
Cells 
Bone marrow cells (1 x 10
5
/well) were co-cultured with different 
concentrations of K7 antigen and in the presence of appropriately diluted rmIL-3 in 
96-well flat-bottomed microtiter plates in a final volume of 0.2 ml. The cytotoxicity of 
K7 antigen on rmIL-3-stimulated bone marrow cells was determined after 6 hr and 
24 hr incubation by counting the number of dead cells in a total of 600 cells using the 
trypan blue exclusion method. Results were expressed as mean (% of dead cells) 土 
S.E. of triplicate cultures. 
2.2.2.10 Colony Assay of Murine Bone Marrow Cells 
Semi-solid agar cell cultures were set up in the wells of leucocyte 
migration plates (Sterilin, Middlesex, U.K.). Cultures (0.4 ml) containing 0.33% Bacto 
agar (Difco, Detroit, MI), 2 x 10
4
 BALB/c bone marrow cells, RPMI complete 
medium, 20% FCS, and 1% PSF were incubated at 37°C in a humidified atmosphere 
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containing 5% C〇2-95% air. Colonies consisting of more than 50 cells were counted 7 
days after incubation. Results were expressed as mean 土 S.E. of triplicate cultures. 
2.2.2.11 Assay of Differentiation of Murine Bone Marrow Cells 
Murine bone marrow cells (5 x 10
5
/well) were seeded onto a 96-well flat-
bottomed microtiter plate. The cells were treated with rmIL-3 and /o r K7 antigen in 
0.2 ml RPMI complete medium for 3 days at 37°C in a humidified atmosphere 
containing 5% C〇2-95% air. The differentiation-inducing activity of different 
samples was evaluated by morphological staining using the modified Wright 
Giemsa Stain. Briefly, 30 bone marrow cells were centrifuged (500 rpm, 5 min) 
onto microscopic slides using Shandon Cytospin 3 centrifuge (Shandon Scientific 
Ltd.). Cells were then stained with the modified Wright-Giemsa stain (Sigma 
Chemical Co.) for 30 sec. Afterwards, they were destained in Wright's Stain Buffer 
for 2 min, followed by rinsing in a running water bath. The air-dried slides were 
mounted with the neutral mounting medium, Canada Balsam (Beijing Chemical 
Works). Differential counts were performed by counting at least 300 cells. 
Intermediate stage cells (myelocytes and promonocyte-like cells) and mature cells 
with macrophage-like characteristics were counted as differentiated cells. The results 
were expressed as mean 士 S.E. (Mak et al., 1993). 
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2.2.3 Assay for Macrophage Activating Activities of Klebsiella K7 
Capsular Antigen 
2.2.3.1 Preparation of Murine Peritoneal Exudate Cells (PEC) 
BALB/c mice were sacrificed by cervical dislocation. The skin was cleaned 
with 70% ethanol. The skin of the abdomen was cut and pulled apart. Cold HBSS (5 
ml) was injected intraperitoneally (i.p.) using a 5 ml syringe fitted with a 20-gauge 
needle. The peritoneal cavity of mouse was lavaged twice to obtain the PEC The 
cells were washed with cold RPMI plain medium and resuspended with RPMI 
complete medium. 
2.2.3.2 Assay of Phagocytic Activity of Peritoneal Macrophages 
Phagocytic activity of peritoneal macrophages was determined by-
measuring their ability to engulf latex beads. Briefly, resident PEC (8 x 10
5
) were 
added onto a coverslip and allowed to incubate at 37°C. After 3 hr of incubation, the 
coverslip was washed three times with warm medium to remove the non-adherent 
cells. The adherent cells were then incubated with K7 antigen (12.5 & 100 |ig/ml) at 
37°C for 8 hr in a humidified atmosphere containing 5% C02-95% air. The coverslip 
was then washed once with warm medium and incubated with latex beads (2.4 x 
10
7
) in RPMI medium containing 10% HI-FCS for 20 min at 37°C. The coverslip was 
washed at least twice with warm PBS to remove the non-ingested latex beads. The 
percentage of phagocytic cells (i.e. the cells that had engulfed at least three latex 
beads) was determined by counting at least 300 cells under light microscopy and the 
results were expressed as mean 土 S.E. of triplicate cultures. 
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2.2.3.3 In Vitro Macrophage-Mediated Cytostatic Activity 
On day 0, each BALB/c mouse was injected i.p. with freshly prepared 
solution of picolinic acid (PLA, 100 mg /kg of body weight). On day 3, the PEC were 
harvested with cold HBSS. After washing twice with cold RPMI plain medium, the 
cells were resuspended in RPMI complete medium at 3.5 x 10
6
 cells/ml. 0.1 ml PEC 
suspension was added into each well of a flat-bottomed 96-well microliter plate. 
After 6 hr of incubation at 37°C, non-adherent cells were removed by three washes 
with warm RPMI plain medium. The adherent cells were then incubated with 10
4 
MBL-2 cells and 2 ng /m l of LPS in the presence or absence of K7 antigen in a final 
volume of 0.2 ml. After incubating for 48 hr at 37°C in a humidified atmosphere 
containing 5% C02-95% air, the cells in each well were pulsed with 0.5 ^iCi [
3
H]-TdR 
for 6 hr. Cultures were then harvested onto Whatman GF/C glass microfibre filters. 
Incorporation of [
3
H]-TdR into cells was determined by a Beckman liquid 
scintillation counter. Results were expressed as percentage growth suppression of 
MBL-2 cells induced by the activated macrophages as follows: 
pH]-TdR incorporation of MBL-2 
cells in the presence of macrophages 
% Suppression = 1 —
 x
 100 % 
pH]-TdR incorporation of MBL-2 
cells in the absence of macrophages 
2.2.3.4 Nitric Oxide (NO) Production of Peritoneal Macrophages 
NO produced by peritoneal macrophages was determined by assay of 
culture supernatant for nitrite, a stable reaction product of NO with molecular 
oxygen. On day 0, each BALB/c mouse was injected i.p. with 1.5 ml TG broth. On 
day 3, the PEC were harvested with cold HBSS. After washing twice with RPMI 
plain medium, the cells were resuspended in cold RPMI complete medium at 5.5 x 
10
6
 cells/ml. 0.1 ml PEC suspension was added into each well of a flat-bottomed 96-
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well microtiter plate. After 3 hr of incubation at 37°C, non-adherent cells were 
removed by three washes with warm RPMI plain medium. The cells were then 
incubated with different concentrations of K7 antigen in vitro at 37°C. 100 )oI of cell 
free culture supernatant collected 24,48 and 72 hr later was allowed to react with an 
equal volume of Griess reagent (0.5 % sulfanilamide, 0.05 % N-(l-
naphthyl)ethylenediamine dihydrochloride in 2.5 % ftP〇4) in 96 well microtiter 
plates for 15 min at r.t. in the dark. The absorbance of each assay sample was 
measured on a microplate reader (Bio-Rad Model 3550) at 570 nm. Nitrite 
concentrations were determined by comparison with a standard curve prepared 
using NaN〇2. 
2.2.3.5 In Vivo Migration of Macrophages 
The method described by Gervais et al (1984) was adopted. Briefly, BALB/c 
mice pre-treated either with K7 antigen (3 mg/kg , i.p.) or PBS on day -2, were 
injected with 2 ml PP solution on day 0. Three days later, the elicited plastic-
adherent PEC were evaluated as described in detail previously (Mak et al., 1982). 
2.2.3.6 Tumour Necrosis Factor (TNF) Production by Peritoneal 
Macrophages 
On day 0, each BALB/c mouse was injected with 1.5 ml of TG broth. On day 
3, PEC were harvested with cold HBSS. After washing twice with RPMI plain 
medium, the cells were resuspended in cold complete RPMI medium at 3 x 10
6 
cells/ml. 0.1 ml PEC suspension was added into each well of a flat-bottomed 96-well 
microtiter plate. After 3 hr of incubation at 37°C, non-adherent cells were removed 
by three washes with warm RPMI plain medium. The cells were then incubated with 
different concentrations of K7 antigen or 1 jag/ml of LPS in vitro at 37°C. 100 jjI of cell 
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free culture supernatant was collected 24 hr later and TNF activity of the supernatant 
was determined by the TNF bioassay. 
2.2.3.7 TNF Bioassay 
2 x 10
4
 L929 fibroblasts in 100 |il were seeded onto each well of 96-well 
flat-bottomed microtiter plate and incubated at 37°C in a humidified atmosphere 
containing 5% C02-95% air. The supernatant was removed 22 hr later by aspiration. 
L929 fibroblasts were incubated with 50 jil of 4 ng /ml actinomycin D and 50 of 
serially diluted cell free culture supernatant for 18 hr. The cells were then washed 
with PBS, fixed with 5 % formyl saline for 10 min. After fixation, the cells were 
stained with 0.5% (w/v) crystal violet for 15 min at r.t., and washed twice with 
running tap water. Crystal violet dye in cells was then extracted with 100 of 33% 
acetic acid. The TNF activity was expressed as percentage cytotoxicity by measuring 
the absorbance at 540 nm and was calculated as follows: 
(C-S) 
The percentage cytotoxicity = x 100 % 
」 J C 
where S is the absorbance in sample wells containing cell-free supernatant and C is 
the absorbance in control wells containing medium only. The absorbance of target 
cells incubated with medium alone represents 0% lysis whereas the absorbance of 
target cells treated with distilled water represents 100% lysis. 
2.2.3.8 Gene Expression Analysis in Peritoneal Macrophages 
2.2.3.8.1 Preparation of Cell Lysate 
Cell lysates were prepared according to the method of Chirgwin et al. 
(1979) with minor modifications. Briefly, TG-elicited PEC (5 x 10
7
) were incubated in 
75 cm
2
 culture flask. After 3 hr of incubation at 37°C, non-adherent cells were 
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removed by three washes with warm RPMI plain medium. The adherent cells were 
then cultured with 50 j ig/ml K7 antigen at 37°C in 75 cm
2
 culture flask for different 
periods of time (8, 24 and 48 hr). Untreated TG-elicited adherent cells were included 
as a control sample. After different periods of time, the macrophages were washed 
once with warm PBS and then lysed by the direct addition of 4 M guanidine 
thiocyanate solution to the culture flask. The resulting lysates were then stored at 
-70°C until use. 
2.2.3.8.2 RNA Isolation 
The frozen cell lysates were thawed by incubating in a 65°C water bath 
with constant vortexing in order to shear the DNA molecules. The shearing action on 
DNA molecules prevented the formation of impenetrable DNA mat that would 
otherwise block the sedimentation of the RNA molecules, which thereby facilitating 
the purification of RNA. The thawed cell lysates were then chilled on ice 
immediately after 5 min of incubation at 65°C. Each cell lysate sample was then 
layered onto a sterile, DEPC-treated polyallomer ultra-centrifuge tube (Beckman 
Instruments Inc.) filled one-quarter with a cushion of 5.7 M cesium chloride 
(Pharmacia Fine Chemicals) and centrifuged with the Beckman J-21 ultra-centrifuge 
(Beckman Instruments Inc.) fitted with SW65Ti rotor at 35,000 rpm for 18 hr at 18。C. 
The overlaying solution was then removed by aspiration, and the 
polyallomer tube was inverted quickly and drained for 15 min. The tube was 
aspirated dry whilst still inverted and 0.5 cm from the bottom of tube containing the 
clear RNA pellet was cut off with a sterile scalpel blade. The RNA pellet was rinsed 
out to a new Eppendorf tube with a total volume of 400 jLil of sterile and DEPC 
treated water, and was vortexed for a few min to ensure complete dissolution. The 
RNA molecules were then precipitated after the addition of 1 ml absolute ethanol 
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and 45 jlJ of 3 M sodium acetate by centrifuging at 20,000 x g for 30 min at r.t.. 
Afterwards, the pellet was washed thoroughly with 70% ethanol and then with 
absolute ethanol to remove any residual salts and was vacuum-dried. The resulting 
pellet was resuspended in 50 [A DEPC-treated water and stored at -70°C before use. 
Meanwhile, the concentration of RNA was estimated by measuring the absorbance 
at 260 nm with an extinction coefficient (1 cm path length) of 250. One unit of 〇.D. 
corresponds to approximately 40 p.g/ml for single stranded RNA. The absorbance at 
280 nm was also measured to estimate the purity of each RNA sample (Maniatis et 
al, 1982). 
2.2.3.8.3 Reverse Transcription of RNA 
Each sample of total cellular RNA was incubated at 65°C for 5 min before 
being used in the synthesis of cDNA. The reaction was initiated by the addition of a 
mixture containing 40 units of rRNasin ribonuclease inhibitor, 10 mM dithiothreitol 
(GIBCO BRL), 0.5 mM of each dNTP, 0.1 ^tg oligo-dTms, l x first strand buffer and 
200 units of M-MLV reverse transcriptase to 1 |ag total cellular RNA. The reaction 
was allowed to proceed for 1 hr at 37。C and was terminated by chilling on ice. The 
resulting cDNA samples were then stored at -20°C until use (Fung et al, 1992). 
2.2.3.8.4 Polymerase Chain Reaction (PCR) 
The cDNA prepared by reverse transcription was first boiled for 5 min 
followed by immediate ice chilling. 60 \d reaction mixture containing the pre-boiled 
cDNA sample (0.1 jig), 0.2 mM of each dNTP, 1 pmole/ | i l of each oligonucleotide 
primer, 1.5 mM MgCl2 (Advanced Biotechnologies Ltd.), l x reaction buffer IV and 
0.6 unit of Thermoprime
 p l u s
 DNA polymerase was overlaid with mineral oil (Sigma 
Chemical Co.). 
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The reaction mixture was then subjected to defined rounds of temperature 
cycling, using the MJ Research temperature cycler. Normally, an initial denaturation 
for 5 min at 94°C was included in the first cycle. In every cycle of amplification, 
denaturation and extension were performed for 1 min at 94°C and 72°C respectively 
(Fung et al" 1992). The annealing temperature and the number of PCR cycles were 
optimized empirically for each primer set (Table 2.2) (Williams, 1989). The amplified 
PCR products were then stored at -20°C until use. 
The amount of RNA used in PCR amplification was normalized by 
comparison with the amplification of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA. Moreover, the absence of contaminants was regularly checked by 
the co-amplification of a negative control reaction tube containing no cDNA 
template. All analyses were performed at least twice independently (Mak et al., 
1993). 
Table 2.2: Summary of Cycling Profiles Used in RT-PCR Study 
Gene Annealing Temperature (°C) Number of Cycles 
GAPDH 52 2Q 
~~TNF-a 56 25,27,30 
IL-la 25~ 
~~IWLp 54 20,25 
_ — — — 
~ T G F - p 76 20,25,30 —— 
iNOS 54 20,25,30 
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2.2.3.8.5 Agarose Gel Electrophoresis 
Prior to the loading of samples, the resulting PCR products were allowed 
to return to r.t.. Afterwards, 20 of the PCR product was loaded together with lx 
gel loading solution and was subject to electrophoresis in l x TBE electrophoresis 
buffer on a 2% agarose gel (Sigma Chemical Co.) at a constant voltage of 5 volts/cm 
for 3-4 hr (Sealey and Southern, 1990). 1.5 |Lig 1 kb DNA ladder (GIBCO BRL) was 
loaded as size marker. After the electrophoresis run was completed, the agarose gel 
was stained with lx TBE electrophoresis buffer containing 0.5 mg /m l ethidium 
bromide (Sigma Chemical Co.) for 25 min on a shaking platform. The stained 
agarose gel was then destained in double distilled water for at least 30 min to reduce 
the background staining. It was visualized under short-wavelength ultraviolet 
illumination and photographed with a red filter to eliminate any red emission from 
the ultra-violet illuminator using the Polaroid Type 667 instant pack film (Ogden 
and Adams, 1987). 
2.2.3.8.6 y End Labelling of Oligonucleotide Probes 
Oligonucleotide probes were end-labelled with DIG-ll-ddUTP using the 
DIG oligonucleotide 3。end labelling kit according to the standard protocol described 
by the manufacturer (Boehringer Mannheim). Briefly, a 20 pi reaction mixture 
containing lx reaction buffer, 5 mM CoCl2 /100 pmoles oligonucleotide probe, 50 jaM 
DIG-ll-ddUTP and 50 units terminal transferase was incubated at 37°C for 15 min 
and then chilled on ice. The reaction was terminated by the addition of 2 jxl glycogen 
solution (0.1 }ig/|il in 0.2 mM EDTA, pH 8.0). The labelled oligonucleotide was then 
precipitated at -20°C for 2 hr with the addition of 2.5 (il 4 M lithium chloride (Sigma 
Chemical Co.) and 75 jal absolute ethanol pre-chilled at -20°C. After centrifugation, 
the pellet was washed with 70% cold ethanol and vacuum-dried with the Savant 
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SC110 Speed-Vac®. The resulting pellet was resuspended in 50 i^l double distilled 
water and stored at -20°C for future use (Van Miltenburg, 1995). 
2.2.3.8.7 Dot Blot Hybridization 
The resulting PCR products (15 pi), except those for GAPDH and TGF-P 
gene, were allowed to return to r.t. and then immobilized on positively charged 
nylon membrane (Boehringer Mannheim) using the Bio-Dot® Microfiltration 
Apparatus (Bio-Rad Laboratories). The PCR products were first denatured in a total 
volume of 200 jul of 0.2 M NaOH for 15 min at r.t. before they were applied to the 
pre-wetted nylon membrane. Afterwards, the membrane was neutralized by-
washing twice with 20x SSC. The blotted membrane was then baked at 120°C for 30 
min to crosslink the DNA and stored at r.t. until use (Anderson and Young, 1985). 
All solution used for hybridization were pre-warmed to the specified hybridization 
temperature (56°C for all samples) before use. After 4 hr of pre-hybridization with 
the hybridization buffer at the anticipated hybridization temperature, the membrane 
was then hybridized with the labelled, probe by incubating with the hybridization 
buffer containing 4 pmoles/ml DIG-labelled oligonucleotide probe for 16 hr under 
identical conditions. Afterwards, a stringent wash was performed at the same 
temperature with 2x SSC and 0.1% (w/v) SDS (Sigma Chemical Co.) for 5 min, 
followed by another 5 min washed with 0.5x SSC and 0.1% (w/v) SDS. The blot was 
then used immediately for immunological chemiluminescent detection with CSPD® 
(Holtke^aZ., 1992). 
2.2.3.8.8 DIG Chemiluminescent Detection 
DIG-labelled hybrids were detected with CSPD® using the DIG 
luminescent detection kit. Except specified, the detection process was performed at 
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r.t. with continuous shaking. After hybridization and stringency washes, the 
membrane was rinsed for 5 min with maleic acid buffer containing 0.3% (v/v) 
Tween® 20 (Bio-Rad Laboratories). Non-specific binding sites were blocked with the 
blocking reagent (1% in maleic acid buffer, w / v ) for 30 min. The blocked membrane 
was then incubated with 0.075 units /ml anti-DIG-AP conjugate (freshly diluted with 
1% (w/v) blocking reagent in maleic acid buffer) for 30 min. Unbound antibodies 
were removed by washing the membrane twice, 5 min per wash, with maleic acid 
buffer containing 0.3% (v/v) Tween® 20. 
Afterwards, the membrane was equilibrated with the detection buffer for 5 
min and then incubated with freshly prepared CSPD® substrate solution (diluted 100 
folds with detection buffer) for 5 min. The wet membrane was wrapped in Sarawrap 
and luminescent reaction was enhanced by incubating it at 37°C for 15 min. The 
resulting chemiluminescence was recorded by exposing the blots for 5 min at r.t. to 
Kodak BioMax™ MR X-ray film (Kodak Scientific Imaging Film) (Van Miltenburg, 
1995). Exposed film was then developed using Kodak M35 X-OMAT Processor 
(Kodak Scientific Imaging Film). The X-ray film was analyzed for the hybridization 
signal using the Personal Densitometer SI™ (Molecular Dynamics). Both the data 
acquisition and data analysis were performed with the ImageQuaNT™ software 
(Molecular Dynamics). 
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2.2.4 Assay for Anti-Tumour Activities of Klebsiella K7 Capsular Antigen 
2.2.4.1 Assay of Tumour Cell Proliferation 
The proliferative response of various cultured tumour cell lines was 
measured by [
3
H]-TdR incorporation. Briefly, tumour cells were incubated in 200 [il 
RPMI complete medium containing appropriately diluted K7 antigen in the wells of 
96-well flat-bottomed microtiter plates at 37°C for 48 or 72 hr in a humidified 
atmosphere containing 5% C〇2-95% air. The cells were then pulsed with 0.5 |LiCi of 
[
3
H]-TdR in 20 jj! RPMI complete medium for 6 hr. Afterwards, they were harvested 
onto Whatman GF/C glass microfibre filter. Radioactivity in cpm was measured 
using the Beckman LS1801 liquid scintillation counter. Quadruplicate results were 
expressed as percentage of inhibition of [
3
H]-TdR incorporation, using untreated 
tumour cells as a control (Leung et al., 1994). 
2.2.4.2 Assay of Anti-Tumour Activity In Vivo 
To study the effect of K7 antigen on the growth of EAT carcinoma in vivo, 
BALB/c mice in groups of five were injected i.p. with 10
5
 EAT cells on day 0. K7 
antigen (25 j ig/mouse/day) was then injected i.p. for 4 consecutive days (days 5 - 8 ) 
whereas control mice were injected with an equal volume of PBS. On day 9, EAT 
cells in the peritoneal cavity of each mouse were harvested by exhaustive drainage. 
Cells recovered were counted with a hemocytometer by the trypan blue exclusion 
method (Philip, 1973). 
2.2.4.3 Assay of Lymphocyte-Activated Killer Cell Activity 
(a) Preparation of Effector cells 
BALB/c mice in group of four were injected i.p. with K7 antigen (50 
jxg/mouse/day) or PBS for 7 consecutive days (day 1 - day 7). On day 8, the 
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splenocytes were prepared and cultured with (1) medium only; (2) rmIL-2 (50 
U/ml); or (3) K7 antigen (50 | ig/ml) for 3 days at 37°C in a humidified atmosphere 
containing 5% C〇2-95% air. Viable splenocytes, designated as effector cells, were 
obtained by FicoU-isopaque gradient centrifugation (1300 x g, 20 min) of the cultured 
cells. 
(b) Determination of LAK Cell Activity 
The LAK cell activity was determined by measuring the cell-mediated 
cytotoxicity of effector cells on LAK-sensitive target cells using a modification of the 
colorimetric assay (Mxillbacher et al, 1984). 100 jil of WEHI-164 cells (3 x 10^), 
designated as target cells, was seeded onto each well of 96-well flat-bottomed 
microtiter plates and incubated at 37°C overnight. Different effector cells (7.5 x 10
5
) 
in 100 jul volume were then added to the target cells in each well so that the effector 
cells/target cells ratio was 25 :1. After 24 hr incubation at 37°C, the LAK cell activity 
was estimated by neutral red uptake method. Briefly, the cell mixture was washed 
once gently with warm PBS. 50 ]ul of 0.5% (w/v) neutral red solution in normal 
saline was added to each well and the mixtures were incubated at 37°C for 30 min. 
The plate then was washed twice with warm PBS and dried completely in a 60°C -
70°C oven. Finally, the neutral red was extracted by adding 100 |il of 1% SDS to each 
well with continuous shaking in a microtiter plate shaker (Flow Lab., U.K.) for 15 
min. The absorbance in each well was measured at 540 nm using a Bio-Rad 
microtiter plate reader. The results were expressed as the percentage cytotoxicity on 
WEHI-164 cells which was calculated as follows: 
C - T 
Percentage cytotoxicity on WEHI-164 cells = x 100 % 
C 
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where C is the absorbance in control wells containing medium only and T is the 
absorbance in wells containing effector cells. The absorbance of target cells incubated 
with medium alone represents 0% lysis whereas the absorbance of target and cells 
treated with concentrated NaOH represents 100% lysis. 
2.2.4.4 Assay of Natural Killer Cell Activity 
NK activity was measured by the
 51
Cr release method as described 
previously (Leung and Ada, 1981). Briefly, 5 x 10
6
 YAC-1 cells were labelled with 500 
l i d Na
51
Cr〇4 (specific activity = 250 - 500 mCi/mg, Amersham International) for 1 
hr at 37°C with occasional gentle shaking. The cells were then washed twice with 
M 
RPMI plain medium and adjusted to a cell concentration of 2 x 10
5
 cells/ml in RPMI 
I 
medium supplemented with 10% HI-FCS. Different concentrations of effector cells in 
I 
RPMI medium supplemented with 10% HI-FCS (100 )^ 1) were added onto 96-well 丨 
flat-bottomed microtiter plate and cultured with 2 x 10
4
 siCr-labelled YAC-1 target 
I 
cells/well in total volume of 200 \xl so that the effector cells / target cells ratios were 
50 : 1 and 100 :1. After 6 hr of incubation at 37°C, 100 of supernatant was removed 
and counted for radioactivity in a gamma counter (Pharmacia). The spontaneous 
release count was measured as the radioactivity released from labelled target cells 
incubated with the medium alone and the maximum release count was measured 
after treating the labelled target cells with 100 pi of 10% Triton-X 100 detergent. The 
percentage specific cytolysis was calculated as follows: 
T - S 
Percentage specific cytolysis = x 100% 
‘ M - S 
where T is the test sample count, M is the maximum release count and S is the 
spontaneous release count. 
Materials & Methods Page 8*7 
2.2.4.5 Assays for Differentiation-Associated Characteristics of Myeloid 
Leukemia Cells 
2.2.4.5.1 Determination of the Viability of Myeloid Leukemia JCS Cells 
JCS cells (5 x 10
5
/well) were incubated with different concentrations of K7 
antigen in 96-well flat-bottomed microtiter plates in a final volume of 0.2 ml. The 
cytotoxicity of K7 antigen on JCS cells was determined after 8 hr and 24 hr of 
incubation by counting the number of dead cells in 100 cells using the trypan blue 
exclusion method (Philip, 1973). Results were expressed as arithmetic mean 土 S.E. of 
triplicate cultures. 
2.2.4.5.2 Assessment of Cell Morphology 
Morphological changes were examined on cytocentrifuge preparations. K7 
antigen-treated JCS cells (5 x 10
4
) were fixed on a microscopic slide by 
cytocentrifugation at 500 rpm. for 5 min. The slide was then stained with modified 
Wright-Giemsa Stain for 30 sec, destained with Wright's stain buffer for 2 min and 
then rinsed with running tap water. The air-dried slides were mounted with the 
neutral mounting medium, Canada Balsam (Beijing Chemical Works). Differential 
counts, were performed and cells were scored as blast cells (myeloblasts and 
promyelocytes), intermediate stage (myelocytes and promonocyte-like cells) or 
mature cells (macrophage-like cells). At least 300 cells were scored on each slide and 
the results were expressed as mean 土 S.E. (Mak et al., 1993). 
2.2.4.5.3 Surface Antigen Immunophenotyping 
Cells harvested from 25 cm
2
 culture flasks were washed with FACS 
washing buffer (PBS containing 2% HI-FCS and 0.05% sodium azide) in order to 
inhibit the internalization of membrane components or antigen-antibody complexes. 
In order to alleviate the problem of non-specific binding through Fc receptors, the 
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cells (2 x 10
5
) were first incubated with mouse IgG and rat IgG blocking antibodies 
(10 | ig/ml) at 4°C for 30 min. They were then washed once with FACS washing 
buffer and incubated with 50 \xl of hybridoma-derived antibody in a total volume of 
100 jul for another 30 min at 4°C. Unbound antibodies were removed by washing the 
cells twice with FACS washing buffer. Afterwards, the cells were stained in dark 
with 1 jig FITC-conjugated goat anti-rat IgG antibody. After 30 min of incubation at 
40Q the mixtures were washed three times with FACS washing buffer and fixed 
with 1% paraformaldehyde (w/v) in 0.85% saline solution (Lanier and Warner, 
1981). 
Stained cells (1 x 10
4
) were then analyzed for fluorescence intensity using 
the FACSort flow cytometer. Data acquisition and data analysis were performed 
with the Lysys II software (Leung et al., 1994). 
2.2.4.5.4 Assay of Non-specific Esterase Activity 
Non-specific esterase activity was determined by the hydrolysis of 
fluorescein diacetate (FDA) (Stock solution : 20 mg /m l in DMSO, Sigma Chemical 
Co.). Hydrolysis of FDA causes the formation of a highly fluorescent product, 
fluorescein, which was then entrapped inside the cells. Enzymatic activity was then 
estimated by analyzing the fluorescence intensity of fluorescein using flow 
cytometry (Darzynkiewicz et al., 1994). 
Myeloid leukemia JCS cells (2父 105) in RPMI medium containing 10% HI-
FCS were incubated in dark for 30 min at r.t. with 20 |J.g/ml FDA. The cells were 
then washed three times with FACS washing buffer and fixed with 1% 
paraformaldehyde. Fixed cells (1 x 10
4
) were then analyzed for fluorescence intensity 
using the FACSort flow cytometer. 
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2.2.4.5.5 Assay of Phagocytosis 
Phagocytic activity was determined by the engulfment of latex beads. 
Briefly, latex beads (1 x 10
7
) were incubated with JCS cells (1 x 10
5
) in RPMI medium 
containing 20% HI-FCS. After 8 hr of incubation at 37°C, cells were harvested and 
washed once with plain RPMI medium. The percentage phagocytic cells (i.e. the cells 
that had engulfed at least three latex beads) was determined by counting at least 300 
cells under light microscopy and the results were expressed as mean 士 S.E. of 
triplicate cultures. 
2.2.5 Statistical Analysis 
Each experiment was performed at least twice and one representative 
experiment was presented. The results were expressed as mean 土 S.E.. Statistical 
analysis was performed using Student's t-test with a confidence interval set at 95% 
for group comparisons. Normally p<0.05 was regarded as significantly different. 
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CHAPTER 3 
EXTRACTION, PURIFICATION & 




In recent years, there has been an increasing interest in the search for novel 
and more effective naturally-occurring compounds with immunomodulatory and 
anti-tumour activities. A review of literature has shown that bioactive 
polysaccharides with immunomodulatory and anti-tumour activities can be isolated 
from a number of Chinese medicinal plants (Shen et al, 1991; Choy et al.f 1994; Wong 
et al.t 1994a & Lee et al, 1997), fungi (Gao and Yang, 1991) or bacteria (Wang et al" 
1995). Previous work from our laboratory has shown that polysaccharide fractions 
isolated from Pseudostellaria heterophylla and containing high uronic acid contents 
possess significant immunomodulatory and anti-tumour activities (Wong et al" 
1994b & Wong et al, 1994d). Interestingly, Sakagami et al (1987) had also reported 
that the in vivo anti-tumour activity of acidic polysaccharide fractions extracted from 
pine cones depends upon their acidity, and the uronic acid residues in the 
polysaccharides were suggested to be an essential determinant of their anti-tumour 
activity. More recently, Lee et al (1997) showed that an acidic polysaccharide 
(ginsan) purified from Panax ginseng could activate multiple effector arms of the 
immune system and exhibited potent anti-tumour activity in vivo. Although many 
bioactive polysaccharides isolated from plants or fungi are good candidates as anti-
neoplastic agents and/or immunopotentiators, the extraction and purification 
procedures for these polysaccharides are rather complicated and tedious because 
these polysaccharides are always heterogeneous in structure. Therefore, the search 
for other sources of bioactive polysaccharides with more simple extraction 
procedures is highly desirable. 
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The bacterial capsular polysaccharides are known to be the conserved and 
most exposed bacterial surface antigens. They have become potential vaccine 
candidates as they are relatively non-toxic, can be easily isolated and purified, and 
can elicit protective immunity against encapsulated bacteria (Lee, 1996). Previous 
work had shown that the structures of the Klebsiella capsular polysaccharide antigens 
are homogeneous in nature (Cryz et al., 1985). Among the various Klebsiella strains, 
the K7-encapsulated isolate was found to be significantly less toxic to experimental 
animals (Podschun and Ullmann, 1992) and the procedures for the extraction of 
capsular antigen from Klebsiella pneumoniae are relatively simple and well-
established (Choy and Dutton, 1973 & Dutton et al, 1974). In addition, K7 antigen 
was reported to contain a high content of glucuronic acid (Dutton et al., 1974). Thus, 
K7 antigen appears to be a good prototype for the studies of the immunomodulatory 
and anti-tumour activities of bacterial capsular polysaccharides. In this chapter, the 
K7 antigen was extracted and purified from the culture of Klebsiella pneumoniae 
serotype 7. It was then characterized for its biochemical components and attempt 
was made to determine its bio-toxicity and cellular toxicity using the brine shrimp 
assay and the trypan blue dye exclusion test respectively. 
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3 .2 R E S U L T S 
3.2.1 Extraction and Purification of K7 Capsular Antigen from Klebsiella 
pneumoniae Serotype 7 
Klebsiella pneumoniae serotype 7 was grown for 2 days at 37°C, the bacteria 
were harvested and killed with 1% phenol in normal saline. The crude extract 
containing K7 capsular polysaccharide was obtained by ultracentrifugation, in which 
the cell-free supernatant was dialysed in double-distilled water and then 
lyophilized. K7 antigen was then purified from the crude polysaccharide fraction by 
coprecipitation with a quaternary ammonium salt (Cetavlon) and followed by 
alcohol precipitation. The yield of purified K7 antigen from the crude polysaccharide 
fraction was found to be 〜29%. 
3.2.2 Gel Filtration Chromatography of K7 Capsular Antigen 
Since the immunogenicity of bacterial capsular antigens was found to be 
dependent upon their molecular weight (Gotschlich et al., 1972 & Wong et al., 1977), 
therefore, the molecular weight of K7 antigen was estimated by gel filtration 
chromatography on a Sepharose CL-2B column. As shown in Fig. 3.1, the purified K7 
antigen was eluted as a single peak near the void volume which was determined by 
gel filtration of dextran (average molecular weight = 5 - 40 x 10
6
) over the same 
column (Fig. 3.2). Thus, the estimated molecular weight of K7 antigen was found to 
be slightly less than 5 x 10
6
. 
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Figure 3.1: Gel filtration of K7 capsular antigen. K7 antigen (1.2 mg) was 
dissolved in 3 ml of 0.15 M NaCl solution and applied onto a Sepharose CL-2B 
colum (2.6 x 57 cm). Fractions were eluted with 0.15 M NaCl solution. Elution was 
carried out at a flow rate of 17.6 ml/hr , and 4.4 ml fractions were collected. The 
eluate in each fraction was monitored for carbohydrate content by the phenol 
sulphuric acid method (O.D. 490). K7 antigen was eluted at 114 ml. 
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Figure 3.2: Gel filtration of dextran for determination of void volume. 
Dextran (2.5 mg) with average M.W. of 5 - 40 x 10
6
 was dissolved in 1 ml of 0.15 M 
NaCl solution and applied onto a Sepharose CL-2B column (2.6 x 57 cm). Fractions 
were eluted with 0.15 M NaCl solution. Elution was carried out at a flow rate of 16 
ml /hr , and 4 ml fractions were collected. The eluate in each fraction was monitored 
for carbohydrate content by the phenol sulphuric acid method (O.D. 490). Dextran 
was eluted at 108 ml (i.e. void volume). 
Extraction, Purification <& Characterization of K7 Antigen Page 96 
3.2.3 Characterization of K7 Capsular Antigen 
The carbohydrate, protein, uronic acid and nucleic acid contents of K7 
antigen were determined and shown in Table 3.1. K7 antigen was found to contain 
mainly carbohydrate (83%) of which 16% (w/w) is uronic acid. Only trace amounts 
of protein (0.2%) and nucleic acid (0.7%) were detectable in K7 antigen. 
3.2.4 Determination of Bio-toxicity and Cellular Toxicity of K7 Capsular 
Antigen 
The brine shrimp assay is commonly used for assessing the bio-toxicity of 
natural products or drugs in vivo (Anderson et al., 1991). As shown in Table 3.2, K7 
antigen was found to be non-toxic, since the LCso of K7 antigen was greater than 
1000 j ig/ml as determined in vivo by the brine shrimp assay. As a positive control, 
hippuric acid was found to have a LCso value of 〜310 ^ig/ml (Table 3.2). 
On the other hand, the trypan blue dye exclusion assay is commonly used for 
evaluating the cytotoxicity of test compounds in vitro (Philip, 1973). The results in 
Table 3.3 show that K7 antigen did not exhibit any significant cytotoxicity to murine 
lymphocytes in vitro. . 
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Table 3.1: Composition of K7 Capsular Antigen 
Components dry weight (%) 
Carbohydrate 82.9 ±0.09 
Protein 0.2 士 0.02 
Uronic acid 15.5 士 1.21 
Nucleic acid 0.7 ±0.02 
Bovine serum albumin (BSA), dextran T500 (M.W. 519,000) and D-
glucurono-6,3-lactone were used as standards for the assays of 
protein, carbohydrate and uronic acid, respectively. Carbohydrate 
content was determined by phenol sulphuric acid method. 
Protein and uronic acid contents were determined by Bradford 
method and carbazole reaction respectively. Nucleic acid content 
was quantitated by determining the absorbance of K7 antigen 
solution (1 mg /m l in water) at 260 nm in a 1 cm cuvette. Results 
were expressed as mean 土 S.E. of triplicate determinations. 
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Table 3.2: Determination of the Toxicity (LCso) of K7 
Capsular Antigen by Brine Shrimp Assay 
LC50 (iig/rnl) 
Hippuric acid 310 
K7 antigen > 1000* 
K7 antigen at 1000, 100 and 10 |ng/ml were mixed with the 
brine shr imps (Artemia salina LEACH). The number of 
shrimps being killed was counted two days later and the 
toxicity (LC50) was determined. Hippuric acid was used as a 
positive control. LC50 is defined as the concentration of sample 
(jig/ml) which causes 50% of the total shrimps death in the 
brine medium. 
* LC50 value greater than 1000 fig/ml indicates that the tested 
sample has no toxic effect 
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Table 3.3: In Vitro Cytotoxicity of K7 Capsular Antigen on 
Splenocytes 
Incubation time* K7 antigen % of cytotoxicityt 
()j.^/ml) mean 士 S.E.t 
6 hr Nil 4.26 ± 0.4 
12.5 6.05 土 0.1 
25 7.31 土 0.5 
50 6.00 土 0.4 
100 6.40 士 0.2 
150 5.86 士 0.4 
24 hr Nil 44.16 士 3.4 
1 2 . 5 1 8 . 7 0 士 1 . 6 
2 5 2 3 . 9 3 土 1 . 2 
50 19.75 土 1.0 
1 0 0 1 7 . 3 1 土 0 . 6 
1 5 0 1 8 . 6 9 土 1 . 1 
• Splenocytes were co-incubated with different concentrations of K7 
antigen for 6 or 24 hr at 37°C. 
t Number of dead cells / 200 cells counted in a hemacytometer by 
the trypan blue exclusion method. 
t Results were expressed as arithmetic mean 士 S.E. of triplicate 
- cultures. 
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3 . 3 D I S C U S S I O N 
In the present study, it was found that the purification method used gives a 
good yield (29%) of purified K7 antigen from the crude polysaccharide fraction. The 
method of purification of K7 antigen, which as a first step uses the cationic 
detergent, Cetavlon, to precipitate the acidic macromolecules from the crude 
polysaccharide fraction, reliably yields highly purified polysaccharide preparation. 
Previously, Gotschlich et al. (1969) had suggested that Cetavlon precipitation was 
more preferable than that of rotatory evaporation for the preparation of group A & C 
polysaccharide antigens from Neisseria meningitides, in that the former method could 
prevent the enzymatic depolymerization of polysaccharide antigens. Thus, the 
method of Cetavlon precipitation provides a faster and safer way to purify acidic 
Klebsiella capsular antigen from the crude polysaccharide fraction. 
Although a single and symmetrical peak was obtained from the elution 
profile of K7 antigen using gel filtration chromatography on Sepharose CL-2B 
column, it is difficult to ascertain that K7 antigen is homogeneous in nature, as K7 
antigen was eluted near the void volume. Our results indicate that K7 antigen is a 




In addition, the K7 antigen was found to compose mainly of carbohydrate 
83%), with very small amounts of protein and nucleic acid. The carbohydrate content 
of K7 antigen determined in the present study was in agreement with that of K7 
antigen (〜87% carbohydrate) prepared by Cryz et al (1985) using similar methods. 
Moreover, K7 antigen contains significant amount (〜16%) of uronic acid and this 
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may contribute to the acidity of K7 antigen. Besides, K7 antigen was found to be 
non-cytotoxic to murine lymphocytes in vitro and non-toxic in nature. Collectively, 
our results demonstrated that K7 antigen is a uronic acid-containing high molecular 
weight polysaccharide antigen which is relatively non-toxic in vitro and in vivo. Since 
K7 antigen is readily available in large quantity using simple extraction and 
purification procedures, and in view of the earlier findings that acidic or uronic acid-
containing polysaccharides exhibit potent immunomodulatory and anti-tumour 
activities (Sakagami et al, 1987; Wong et al, 1994b; 1994d & Lee et al" 1997), 
therefore, the purified Klebsiella K7 capsular antigen represents a good candidate for 
the systematic studies of the hematopoietic, immunomodulatory and anti-tumour 
activities of the bacterial polysaccharides, and the results will be reported in 
subsequent chapters (Chapter 4-6) . 
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CHAPTER 4 
HEMATOPOIETIC & MITOGENIC ACTIVITIES 
OF KLEBSIELLA K7 CAPSULAR 
ANTIGEN 
4 .1 INTRODUCTION 
Hematopoiesis is a complex and well-controlled process that generates many 
types of blood cells from a pool of pluripotent stem cells in the bone marrow in order 
to meet the changing need of our body (Alberts et al., 1994). The proliferation and 
differentiation of hematopoietic progenitor cells and the function of mature blood 
cells are regulated by a number of hematopoietic growth factors, including colony-
stimulating factors (CSFs), IL-3, IL-4, IL-5 and IL-6 (Heyworth et al, 1990), which act 
in an autocrine or paracrine maimer on the target cells. T lymphocytes, monocytes, 
macrophages, endothelial cells and stromal cells are the major cell sources for the 
production of these growth factors. 
In addition to the hematopoietic growth factors, polysaccharides isolated 
from different natural sources, such as yeast (Patchen and Lotzov焱，1980), fungi 
(Hashimoto et al" 1990) and higher plants (Ma and Xie, 1983; Wong et al, 1994c & 
Egger et al., 1996), were reported to be capable of modulating the hematopoietic 
response of murine bone marrow cells. However, there are very few studies on the 
effects of bacterial polysaccharides on the proliferation and differentiation of murine 
bone marrow cells. Since hematopoiesis is important for the generation of immune 
cells like macrophages, granulocytes and lymphocytes; therefore, in the first part of 
this chapter, the ability of Klebsiella K7 capsular antigen to induce the proliferation 
and differentiation of pluripotent hematopoietic stem cells in vitro was examined. In 
addition, the modulatory effect of K7 antigen on the rmIL-3-induced proliferation 
and colony formation of murine bone marrow cells was also investigated. 
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Besides modulating the hematopoietic response, polysaccharides isolated 
from various natural sources had been reported to possess mitogenic activity on 
lymphocytes. These polysaccharides were derived from slime mould (Yamada et al., 
1978), yeast (Domer et al.f 1988), brown seaweed (Sugawara and Ishizaka, 1982), 
bacteria (Nakashima and Kato, 1974; Daley et al., 1985; Lucas and Asser, 1986 & 
Millet et al" 1987). Generally, polysaccharides are considered to be TI antigens which 
usually refer to antigens that can induce the humoral responses without an absolute 
need for stimulation of T cells (Bondada and Garg, 1994). Although the majority of 
the current immunological literature is focused on immune responses to thymus-
dependent (TD) antigens, the study of TI antigens is also very important because 
antibody responses to TI antigens are a major protective mechanism in the host 
defence against many common bacterial infections (Austrian, 1985). For example, 
antibody to the capsular polysaccharides plays a major role in protection against 
pathogens such as Streptococcus pneumoniae (Lee and Wang, 1994), Neisseria 
meningitidus (Lee, 1996), Haemophilus influenza Type b (Black et al., 1991) and 
Klebsiella pneumoniae (Cryz, 1990). 
Previous work showed that CPS-K could non-specifically stimulate 
immunoglobulin synthesis in vivo (Nakashima and Kato, 1974) and in vitro 
(Nakashima et al" 1976). Moreover, CPS-K also enhanced the in vivo 
immunoglobulin synthesis induced by BSA (Nakashima and Kato, 1975). Although 
there have been many studies on the vaccine potential of Klebsiella capsular 
polysaccharide (Cryz, et al" 1985 & Cryz, 1990), nevertheless, the modulatory effect 
of Klebsiella capsular polysaccharide on lymphocytes have not yet been thoroughly 
investigated. Therefore, in the second part of this chapter, the in vivo and in vitro 
mitogenic and co-mitogenic activities of Klebsiella K7 capsular antigen on splenocytes 
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and thymocytes were examined. Attempts were also made to characterize the 
lymphocyte population(s) responding to K7 antigen. 
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4.2.2 Effect of K7 Capsular Antigen on rmIL-3-Stimulated Proliferation of 
Murine Bone Marrow Cells 
彻 P- l i fera t ion of murine bone marrow ceUs was maintained by a group of 
hematopoietic growth factors, such as IL-3 and CSFs. Therefore, the effect of K7 
antigen on rmIL-3-induced proliferative response of murine bone marrow cells was 
- i n v e s t i g a t e d . 彻 results in Fig. 4.3 show that K7 antigen m a r k e d l y _ _ ^ 
proliferation of m u r i n e bone marrow cells stimulated by an op t ica l concentration 
( 5 0 Q U / m l ) O f 通 - 3 . 计 was found that the inh ib i to r effect of K7 antigen on 
rmIL-3-stixnulated bone marrow cells could not be attributed to the direct 
cytotoxicity of K7 antigen on rmIL-3-stixnulated bone marrow ceHs as K7 antigen 
exhibited vexy Httle (< 5%), if any, cytotoxicity on rmlL^ t r ea t ed bone marrow ceHs, 
even up to a concentration of 100 ^g /ml (Table 4.1). 
^ m — I 
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Figure 4.1: Effect of recombinant murine interleukin-3 on the proliferation 
of bone marrow cells. Murine bone marrow cells (1 x 10
5
 cells/well) were co-
cultured in the presence or absence of rmIL-3 in a total volume of 0.2 ml. The 
cultures were incubated at 37°C in a humidified atmosphere containing 5% C〇2-95% 
air for 72 hr, and then pulsed with pH]-TdR (0.5 |nCi/20 )al/well) for another 18 hr 
before harvest. Radioactivity incorporated in cpm was measured using liquid 
scintillation counting. Results were expressed as mean S.I. 士 S.E. of quadruplicate 
cultures. The basal proliferative activity ([
3
H]-TdR incorporation) of the control 
culture was 564 土 4 cpm. 
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Figure 4.2: Effect of K7 capsular antigen on the proliferation of bone 
marrow cells. Murine bone marrow cells (1 x 10
5
 cells/well) were co-cultured in the 
presence or absence of K7 antigen in a total volume of 0.2 ml. The cultures were 
incubated at 37°C in a humidified atmosphere containing 5% C〇2-95% air for 72 hr, 
and then pulsed with [
3
H]-TdR (0.5 p.Ci/20 ^1/well) for another 18 hr before harvest. 
Radioactivity incorporated in cpm was measured using liquid scintillation counting. 
Results were expressed as mean S.I. 土 S.E. of quadruplicate cultures. The basal 
proliferative activity ([
3
H]-TdR incorporation) of the control culture was 328 土 10 
cpm. 
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Figure 4.3: Effect of K7 capsular antigen on the proliferation of bone 
marrow cells stimulated with recombinant murine interleukin-3 in vitro. Murine 
bone marrow cells (1 x 10
5
 cells/well) were co-cultured with rmIL-3 in the presence 
or absence of K7 antigen in a total volume of 0.2 ml. The cultures were incubated at 
37°C in a humidified atmosphere containing 5% C〇2-95% air for 72 hr, and then 
pulsed with pH]-TdR (0.5 jiCi/20 pi/well) for another 18 hr before harvest. 
Radioactivity incorporated in cpm was measured using liquid scintillation counting. 
Results were expressed as mean S.I. 土 S.E. of quadruplicate cultures. The basal 
proliferative activity ([
3
H]-TdR incorporation) of the control culture was 906 土 11 
cpm. 
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Table 4.1: In Vitro Cytotoxicity of K7 Capsular Antigen on rmIL-3-
Stimulated Bone Marrow Cells 
% of dead cells (mean 士 S.E.) at 
K7 antigen 
(fxg/ml) I 6h r 24 hr 
0 5.7 土 0.4 7.7 ±0.3 
12.5 7.7 士 0.5 8.0 土 0.1 
25 6.8 ±1.2 7.7 土 0.8 
50 8.9 士 0.2 8.9 ±1.1 ^ 
100 10.7 士 1.6 12.0 士 0.4 
Murine bone marrow cells (1 x 10
5
 cells/well) were co-cultured with 
rmIL-3 (500 U/ml) in the presence or absence of K7 antigen in a total ！ 
volume of 0.2 ml. The cultures were incubated at 37°C in a humidified 
atmosphere containing 5% C02-95% air for 6 or 24 hr, and dead cells were 
then counted in a total of 600 cells by the trypan blue exclusion method. 
Results were expressed as mean (% of dead cells) 士 S.E. of triplicate 
cultures. 
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4.2.3 Effect of K7 Capsular Antigen on the In Vitro Differentiation of 
Murine Bone Marrow Cells 
Fig. 4.4A(a) & 4.4B(a) show the morphology of pluripotent hematopoietic 
stem cells in the murine bone marrow cells. The cells had a relatively large nucleus 
to cytoplasm (N/C) ratio (over 90%). Exposure of the bone marrow cells to rmIL-3 
(50 U / m l or 500 U/ml) for three days at 37°C induced differentiation in about 22 % 
and 30 % of the cells respectively which had promonocyte-like or macrophage-like 
characteristics (Fig. 4.4A(b) & (c)). The differentiated cells were increased in size, the 
N / C ratio became smaller and many vacuoles were found in their cytoplasm. 
Similar to that of rmIL-3, K7 antigen (100 jig/ml) alone also induced the 
differentiation in about 49% of the bone marrow cells (Fig. 4.4B(b)). However, the | 
combination of rmIL-3 (50 U/ml) and K7 antigen (100 jig/ml) induced the 
t 
I 





4.2.4 Effect of K7 Capsular Antigen on the In Vitro Murine Bone Marrow 
Colony Formation 
Using semi-solid agar culture, the hematopoietic stem cells will form 
‘ f 
granulocyte or macrophage colonies in the presence of rmIL-3. In this study, the | 
effect of K7 antigen on the rmIL-3-induced colony formation in murine bone marrow 
cells was examined. As shown in Fig. 4.5, K7 antigen significantly reduced the 
number of colonies in rmIL-3-stimulated bone marrow cultures after 7 days of 
incubation in a dose-dependent manner. 
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Figure 4.4A: Morphological changes of rmIL-3-treated bone marrow cells. ！ 
Murine bone marrow cells (1 x 10
5
 cells/ml) were incubated with two different 
concentrations of rmIL-3 (50 U /m l & 500 U/ml) at 37°C for 72 hr. Cytocentrifuge 
preparations were made and cells were stained with the modified Wright-Giemsa 
stain. Murine bone cells were incubated with [A] culture medium; [B] rmIL-3 (50 
U/ml) and [C] rmIL-3 (500 U/ml). (Magnification x 400) 
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Figure 4.4B: Morphological changes of K7 antigen, or K7 antigen and rmIL-3- I 
treated bone marrow cells. Murine bone marrow cells (1 x 10
5
 cells/ml) were 
incubated with K7 antigen (100 fig/ml), or K7 antigen (100 ^ig/ml) and rmIL-3 (50 
U/ml) at 37°C for 72 hr. Cytocentrifuge preparations were made and cells were 
stained with the modified Wright-Giemsa stain. Murine bone cells were incubated 
with [A] culture medium; [B] K7 antigen (100 jug/ml), and [C] K7 antigen (100 
卩g/ml) and rmIL-3 (50 U/ml). (Magnification x 400) 
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Table 4.2: Effect of K7 Capsular Antigen and nnIL-3 on the In Vitro 
Differentiation of Murine Bone Marrow Cells 
% of differentiated cells 
Treated with (mean 土 S.E.) 
Medium only 3.1 ±0.2 
rmIL-3 (50 U/ml) 22.4 土 0.7 
rmIL-3 (500 U/ml) 30.4 ±1.2 
K 7
 antigen (100 |ug/ml) 49.0 土 1.9 w 
K7 antigen (100 j.ig/ml) + rmIL-3 (50 U/ml) 40.1 土 2.6 | 
— — — — — — — — 
I 
Murine bone marrow cells (1 x 10
5
 cells) were co-incubated with either rmIL-3 
(50 or 500 U/ml), K7 antigen (100 |ag/ml) or both for 72 hr at 37。C in a | 
humidified atmosphere containing 5% C02-95% air. Cytocentrifuge \ 
preparations were made and cells were stained with modified Wright-Giemsa I 
stain for morphological identification of the cells. Differential counts were ( 
performed by counting at least 300 cells. Intermediate stage cells (myelocytes i 
and promonocyte-like cells) and mature cells with macrophage-like 
characteristics were counted as differentiated cells. i 
« 
f 
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Figure 4.5: Effect of K7 capsular antigen on in vitro rmIL-3-stimulated \ 
colony formation of bone marrow cells. Murine bone marrow cells were plated at 
a density of 2 x 10
4
 cells per culture in soft agar containing medium and diluted 
rmIL-3 (1200 U/ml) in the presence or absence of K7 antigen in the wells of 
leukocyte migration plates. The cultures were incubated in a humidified 
atmosphere containing 5% C〇2-95% air at 37°C. After 7 days, the number of 
colony per culture was counted. Results were expressed as mean 土 S.E. of triplicate 
cultures. *P< 0.01 & **P< 0.02. 
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4.2.5 Effect of K7 Capsular Antigen on the Viability of Splenocytes In 
Vitro 
The effect of K7 antigen on the viability of splenocytes was examined in vitro. 
As shown in Table 4.3, after 6 hr of incubation, K7 antigen was found to be non-
cytotoxic to splenocytes as compared to the control culture. Interestingly, after 1-day, 
2-day or 3-day incubation, the percentage viability of the K7 antigen-treated 
splenocytes was found to be significantly higher than that of control culture (Table 
4.1). It can be seen that K7 antigen increased the number of viable cells in the culture 
in a time- and dose-dependent manner. In addition, K7 antigen also decreased the 
number of dead splenocytes after 24 and 48 hr of incubation. 
** 
I 
4.2.6 In Vitro Mitogenic Effect of K7 Capsular Antigen on Splenocytes and 
Thymocytes 
I 
Mitogenic activity is one of the parameters that has been used to examine the
 1 
3 
immxinomodulating activity of biological response modifiers. Thus, the in vitro 
\ \ 
mitogenic activity of K7 antigen on splenocytes was investigated. The results in Fig. 
4.6 show that K7 antigen stimulated the DNA synthesis of murine splenocytes in a 1 
dose-dependent manner. Similarly, K7 antigen also stimulated the proliferation of 
f 
thymocytes in a dose-dependent manner, but to a much smaller extent (Fig. 4.7). As , 
shown previously in Table 4.3, the number of viable splenocytes increased in a time-
and dose-dependent manner when incubated with K7 antigen. Collectively, these 
results show that K7 antigen not only induced the DNA synthesis of splenocytes but 
actually increased the number of viable splenocytes in the culture. 
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Table 4.3: Effect of K7 Capsular Antigen on the Viability of Splenocytes In 
Vitro After Different Incubation Times 
Incubation K7 antigen Viable cell no. Dead cell no. % viability* 
time® (jLig/ml) (x 10Vwell)t (x W/we \ i ) t 
6 h r Nil 47.9 土 0.3 2.1 土 0.2 95.8 土 0.5 
12.5 47.0 土 1 . 0 3.0 土 0.1 94.0 士 0.3 
1 5 0 47.1 土 1 . 5 2 . 9 土 0 . 2 94.2 ± 0 . 5 
1 day Nil 35.3 土 1.2 21.5 土 0.3 62.2 土 1.0 
12.5 42.9 ±3.5 13.7 ± 0.9 75.8 ±2.2* 
1 5 0 5 5 . 5 土 1 . 0 1 2 . 4 ± 0 . 3 8 1 . 7 土 0 . 5 * m 
> 
2 days Nil 28.1 土 3.6 27.7 士 1.8 50.2 士 4.1 
1 2 . 5 3 9 . 9 士 0 . 5 1 5 . 2 士 0 . 2 7 2 . 4 土 0 . 4 * | 
1 5 0 6 2 . 9 土 1 . 9 1 4 . 9 士 0 . 1 8 0 . 9 土 0 . 5 * ii 
3 days Nil 21.7 土 1.3 28.4 士 0.2 43.3 ±1.7 I 
12.5 44.7 土 2 . 9 2 1 . 9 ±0.5 67.1 ± 1 . 8 + j 




@ Splenocytes (5 x 10
5
/well)were co-incubated with different concentrations of < 
K7 antigen (12.5 & 150 ng/ml) for 1-3 days at 37。C. i 
\*t 
t Number of viable cells /wel l counted in a hemocytometer by the trypan blue , 
exclusion method and results were expressed as arithmetic mean 土 S.E. of s 
triplicate cultures. | 
t Number of dead cell /wel l counted in a hemocytometer by the trypan blue 
exclusion method and results were expressed as arithmetic mean 士 S.E. of 
triplicate cultures. 
#
 % viability is equal to number of viable cells divided by the total number of 
viable cells and dead cells. 
* P< 0.0001. 
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Figure 4.6: Effect of K7 capsular antigen on the proliferation of mouse 
splenocytes. Splenocytes (5 x 10
5
 cells/0.2 ml) were incubated with different 
concentrations of K7 antigen (0-150 ^ig/ml) at 37°C for 48 hr. The cultures were then 
pulsed with [
3
H]-TdR (0.5 }iCi/20|il) for 6 hr before harvesting. Radioactivity in cpm 
was measured by liquid scintillation counting. Results were expressed as mean S.I. 士 
S.E. of quadruplicate cultures. The [
3
H]-TdR incorporation of the control cultures 
was 515 土 57 cpm. 
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Figure 4.7: Effect of K7 capsular antigen on the proliferation of mouse , 
thymocytes. Thymocytes (5 x 10
5
 cells/0.2 ml) were incubated with different 
concentrations of K7 antigen (0-150 jig/ml) at 37。C for 48 hr. The cultures were then 
pulsed with [
3
H]-TdR (0.5 jiCi/20|il) for 6 hr before harvesting. Radioactivity in 
counts per minute (cpm) was measured by liquid scintillation counting. Results were 
expressed as mean S.I. 土 S.E. of quadruplicate cultures. The [3H]-TdR incorporation 
of the control culture was 1000 土 162 cpm. 
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4.2.7 Characterization of the Lymphocyte Population(s) Responding to K7 
Capsular Antigen 
Splenocytes enriched for B or T lymphocytes by complement lysis method 
were co-cultured, with or without a predetermined optimal concentration of LPS (25 
lug/ml), Con A (1 |ig/ml), or K7 antigen (150 jag/ml). As shown in Table 4.4, 
splenocytes treated with anti-Thy 1.2 antibody plus complement, which contained 
mainly B lymphocytes, still had strong mitogenic responses to K7 antigen and LPS (a 
well-known B cell mitogen) (Andersson et al., 1972) whereas the mitogenic response 
to Con A (a well-known T cell mitogen) (Andersson et al., 1972 & Stobo et al., 1972) 
was greatly diminished. However, splenocytes treated with anti-LR-1 antibody plus 
complement, which contained mainly T lymphocytes, demonstrated strong | 
mitogenic response to Con A but not to LPS and K7 antigen. The requirement of | 
I 
macrophages for the mitogenic response of splenocytes to K7 antigen was also 
I 
assessed. The results in Table 4.4 show that the mitogenic response of splenocytes to j 
ii 
K7 antigen was macrophage-independent. Therefore, the results indicate that K7 f 
antigen is a potent mitogen for murine B lymphocytes. Since B cell mitogens can 
j i 
non-specifically stimulate the expansion of different clones of B cells and bring about 
an increase in the number of B cells, therefore, the B cell population after in vitro i) 
culture of splenocytes with K7 antigen was assessed by flow cytometric method. The 
results in Fig. 4.8 show that there was an increase in the number of B cells in the 
culture in a dose-dependent manner after 3 days of incubation. In addition to the B 
cell population, the T cell population was also examined by flow cytometric method 
with monoclonal antibody against the T cell marker (CD3 antigen). It was found that 
the number of T cells in the culture decreased in a dose-dependent manner after 3 
days of incubation (Fig. 4.9). 
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Table 4.4: Characterization of Lymphocyte Population(s) Responding to 




cpm 士 S.E.t (S.I.) 
Medium only Nil 263.1 土 49 
LPS 10,276 土 150 (39.1) 
Con A 13,575 士 226 (51.6) 
K7 10,3671 252(39.4) 
Medium + C Nil 244 土 21 
LPS 10,498 土 91 (43.0) 
Con A 9,029 ± 169 (36.9) 
K7 10,478 士 156 (42.9) 
Anti-Thy 1.2 + C Nil 328 土 4 
LPS 1〜014± 259 (39.7) ” 
Con A 1,401 ±34 (4.3) I 
K7 1：3,224 ± 243 (40.4) | 
Anti-LR-1 + C Nil 215 土 30 ！ 
LPS 779 士 30 (3.6) j 
Con A 9,657 士 271 (45.0) 
K7 1,072 土 42 (5.0) ！ 
I 
M(t> depletion Nil 301 土 36 [ 
LPS 13,142 土 227 (43.7) ( 
Con A 7,723 ± 109 (25.7) i 
K7 1；3,008 ± 158 (43.3) 
• Splenocytes were either treated with RPMI 1640 medium, monoclonal f 
anti-Thy 1.2 antibody (1:1,000 dilution), or anti-LR-1 antibody (1:10,000 ！ 
dilution) plus Low-Tox®-M rabbit complement (C'), or were depleted of 
macrophages. 
#
 K7 antigen (150 ^ig/ml), LPS (25 jug/ml), or Con A (1 H-g/ml) was added 
to the cultures. 
t Treated cells were incubated at 37°C for 48 hr in microtiter plates at a cell 
density of 5 x 10
5
 cells/ml in a total volume of 0.2 ml, and [
3
H]-TdR 
incorporation was expressed as arithmetic mean 土 S.E. of quadruplicate 
cultures. 
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Figure 4.8: FACS analysis of 6 cell population on K7 antigen-treated (丨 
splenocytes. Splenocytes (2.5 x 10
6
 cells/ml) were incubated with of K7 antigen (12.5 
& 100 |j,g/ml) at 37°C for 72 hr. Cells were then stained with rat monoclonal 
antibody to LR-1 antigen on B cells. Paraformaldehyde-fixed cells (10,000 cells) were 
analyzed for fluorescence intensity using the FACSort flow cytometer. Splenocytes 
were incubated with [A] culture medium; [B] K7 antigen (12.5 | ig/ml) and [C] K7 
antigen (100 卩g/ml). The x-axis was plotted in a logarithmic scale. 
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Figure 4.9: FACS analysis of T cell population on K7 antigen-treated 
splenocytes. Splenocytes (2.5 x 10
6
 cells/ml) were incubated with K7 antigen (12.5 & 
100 jug/ml) at 37°C for 72 hr. Cells were then stained with rat monoclonal antibody 
to CD3 antigen on T cells. Paraformaldehyde-fixed cells (10,000 cells) were analyzed 
for fluorescence intensity using the FACSort flow cytometer. Splenocytes were 
incubated with [A] culture medium; [B] K7 antigen (12.5 |ng/ml) and [C] K7 antigen 
(100 jig/ml). The x-axis was plotted in a logarithmic scale. 
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4.2.8 Effect of Polymyxin B Sulphate on the Mitogenic Activity of K7 
Capsular Antigen 
Lipid A has been known to be the toxic and immunostimulating component 
of LPS (Burrell, 1990) and treatment of LPS with polymyxin B sulphate (PB) was 
shown to abolish the mitogenic activity of LPS on murine splenocytes (Jacobs and 
Morrison, 1977). Therefore, the effect of PB on the mitogenic activity of K7 antigen to 
murine splenocytes was studied. The results in Fig. 4.10 show that 10 jug/ml of PB 
completely abolished the mitogenic activity of 20 fig/ml LPS, but it only reduced the 
mitogenic activity of K7 antigen to 40% when compared to the mitogenic activity of 
untreated K7 antigen. Thus, the results suggest that the mitogenic activity of K7 
antigen cannot be totally explained by the contamination of LPS. j 
！ 
I 
4.2.9 In Vivo Mitogenic Activity of K7 Capsular Antigen 
. ® 
Since K7 antigen exhibited potent mitogenic activity to lymphocytes in vitro, 
\ 
therefore, the in vivo mitogenic activity of K7 antigen was also investigated. The , 
results in Table 4.5 show that the ratio of spleen weight to body weight was j 
I 
significantly increased in a time-dependent manner after i.p. injection of K7 antigen ^ 
(50 |ng/mouse for 3 or 7 days). The enlargement of spleen was found to be ) 
accompanied by the increase in number of splenocytes recovered in the spleen, as | 
measured by the trypan blue dye exclusion assay (Table 4.5). The results also 
indicate that the enlargement of spleen could be due to the in vivo stimulation of 
splenocyte proliferation by K7 antigen, as shown by increased [
3
H]-TdR 
incorporation in splenocytes from K7 antigen-treated mice (Table 4.5). These results 
indicate that K7 antigen is also mitogenic to murine splenocytes in vivo. 
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Figure 4.10: Effect of PB on the mitogenic activities of LPS and K7 capsular 
antigen. Splenocytes (5 x 10
5
 cells/well) were co-incubated with different 
concentrations of (A) LPS or (B) K7 antigen in the absence or in the presence of PB (5 
or 10 pg/ml) for 48 hr at 37°C. The cultures were then pulsed with [
3
H]-TdR (0.5 
p.Ci/20 fil) for 6 hr. Radioactivity in cpm was measured by liquid scintillation 
counting. Results were expressed as mean S.I. 土 S.E. of quadruplicate cultures. The 
[
3
H]-TdR incorporation of the control cultures was 528 士 103 cpm. 
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Table 4.5: In Vivo Mitogenic Effect of K7 Capsular Antigen on BALB/c Mice 
T S
 S p l
= f / n
b
3 ， ^ e n o c y t e s / b o d y i n ^ o r a L 
~ —







) weight (x 106 ceHs/g) ( C p m ) 
P B S
 5.96 土 0.15 3.20 ±0.04 2085 ±110 
H S ^ r T
 1 L 9 2 土 0 册 6 . 8 4 土 0 . 肥 12048 ± 7 5 7 -
(for 3 days) 
5
K 7 ^ e T 腳 蕭 , 8 3 着 10981 ± 1 5 3 - ； 
(for 7 days) 
！ 
BALB/c mice in groups of three were injected with K7 antigen (50 ^g/mouse/day)
 ! 
°





 I ~ ° )
 o r 7 习-Day 0) consecutive days. On day 0 the 1 
m t l 0
 °
f S p l e e n
 ― 咖 t 0 ― 讽 the number of splenocytes to body weight 1 
and the pH]-TdR incorporation into the splenocytes were determined. The , 
splenocytes were isolated and seeded onto a 96-weH microliter plate at 5 x 105 I 
cells/well and then pulsed with PH]-TdR (0.5 „Ci/20 pi/weH) for 6 hr and ！ 
radioactivity incorporated was determined. Results were expressed as m e a n i S E of ‘ 
quadruplicate cultures. 1 ¾ difference between the control group and treatment ) 
group was determined by the Student's t-test. *P< 0.001 & **p< 0.0001.
 1 
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4.2.10 Flow Cytometric Analysis of Splenocytes from K7 Capsular Antigen-
Treated Mice 
The change in cell populations of splenocytes from K7 antigen-treated mice 
was investigated. The results from flow cytometric analysis show that the B cell 
population was slightly increased in splenocytes obtained from mice treated with K7 
antigen (50 jig/mouse/day) for 7 consecutive days (Fig. 4.11). 
4.2.11 In Vitro Co-mitogenic Activity of K7 Capsular Antigen 
The possible co-mitogenic activity of K7 antigen was tested by co-culturing 
murine splenocytes with different concentrations of K7 antigen (0-150 jag/ml) and 
various mitogens (Con A or LPS) at their optimal/ sub-optimal concentrations. As 
I 
shown in Fig. 4.12, the Con A (0.25 jag/ml and 1 |ig/ml)-induced ( 
I 
lymphoproliferative response was greatly enhanced (〜88% and 38% increase \ 
^
 1 4 A
 “ li 
respectively) at a K7 antigen concentration of 150 |ig/ml. Similarly, the LPS (0.5 
!l 
jag/ml and 10 jLig/ml)-induced lymphoproliferative response was also enhanced by ’ 
K7 antigen (〜86% and 23% increase respectively) at a concentration of 150 |xg/ml v 
II 
(Fig. 4.13). 
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Figure 4.11: FACS analysis of B cell population from splenocytes of K7 
antigen-injected mice. Splenocytes prepared from (A) PBS-treated or (B) K7 antigen-
treated (50 ^ig/mouse/day for 7 days) mice were depleted of red blood cells and 
dead cells by Ficoll-isopaque gradient centrifugation. The splenocytes (5 x 10
5
 cells) 
were then stained with rat monoclonal antibody to LR-1 antigen on B cells. 
Paraformaldehyde-fixed cells (10
4
 cells) were analyzed for fluorescence intensity 
using the FACSort flow cytometer. The x-axis was plotted in a logarithmic scale. 
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Figure 4.12: Co-mitogenic effect of K7 capsular antigen on Con A-
stimulated murine splenocytes. Splenocytes (5 x 10
5
 cells/well) were co-incubated 
with different concentrations of K7 antigen in the absence or in the presence of Con 
A (0.25 or 1 |j,g/ml) for 48 hr at 37°C. The cultures were then pulsed with [
3
H]-TdR 
(0.5 |iCi/0.2 jal) for 6 hr. Radioactivity in cpm were measured by liquid scintillation 
counting. Results were expressed as mean S.I. 士 S.E. of quadruplicate cultures. The 
[
3
H]-TdR incorporation of the control culture was 538 土 9 cpm. 
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Figure 4.13: Co-mitogenic effect of K7 capsular antigen on LPS-stimulated 
murine splenocytes. Splenocytes (5 x 10
5
 cells/well) were co-incubated with 
different concentrations of K7 antigen in the absence or in the presence of LPS (0.5 or 
10 |xg/ml) for 48 hr at 37°C. The cultures were then pulsed with [
3
H]-TdR (0.5 
jj.Ci/0.2 jal) for 6 hr. Radioactivity in cpm were measured by liquid scintillation 
counting. Results were expressed as mean S.I. 土 S.E. of quadruplicate cultures. The 
[
3
H]-TdR incorporation of the control culture was 3019 土 133 cpm. 
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4 . 3 D I S C U S S I O N 
The major side-effect of some common cancer therapies, including 
chemotherapy and radiotherapy, is myelosuppression, and thus limits both the 
doses of drugs used and the frequencies of treatment. Myelosuppression such as 
neutropenia causes sepsis which results in deaths of most cancer patients by 
microbial infection. Therefore, the development of agents capable of enhancing the 
proliferation of granulocytes, macrophages and lymphocytes has important 
implications in cancer treatment. Therefore, in this chapter, the effects of K7 antigen 
on lymphocyte proliferation and hematopoietic cell development were investigated. 
Hematopoietic cells have the characteristics of self-renewal capacity under 
the influence of hematopoietic growth factors such as IL-3, IL-4, IL-5, IL-6 and CSFs. 
Previous studies have shown that some polysaccharides isolated from natural 
products could induce the DNA synthesis of bone marrow cells in vitro (Liu et al.f 
1991 & Wong et al" 1994c) or enhance the in vivo hematopoietic response of mice 
(Patchen and Lotzova, 1980; Ma and Xie, 1983; Hashimoto et al, 1990 & Egger et a\„ 
1996). In the present investigation, our results show that K7 antigen alone could 
stimulate the in vitro proliferation of murine bone marrow cells in a dose-dependent 
manner. Quite unexpectedly, K7 antigen was found to be inhibitory to the 
proliferation of rmIL-3 stimulated bone marrow cells dose-dependently. This 
inhibitory effect could not be attributed to the direct cytotoxicity of K7 antigen, as K7 
antigen exhibited little, if any, cytotoxic effect on IL-3-stimulated bone marrow cells, 
even at a relatively high concentration (100 pg/ml). The mechanism(s) whereby K7 
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antigen can exhibit opposite effects on bone marrow cell proliferation is unclear and 
remains to be determined. 
Progenitor cells in the bone marrow can be differentiated into different 
lineages of blood cells under the influence of hematopoietic growth factors. 
Previously, our laboratory has reported that polysaccharide fraction prepared from 
Pseudostellaria heterophylla could induce the in vitro differentiation of bone marrow 
cells into macrophage-like cells (Wong et al., 1994c), In the present study, our results 
show that K7 antigen alone was found to be more potent than rmIL-3 in inducing 
bone marrow cells to differentiate into mature, macrophage-like cells. However, K7 
antigen exhibited an inhibitory effect on the in vitro colony forming ability of rmIL-3-
stimulated bone marrow cells. Recently, McKinstry et al. (1997) showed that the 
hematopoietic stem cells expressed receptors for IL-la, IL-3, IL-6, and G-CSF while 
progenitor cells expressed receptors for IL-la, IL-3, GM-CSF, G-CSF and IL-6. It is 
well known that cytokine-cytokine receptor interactions are important for the 
proliferation and differentiation of hematopoietic cells (Meunch et al” 1992 & Mixira 
et al" 1993). It is conceivable that the modulation of cytokine receptors would affect 
the proliferation and differentiation of hematopoietic cells. Some compounds, such 
as LPS (Shieh et al., 1994) or cytokines, such as IL-1 (Shieh et al" 1991a) and G-CSF 
(Shieh et al., 1991b), have been reported to have the ability of regulating or 
modulating the expression of cytokine receptors. Whether K7 antigen affects the 
proliferation and differentiation of murine bone marrow cells through the 
modulation of cytokine receptors on hematopoietic stem cells or progenitor cells is 
not clear and the molecular basis for its effect on hematopoiesis remains to be 
elucidated. 
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Interestingly, K7 antigen not only can modulate the hematopoiesis of bone 
marrow cells, but it also exhibits mitogenic activity on lymphocytes, including 
splenocytes and thymocytes. In vitro lymphocyte transformation assay is a typical 
non-specific immune reaction and the mechanism of which has been well 
understood. Moreover, this assay has frequently been used as an immune parameter 
to investigate lymphocyte responsiveness due to its high sensitivity. Using the [
3
H]-
thymidine incorporation assay, it was found that K7 antigen induced a strong 
mitogenic response to splenocytes, and to a lesser extent, to thymocytes in vitro. In 
addition, B lymphocytes in the spleen were found to be the major target cell 
population responding to K7 antigen, as determined by flow cytometric analysis and 
lymphocyte depletion assay. The mitogenic activity of K7 antigen may be resulted 
！ 
from the structural organization of capsular polysaccharide with repeating 
I 
oligosaccharide units (Kjellberg et al., 1995), and its high molecular weight (〜5 x 106) | 
as shown in Chapter 3. Moreover, the in vitro mitogenic activity of K7 antigen on 
splenocytes was found to be T cell- and macrophage- independent Therefore, K7 
I 
antigen is a TI antigen, since helper T cells are not essential for the induction of I 
antibody synthesis (Bondada and Garg, 1994). 
• j 
In vitro experiment showed that K7 antigen enhanced the lymphocyte 
blastogenesis at sub-optimal concentrations of Con A and LPS. Although K7 antigen 
is a polyclonal B cell activator, interestingly it also exerts co-mitogenic activity on T 
cells with T cell mitogens such as Con A. Therefore, it is conceivable that K7 antigen 
may play an indirect role in the activation of T cell functions in vitro. Whether K7 
antigen has any effect on the activation of various T cell subsets such as cytotoxic T 
cells, helper T cells, and suppressor T cells needs further investigation. 
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The results also demonstrated that K7 antigen was mitogenic to murine 
lymphocytes in vivo. B lymphocytes were again found to be the target cell population 
responding to the K7 antigen. Previously, some studies had shown that the in vivo 
antibody responses of some capsular polysaccharides were modulated by T cells, 
including suppressor T cells and amplifier T cells (Muller and Apicella, 1988 & 
Taylor and Bright, 1989). Although the mitogenic activity of K7 antigen seems to be 
T cell independent in vitro, yet whether T cells are involved in the modulation of 
antibody response to K7 antigen in vivo remained to be elucidated. 
I 
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CHAPTER 5 
ACTIVATION OF MACROPHAGES 
BY KLEBSIELLA 
K7 CAPSULAR ANTIGEN 
5.1 INTRODUCTION 
Macrophages are among the most versatile and multifunctional cell types 
that are known to play a central role in the regulation of specific and non-specific 
immunity (Dietert et al., 1996). They represent a ubiquitously distributed population 
of fixed and circulating mononuclear phagocytes that, at least in higher organisms, 
express a variety of functions other than phagocytosis, including cytokine 
production, killing of microbes and tumour cells, and processing and presentation of 
antigens to lymphocytes. Macrophage functions vary depending on what state the 
macrophage is in, and these states can be modulated by various stimuli, generally 
referred to as Macrophage-Activating Factors (MAF). Generally speaking, these 
. ° ‘ } 
activating agents fall into one of the following two classes: microorganisms or their , 
products such as lipopolysaccharide (Raetz, 1990) and muramyl dipeptide (Suzuki et , 
al" 1994); and lymphokines such as IFN-y (Finbloom, 1990). Contact with tumour 
cells has also been reported to be capable of activating macrophages (Fidler and 
Schroit, 1988). The activated macrophages develop altered functions, including i 
increased phagocytic capacity for non-opsonized bacteria, more resolute lysosomal 
degradation of intracellular bacteria, intense secretion of cytolytic proteinase and 
TNF-a, generation of ROI, such as H2O2 (Nathan et al.f 1979a & 1979b) and RNI, such 
as NO (Ding et al" 1988), or the killing of tumour cells (Meltzer, 1981 & Pace and 
Russell, 1981). The process of macrophage activation is complex, as it occurs in 
multiple, sequential steps and has accordingly been referred to as a cascade of 
activation. As noted above, such activated macrophages lyse tumour targets 
independent of specific antigens or MHC restriction, and tumour resistance to such 
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lysis does not develop even in the face of selection pressure. The mechanism of 
killing tumour targets is poorly understood but requires days (1 - 4 days) rather than 
hours to develop fully (Key et al.f 1982). 
In the past decade, there were many studies conducted on the 
immunomodulatory activities of polysaccharides on macrophages. p-Glucan is one 
of the representative candidates showing well known immunomodulating activities 
on macrophages. P-glucans are widely distributed in nature and are found in 
bacteria, fungi, as well as plants with a variety of structure. The immunomodulatory 
activities of the fungal p-glucans such as Lentinan (from Lentinus edodes) (Arinaga et 
a l
"
 1 9 9 2
 & Ladanyi et al" 1993), Schizophyllan (from Schizophyllum commune) I 
t 
(Sakagami et al., 1988), SSG (from Sclerotinia sclerotiorum) (Sakurai et al, 1992a & 
I 
1995), Grifolan (from Grifola frondosa) (Adachi et al, 1994 & Ohno et al., 1996) and 
OL-2 (from Omphalia lapidescens) (Ohno et al.f 1993 & Nemoto et al., 1994) on ^ 
macrophages have been well documented. In addition to p-glucans, polysaccharides ' 
isolated from a variety of microorganisms, including serotype F polysaccharide and 
rhamnose-glucose polymer of Streptococcus mutans (Benabdelmoumene et al., 1991 & 
Soell et al, 1995b), serotype-specific polysaccharide antigens of Actinomyces viscosus  1 
(Takahashi et al., 1991 & Yamaguchi et al., 1996), capsular polysaccharide complex of 
Bacteroides fragilis (Gibson et al" 1996), capsular polysaccharide of Staphylococcus 
aureus (Soell et al" 1995a) and Cryptococcus neoformans (Vecchiarelli et al., 1996), 
lipoarabinomannan of Mycobacterium tuberculosis (Barnes et al., 1992), and 
proteoglycan of Klebsiella -pneumoniae (Sironi et al., 1990 & Hmama et al" 1992) and 
Staphylococcus aureus (Weidemann et al" 1994) have been reported to be capable of 
stimulating macrophages. These immunomodulatory polysaccharides can stimulate 
different aspects of macrophage functions, including phagocytic activity (Sakurai et 
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al, 1992a & 1995), macrophage-mediated cytotoxicity and cytostasis (Tani et al" 1992 
& Lad^nyi et al" 1993), NO production (Sakurai et al" 1995 & Ohno et al” 1996), the 
production of cytokines such as GM-CSF, IL-1 (Takahashi et al., 1991; Barnes et al" 
1992 & Hmama et al" 1992), TNF-a (Benabdelmoumene et al" 1991; Soell et al" 1995b 
& Yamaguchi et al., 1996), IL-6 (Sironi et al., 1990 & Weidemarm et al, 1994), IL-8 
(Soell et al., 1995a & Gibson et al., 1996) and IL-10 (Barnes et al" 1992 & VecchiarelH et 
al., 1996). 
Previous work of Yokochi et al. (1977) showed that the addition of the CPS-K 
to the in vitro cultures of peritoneal macrophages or mouse spleen cells had resulted 
in the enhancement of their phagocytic capacity. Interestingly, CPS-K also blocked | 
t 
the generation of macrophages from their precursor cells in cultures of spleen cells. ； 
I 
Despite this earlier in vitro study, the modulatory effect of Klebsiella capsular 
• E 
polysaccharide on other functional properties of mouse macrophages has not yet f 
been reported. In addition, the ability of Klebsiella K7 capsular polysaccharide to . 
activate macrophages in vivo has not yet been examined. Therefore, in this chapter, 
murine peritoneal macrophages were used as a model to investigate the 
immunomodulatory activities of K7 antigen on macrophages such as induction of ( 
phagocytic activity in vitro and elicitation of macrophage migration in vivo. 
Moreover, the in vitro anti-tumour activities, such as activation of cytostatic activity 
of macrophages, and induction of NO and TNF-a production, were also assessed. 
Finally, the in vitro effect of K7 antigen on triggering the expression of different 
cytokine genes, including IL-la, IL-ip, TNF-a, IL-6 and TGF-P, in murine peritoneal 
macrophages was investigated. 
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5 .2 R E S U L T S 
5.2.1 Effect of K7 Capsular Antigen on the Phagocytic Activity of 
Macrophages In Vitro 
Phagocytosis is generally regarded as a parameter for measuring the 
activation of macrophages (van Forth, 1981). Thus, the effect of K7 antigen on the in 
vitro phagocytic activity of murine resident peritoneal macrophages was 
investigated. The results in Fig. 5.1 show that pre-incubation of resident peritoneal 
macrophages with K7 antigen for 8 hr at 37°C profoundly augmented the phagocytic " 
“‘’ ‘ “ “ • ‘ f 
activi ty of the mac rophages in vitro. ‘ 
5.2.2 Effect of K7 Capsular Antigen on the In Vivo Migration of 
Macrophages 
It has been known that i.p. injection of irritant substances such as 
thioglycollate (TG) broth and proteose peptone (PP) can increase the yield of 
macrophages in the peritoneal cavity of mice (Ogmundsdottir and Weir, 1980). 
Therefore, the effect of K7 antigen alone on the in vivo migration of macrophages 
was studied. It was found that K7 antigen (25 & 100 |ig/mouse, injected i.p.) alone 
could induce an influx of macrophages into the peritoneal cavity of mice in a dose-
dependent manner (Table 5.1). In addition, the effect of K7 antigen on the influx of 
macrophages in response to locally administered sterile PP in vivo was examined. 
The results in Table 5.2 show that mice treated with K7 antigen two days before and 
on the same day as PP injection had about 1.5 fold increase in total PEC and 
adherent PEC number as compared to mice treated with PP alone. 
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Figure 5.1: Effect of K7 capsular antigen on the phagocytic activity of 
resident peritoneal macrophages. Murine resident PEC (8 x 10
5
 cells/coverslip) 
were allowed to incubate at 37°C. After 3 hr, the coverslip was washed three times 
with warm medium to remove the non-adherent cells. The adherent cells were then 
incubated with K7 antigen (12.5 & 100 jag/ml) at 37°C in a humidified atmosphere 
containing 95% air-5% CO2 for 8 hr. The phagocytic activity was then determined by 
the uptake of latex beads. The percentage of phagocytic cells (cells that had ingested 
three or more latex beads) was determined by counting at least 300 cells under light 
microscope and the results were expressed as mean 土 S.E. * P<0.0001. 
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Table 5.1: Effect of K7 Capsular Antigen on the In Vivo Migration of 
Macrophages 
Total PEC* Adherent PEC
# 
K7 antigen recovered per recovered per 
(jag/ mouse) mouse (xl0_
5
 cells) mouse (x 10-
5
 cells) 
0 18.73 8.43 
25 48.00 19.75 
100 94.50 33.00 
‘ f 
\ 
* BALB/c mice in groups of four were pre-treated with PBS or K7 antigen 
(25 & 100 jLig/mouse given i.p.) for three consecutive days (Day 0-Day 2). 
On day 3, the elicited PEC were harvested from each group of mice by 
peritoneal lavage twice with cold HBSS and counted in a hemocytometer. 
Results were expressed as the average number of cells from a pool of four 
mice. 
#
 PEC that remain attached to the plastic surface after incubation at 37°C 
for 3 hr and were not removed by several washing with warm medium. 
Adherent PEC recovered was calculated as follows: Adherent PEC 
recovered = (total PEC recovered - non-adherent PEC recovered after 3 hr 
.incubation). The results were expressed as the average number of cells 
from a pool of four mice. 
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Table 5.2: Effect of K7 Capsular Antigen on In Vivo Migration of 
Macrophages Elicited by Proteose Peptone 
Total PEC* Adherent PEC
# 
Mice treated with recovered per recovered per 
mouse (x 10-
5
) mouse (x 10
5
) 
PBS 10.1 土 1.6 3.6 土 0.5 
K7 antigen 47.3 土 3.7 25.9 土 0.7 
Proteose peptone (PP) 38.5 ±5.4 23.0 ±2.3 -
K7 antigen + PP 66.7 土 6.1 39.0 士 1.7 
* BALB/ c mice in groups of three were pre-treated with PBS or K7 antigen (75 
jug/mouse given i.p.) on day -2 and then injected i.p. with 1.5 ml 10% 
proteose peptone or PBS. Three days later, the elicited PEC were harvested 
by peritoneal lavage twice with cold HBSS and counted in a , 
hemocytometer. The results were expressed as mean 土 S.E. 
#
 PEC that remain attached to the plastic surface after incubation at 37°C for 3 
hr and were not removed by several washing with warm medium. 
Adherent PEC recovered was calculated as follows: Adherent PEC 
recovered = (total PEC recovered，non-adherent PEC recovered after 3 hr 
incubation). The results were expressed as mean 士 S.E. 
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Thus, the results suggest that K7 antigen can also enhance the in vivo migration of 
peritoneal macrophages in response to the locally administered irritant. 
5.2.3 Effect of K7 Capsular Antigen on the In Vitro Cytostatic Activity of 
Picolinic Acid (PLA)-Activated Macrophages 
Previous work of Ruffmann et al. (1984) had shown that i.p. injection of PLA, 
a well-known activator of macrophages in vivo, would induce cytostatic activity in 
peritoneal macrophages against the murine lymphoma MBL-2 cells in the presence 
of nanogram levels of lipopolysaccharides. In this study, the effect of K7 antigen on 
the in vitro cytostatic activity of PLA-activated macrophages was examined. As 
shown in Table 5.3, K7 antigen alone had no significant effect on the proliferation of [ 
( 
MBL-2 lymphoma cells and peritoneal macrophages, as measured by the [
3
H]-
thymidine incorporation. However, K7 antigen could significantly augment the 
cytostatic activity of PLA-activated macrophages towards MBL-2 cells in vitro (Fig. 
5.2). Maximal enhancement of the cytostatic activity of peritoneal macrophages by 丨 
K7 antigen was seen at a concentration of 25 jug/ml, and no further increase in 
cytostatic activity could be observed at higher concentrations of K7 antigen. 
5.2.4 Effect of K7 Capsular Antigen on Nitric Oxide (NO) Production by 
Macrophages In Vitro 
To examine whether K7 antigen can stimulate NO production by 
macrophages in vitro, macrophages were collected from the peritoneal cavity of TG-
injected mice and cultured with increasing concentrations of K7 antigen from 24 to 
72 hr. The results in Fig. 5.3 show that K7 antigen significantly stimulated the 
production of NO by macrophages in a time and dose-dependent manner. 
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Table 5.3: Effect of K7 Capsular Antigen on the In Vitro 




H]-Thymidine uptake (c.p.m. 土 S.E.) 
(^g/ml) MBL-2 cells* PLA-activated M(|)
# 
0 191,566 土 2456 370 士 67 
12.5 199,373 土 5484 495 土 68 
25 185,225 ± 8698 543 ± 121. 
50 195,536 土 8157 704 土 126 
100 土 2771 702 土 
* MBL-2 cells (1 x 10
4
 cells) were co-incubated with various 
concentrations of K7 antigen (0-100 jug/ml) in the presence of 2 
j 
ng /ml LPS for 48 hr at 37。C. The pH]-TdR uptake of MBL-2 cells 
was determined by pulsing the culture with [
3
H]-TdR (0.5 
}iCi/well) for 6 hr. Results were expressed as mean 士 S.E. of 
quadruplicate cultures. 
#
 PTLA-elicited PEC (3.5 x 10
5
 cells/well) were added onto each well 
of a microtiter plate and incubated for 5 hr at 37°C. Non-adherent 
cells were removed by three washes with warm medium. 
Adherent cells were then incubated with various concentrations 
of K7 antigen (0-100 (ig/ml) in the presence of 2 ng /m l of LPS for 
48 hr at 37。C. The pH]-TdR uptake of PLA-elicited peritoneal 
macrophages was determined by pulsing the culture with [
3
H]-
TdR (0.5 jj.Ci/well) for 6 hr. Results were expressed as mean 士 
S.E. of quadruplicate cultures. 
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Figure 5.2 : Effect of K7 capsular antigen on the in vitro cytostatic activity 
of PLA-activated peritoneal macrophages. PLA-elicited PEC (3.5 x 10
5
 cells/well) 
were added onto each well of a microliter plate and incubated for 5 hr at 37°C. Non-
adherent cells were removed by three washes with warm medium. MBL-2 cells (1 x 
10
4
 cells/well) were incubated with peritoneal macrophages (PM(|)) and 2 ng /ml of 
LPS in the presence or absence of K7 antigen for 48 hr at 37°C. The cytostatic activity 
of the PLA-activated PM(|) was measured by their ability to inhibit the growth of 
MBL-2 cells, as determined from the [
3
H]-TdR incorporation of the MBL-2 cells 
grown in the presence or absence of the PM(|). Results were expressed as mean 土 S.E. 
of quadruplicate cultures. 
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Figure 5.3: Effect of K7 capsular antigen on the production of nitric oxide 
from TG-elicited peritoneal macrophages. TG-elicited PM(|) (5 x 10
5
 cells/well) were 
incubated with increasing concentrations of K7 antigen at 37°C. Cell-free 
supernatant (100 jul) collected after 24, 48, or 72 hr were allowed to react with Griess 
reagent and NO generated, as measured by the accumulation of nitrite in the 
supernatant, was quantitated by a colorimetric method using sodium nitrite as a 
standard. The results were expressed as mean 土 S.E. of quadruplicate cultures. 
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5.2.5 Effect of K7 Capsular Antigen on the In Vitro Production of Tumour 
Necrosis Factor (TNF) by Macrophages 
It has been well known that TNFs are important in mediating 
cytotoxic/ cytocidal activities against tumours (Bonta and Ben-Efraim, 1993), and 
participate in various immune regulations (Kehrl et al., 1987 & Scheurich et al., 1987). 
As shown in Fig. 5.4, peritoneal macrophages incubated for 24 hr with increasing 
concentrations of K7 antigen, ranging from 12.5 to 100 jig/ ml, had resulted in a dose-
dependent release of TNF, as measured by the cytotoxicity of the culture 
supernatants on L929 cells. Moreover, TNF released from macrophages stimulated 
with 100 |ng/ml K7 antigen induced 90% cytotoxicity on L929 cells at a dilution of 
1/2400, which is comparable to the cytotoxicity observed with the supernatant of 
macrophages stimulated with 1 jug/ml of LPS (Fig. 5.5). 
It has been reported that macrophages can be activated to produce TNF in 
the presence of trace amount of LPS, therefore, to exclude LPS contamination of K7 
antigen as the activating signal, macrophages were cultured in the presence of 5 
j ig/ml PB. It was found that pre-incubation of K7 antigen with PB did not inhibit the 
TNF production by macrophages. In contrast, PB produced a marked (67%) 
reduction in the cytotoxicity of culture supernatant on L929 cells from macrophages 
I 
stimulated by 1 p.g/ml of LPS (Fig. 5.5). 
5.2.6 Effect of K7 Capsular Antigen on the In Vitro Induction of Gene 
Expression in Macrophages 
To investigate the effect of K7 antigen on the induction of gene 
expression in macrophages in vitro, specifically designed primers (Table 2.1, Chapter 
2) were used for the detection of gene expression in TG-elicited peritoneal 
macrophages. TG-elicited PEC (5 x 10
7
 cells) were seeded onto a 75 cm
2
 flask for 3 hr 
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Figure 5.4: Effect of K7 capsular antigen on the production of TNF by TG-
elicited peritoneal macrophages. TNF produced in cell-free supernatants of TG-
elicited PM(|) (3 x 10
5
 cells/well), stimulated for 24 hr with medium alone or various 
concentrations of K7 antigen (12.5 - 100 jag/ml), was assayed by using the murine 
fibroblast L929 cell line. Serial dilutions (150 - 153600 fold) of the culture 
supernatants and an equal volume of actinomycin D (4 jug/ml) were added to 
monolayers of L929 cells and incubated for 18 hr. Results were expressed as % 
cytotoxicity. Data shown were mean 土 S.E. of triplicate cultures. 
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Figure 5.5: Effect of polymyxin B sulphate on the production of TNF by 
TG-elicited peritoneal macrophages stimulated with K7 capsular antigen or LPS. 
TNF produced in cell-free supernatants of TG-elicited stimulated for 24 hr with 
LPS (1 jig/ml) or with increasing concentrations of K7 antigen (12.5 - 100 |xg/ml) in 
the presence (+) or absence � of PB (5 |ig/ml), was assayed by using the murine 
fibroblast L929 cell line. Diluted supernatants (1 : 1200) and an equal volume of 
actinomycin D (4 |ig/ml) were added to monolayers of L929 cells. Results were 
expressed as % cytotoxicity. Data shown were mean 土 S.E. of triplicate cultures. 
Activation of Macrophages by K7 Antigen Page 150 
at 37°C. Non-adherent cells were removed by washing three times with warm 
medium. The adherent macrophages were then incubated with K7 antigen (50 
jj.g/ml) for different periods of time (8, 24 and 48 hr). Meanwhile, untreated 
adherent macrophages were included as the control sample. Total cellular RNAs 
were prepared from K7 antigen-treated TG-elicited peritoneal macrophages and 
were then reverse transcribed into cDNA by priming with oligo-dT. 
Gene expression levels were analyzed on ethidium-stained agarose gel after 
PCR amplification. The identity of the PCR product was then verified by dot blot 
hybridization (except TGF-p in which a cDNA probe was not available) and semi-
quantitative analysis was performed by cycle titration followed by densitometric 
scanning of the resulting hybridization signals. The absence of contaminants in the 
PCR mixtures was regularly checked by the co-amplification of a negative control 
reaction tube containing no cDNA template. In addition, the amount of RNA used in 
each experiment was normalized by comparison with the amplification of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (Fig. 5.6). 
The modulatory effects of K7 antigen on the gene expression of p r o 
I 
inflammatory cytokines such as TNF-a, IL-la, IL-p and IL-6 by macrophages were 
first analyzed. Using RT-PCR, it was found unstimulated macrophages expressed a 
l o w level of TNF-a mRNA and that K7 antigen markedly enhanced the expression of 
TNF-a gene in K7 a n t i g en - t r e a t e d macrophages at 8 hr after exposure to K7 antigen 
(Fig. 5.7 & 5.8). However, the level of TNF-a mRNA was slightly downregulated by 
48 hr as compared to the control level. 
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Figure 5.6: Analysis of GAPDH gene expression in K7 antigen-treated 
TG-elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured 
with K7 antigen (50 |Lig/ml) at 37°C for different periods of time (0, 8, 24 & 48 hr). 
Total cellular RNAs were prepared using the method of guanidine thiocyanate-
cesium chloride ultracentrifugation. They were then reverse transcribed and 
amplified by PCR for 20 cycles using specific primers. PCR products were then 
analyzed on ethidium bromide-stained 2% agarose gel. The position of the PCR 
product was marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PM(|) (48 hr) 
Lane C: K7 antigen-treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.7: Analysis of TNF-a gene expression in K7 antigen-treated TG-
elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured with 
K7 antigen (50 |ig/ml) at 37。C for different periods of time (0, 8, 24 & 48 hr). Total 
cellular RNAs were prepared using the method of guanidine thiocyanate-cesium 
chloride ultracentrifugation. They were then reverse transcribed and amplified by 
PCR for 27 and 30 cycles using specific primers. PCR products were then analyzed 
on ethidium bromide-stained 2% agarose gel. The position of the PCR product was 
marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PM(|) (48 hr) 
Lane C: K7-antigen treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.8: (Upper Panel) Semi-quantitative dot blot analysis of TNF-a 
gene expression in K7 antigen-treated TG-elicited peritoneal macrophages. 15 \xl 
RT-PCR products were denatured, transferred to a positively charged nylon 
membrane, and subsequently detected for chemiluminescence with the 
corresponding DIG-labelled oligonucleotide probe. Hybridization signals were then 
recorded on X-ray film. (Lower panel) Desitometric analysis of the hybridization 
signals. Hybridization signals of the dot blot (25 cycles) were analyzed by 
densitometric scanning using ImageQuaNT™ software. 
Lane A: untreated PM(|) Lane D: K7-antigen treated PM(|) (48 hr) 
Lane B: K7-antigen treated PMc|) (8 hr) Lane E: negative control (no cDNA 
Lane C: K7-antigen treated PM(|) (24 hr) template 
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On the other hand, untreated macrophages were shown to express a very low 
level of IL-la mRNA which was not detectable in the ethidium bromide stained gel 
(Fig. 5.9) but was revealed in dot blot hybridization analysis (Fig 5.10). Interestingly, 
the K7 antigen-treated macrophages showed a time-dependent increase in the 
expression of IL-la mRNA with maximal expression occurred at 8 hr after 
stimulation while the expression level remained high at 24 hr (Fig. 5.9 & 5.10). 
Similar results were obtained when the expression of the IL-lp gene was analyzed 
(Fig. 5.11 & 5.12). 
As shown in Fig. 5.13 & 5.14, untreated macrophages expressed a very low 
level of IL-6 mRNAs which underwent a rapid but transient increase in its 
expression after stimulation with K7 antigen. The level of its transcript increased 
markedly after 8 hr of stimulation but then returned backed to the control level by 48 
hr. 
TGF-p is an inflammatory cytokine that can be secreted from activated 
macrophages (Assoian et al., 1987). Therefore, the expression of TGF-P gene in K7 
antigen-stimulated TG-elicited peritoneal macrophages was also investigated. The 
results in Fig.5.15 show that TGF-p gene was expressed at a low level in the 
untreated macrophages and its level was slightly increased at 8 hr after exposure to 
K7 antigen. However, at 24 hr and 48 hr there was a dramatic decrease in the level of 
TGF-p mRNA and only trace amount of it was discernible. 
The results in Section 5.2.4 clearly show that K7 antigen can induce the 
production of NO from macrophages. In view of this observation, the effect of K7 
antigen on the expression of inducible nitric oxide synthase (iNOS) gene in TG-
elicited peritoneal macrophages was also studied to determine whether the induced 
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Figure 5.9: Analysis of IL-la gene expression in K7 antigen爾treated TG-
elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured with 
K7 antigen (50 |ng/ml) at 37。C for different periods of time (0, 8, 24 & 48 hr). Total 
cellular RNAs were prepared using the method of guanidine thiocyanate-cesium 
chloride ultracentrifugation. They were then reverse transcribed and amplified by 
PCR for 25 cycles using specific primers. PCR products were then analyzed on 
ethidium bromide-stained 2% agarose gel. The position of the PCR product was 
marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated P M . (48 hr) 
Lane C: K7 antigen-treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.10: (Upper Panel) Semi-quantitative dot blot analysis of IL-la 
gene expression in K7 antigen-treated TG-elicited peritoneal macrophages. 15 |iil 
RT-PCR products were denatured, transferred to a positively charged nylon 
membrane, and subsequently detected for chemiluminescence with the 
corresponding DIG-labelled oligonucleotide probe. Hybridization signals were then 
recorded on X-ray film. (Lower panel) Desitometric analysis of the hybridization 
signals. Hybridization signals of the dot blot (25 cycles) were analyzed by 
densitometric scanning using ImageQuaNT™ software. 
Lane A: untreated PM(|) Lane D: K7 antigen-treated PM(|) (48 hr) 
Lane B: K7 antigen-treated PM(|) (8 hr) Lane E: negative control (no cDNA 
Lane C: K7 antigen-treated PM(|) (24 hr) template 
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Figure 5.11: Analysis of IL-lp gene expression in K7 antigen-treated TG-
elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured with 
K7 antigen (50 |iig/ml) at 37°C for different periods of time (0, 8, 24 & 48 hr). Total 
cellular RNAs were prepared using the method of guanidine thiocyanate-cesium 
chloride ultracentrifugation. They were then reverse transcribed and amplified by 
PCR for 20 and 25 cycles using specific primers. PCR products were then analyzed 
on ethidium bromide-stained. 2% agarose gel. The position of the PCR product was 
marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PM(|) (48 hr) 
Lane C: K7 antigen-treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.12: (Upper Panel) Semi-quantitative dot blot analysis of IL-lp 
gene expression in K7 antigen-treated TG-elicited peritoneal macrophages. 15 |ul 
RT-PCR products were denatured, transferred to a positively charged nylon 
membrane, and subsequently detected for chemiluminescence with the 
corresponding DIG-labelled oligonucleotide probe. Hybridization signals were then 
recorded on X-ray film. (Lower panel) Desitometric analysis of the hybridization 
signals. Hybridization signals of the dot blot (20 cycles) were analyzed by 
densitometric scanning using ImageQuaNT™ software. 
Lane A: untreated PM(|) Lane D: K7 antigen-treated PM(|) (48 hr) 
Lane B: K7 antigen-treated PM(|) (8 hr) “ Lane E: negative control (no cDNA 
Lane C: K7 antigen-treated PM(|) (24 hr) template 
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Figure 5.13: Analysis of IL-6 gene expression in K7 antigen-treated TG-
elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured with 
K7 (50 |ig/ml) at 37。C for different periods of time (0, 8, 24 & 48 hr). Total cellular 
RNAs were prepared using the method of guanidine thiocyanate-cesium chloride 
ultracentrifugation. They were then reverse transcribed and amplified by PCR for 30 
cycles using specific primers. PCR products were then analyzed on ethidium 
bromide-stained 2% agarose gel. The position of the PCR product was marked by the 
arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PM^ (48 hr) 
Lane C: K7- antigen treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.14: (Upper Panel) Semi-quantitative dot blot analysis of IL-6 
gene expression in K7 antigen-treated TG-elicited peritoneal macrophages. 15 |til 
RT-PCR products were denatured, transferred to a positively charged nylon 
membrane, and subsequently detected for chemiluminescence with the 
corresponding DIG-labelled oligonucleotide probe. Hybridization signals were then 
recorded on X-ray film. (Lower panel) Desitometric analysis of the hybridization 
signals. Hybridization signals of the dot blot (30 cycles) were analyzed by 
densitometric scanning using ImageQuaNT™ software. 
Lane A: untreated PM(|) Lane D: K7 antigen-treated PM(|) (48 hr) 
Lane B: K7 antigen-treated PM(|) (8 hr) Lane E: negative control (no cDNA 
Lane C: K7 antigen-treated PM(|) (24 hr) template 
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Figure 5.15: Analysis of TGF-(3 gene expression in K7 antigen-treated 
TG-elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured 
with K7 antigen (50 |iig/ml) at 37。C for different periods of time (0, 8, 24 & 48 hr). 
Total cellular RNAs were prepared using the method of guanidine thiocyanate-
cesium chloride ultracentrifugation. They were then reverse transcribed and 
amplified by PCR for 20, 25 and 30 cycles using specific primers. PCR products were 
then analyzed on ethidium bromide-stained 2% agarose gel. The position of the PCR 
product was marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PM(|) (48 hr) 
Lane C: K7 antigen-treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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production of NO from K7 antigen-stimulated macrophages was due to the increase 
in transcription of the iNOS gene. As shown in Fig. 5.16 & 5.17, untreated 
macrophages expressed a very low level of iNOS mRNA which was then underwent 
a marked increase in expression at 8 hr after exposure to K7 antigen. Although the 
level of its transcript was decreased at 24 hr and 48 hr after stimulation, the level of 
iNOS mRNA was still higher than that expressed in untreated macrophages (Fig. 
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Figure 5.16: Analysis of iNOS gene expression in K7 antigen-treated TG-
elicited peritoneal macrophages by RT-PCR. TG-elicited PM(|) were cultured with 
K7 antigen (50 |iig/ml) at 37°C for different periods of time (0, 8, 24 & 48 hr). Total 
cellular RNAs were prepared using the method of guanidine thiocyanate-cesium 
chloride ultracentrifugation. They were then reverse transcribed and amplified by 
PCR for 20, 25 and 30 cycles using specific primers. PCR products were then 
analyzed on ethidium bromide-stained 2% agarose gel. The position of the PCR 
product was marked by the arrow and its expected size was shown on the right. 
Lane A: 1 Kb DNA ladder Lane D: K7 antigen-treated PM(|) (24 hr) 
Lane B: untreated PM(|) Lane E: K7 antigen-treated PMc|) (48 hr) 
Lane C: K7 antigen-treated PM(|) (8 hr) Lane F: negative control (no cDNA 
template) 
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Figure 5.17: (Upper Panel) Semi-quantitative dot blot analysis of iNOS 
gene expression in K7 antigen-treated TG-elicited peritoneal macrophages. 15 jul 
RT-PCR products were denatured, transferred to a positively charged nylon 
membrane, and subsequently detected for chemiluminescence with the 
corresponding DIG-labelled oligonucleotide probe. Hybridization signals were then 
recorded on X-ray film. (Lower panel) Desitometric analysis of the hybridization 
signals. Hybridization signals of the dot blot (25 cycles) were analyzed by 
densitometric scanning using ImageQuaNT™ software. 
Lane A: untreated PM(|) Lane D: K7 antigen-treated PM(|) (48 hr) 
Lane B: K7 antigen-treated PM(|) (8 hr) Lane E: negative control (no cDNA 
Lane C: K7 antigen-treated PM(|) (24 hr) template 
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5 . 3 D I S C U S S I O N 
The possibility of selective stimulation of macrophages for experimental and 
therapeutic applications would be of great interest, since this cell population is 
capable of developing high bactericidal and tumouricidal activities. The stimulation 
of macrophages to high bactericidal and tumouricidal activities is usually termed 
activation and has been reviewed (Turpin and Lopez-Berestein, 1993). In Chapter 4, 
the modulatory effects of the Klebsiella K7 capsular antigen on lymphocyte 
proliferation and hematopoietic cell development have been described. Therefore, in 
this chapter, the effects of K7 antigen on the activation of different aspects of 
macrophage functions were investigated. 
For the murine peritoneal macrophages, four different stages of activation 
. 
j 
have been defined and cells in these stages are called resident, inflammatory 
. j 
(responsive), primed, and fully activated macrophages respectively. Cells harvested 
from the peritoneal cavity following injection of sterile irritating agents, such as 
casein, proteose peptone, or thioglycollate broth are usually called 'inflammatory 
macrophages'. When exposed in vitro to secretory products of immune cells such as 
IFN-y and products from bacterial cells such as LPS, inflammatory macrophages will 
become fully activated with increased phagocytic activity and with enhanced 
capacity to kill tumour cells. In the present investigation, our results show that K7 
antigen significantly enhanced the phagocytic capacity of resident peritoneal 
macrophages. The results are in agreement with a previous report showing that CPS-
K enhanced the phagocytic capacity of either peritoneal macrophages or 
macrophages generated in the culture of spleen cells (Yokochi et al, 1977). The 
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mechanism(s) whereby K7 antigen can enhance the phagocytic activity of 
macrophage is unclear and remains to be determined. 
In addition to phagocytic capacity of macrophages, the in vivo activation of 
macrophages was also investigated. The results show that K7 antigen alone or in 
combination with PP enhanced the in vivo migration of macrophages. The 
mechanism(s) for this enhancement remains obscure. Interestingly, K7 antigen was 
found to be capable of enhancing the transcription of TGF-p gene in K7 antigen-
treated TG-elicited peritoneal macrophages. Since TGF-P is the most potent 
monocyte chemoattracfant and its maximal chemotactic effect is achieved at 
femtomolar levels (Wahl et al" 1987), it is possible that K7 antigen may stimulate the 
macrophages to produce chemoattractants such as TGF-p which acts in a paracrine 
or autocrine manner to attract more macrophages. Alternatively, K7 antigen may 
directly increase the chemotactic response of macrophages, thus stimulating the in 
vivo migration of macrophages. 
It has recently been realized that NO plays important roles in the body 
(Nathan, 1992 & Ralston et al" 1995). NO synthase in the nervous system or 
endothelial cells is of constitutive type (cNOS) while macrophages possess an 
inducible type of NO synthase (iNOS). Macrophages activated by cytokines (e.g. 
IFN-y) or bacterial products (e.g. LPS) produce NO from the guanidino nitrogen of 
arginine (Iyengar et al" 1987) which has been shown to be instrumental in causing 
cytostasis (Granger et al.f 1988), or cytolysis (Green et al" 1990) of a number of 
microorganisms. In addition, it is also operative in macrophage-mediated lysis of 
tumour cells (Hibbs et al； 1988), and thus NO is important in macrophages' 
tumouricidal activity. In this investigation, it was found that K7 antigen could 
augment the production of NO in a time and dose-dependent manner which might 
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be due to the increased transcription of iNOS gene. Similarly, Keller et al. (1991) had 
reported that heat-killed Klebsiella pneumoniae (wild type) significantly enhanced the 
secretion of reactive nitrogen intermediates from bone marrow-derived mononuclear 
phagocytes. However, whether K7 antigen and heat-killed Klebsiella pneumoniae 
would share the same mechanism in triggering the secretion of RNI from 
macrophages remains to be elucidated. 
In addition to the secretion of NO, activated macrophages are known to 
secrete several inflammatory cytokines such as IL-1, IL-6, IL-8, G-CSF and TNF. TNF 
is a pleiotropic cytokine with tumour necrosis activity and is secreted mainly by 
macrophages, and has been recognized as an important host regulatory molecule 
(Vilcek and Lee, 1991). In this study, we demonstrated that K7 antigen could trigger 
the production of TNF from peritoneal macrophages in a dose-dependent maimer 
and that the increase in TNF production from peritoneal macrophages was resulted 
from the increased transcription of TNF-a gene. The TNF releasing activity of K7 
antigen could not be attributed to the contamination with LPS because TNF release 
was not affected by PB treatment. It has been reported that components of bacteria 
have profound effects on cytokine production from macrophages. In addition to 
TNF-a gene, the gene expression levels of other pro-inflammatory cytokines such as 
IL-la, IL-ip and IL-6 were also enhanced in K7 antigen-treated macrophages. The 
enhancement of these pro-inflammatory cytokine genes has suggested to be 
important for the macrophages to mediate anti-tumour responses because it has been 
reported that TNF can act synergistically with IL-1 against various tumour cells 
(Ruggiero and Baglioni, 1987 & Ichinose et al" 1988) and that IL-6 can act 
synergistically with TNF in promotion of an anti-tumour response (Mule et al., 1990). 
Further investigations should be made to determine whether the increased 
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transcription of these cytokine genes was parallel by the increased secretion of these 
cytokines. 
The ability to kill tumour cells is one of the most important function of fully 
activated macrophages. It is because macrophages can selectively kill the 
transformed cells while leaving the normal cells unharmed (Fidler and Schroit, 
1988). Killing of tumour cells can be classified into two categories: cytostatic or 
cytotoxic pathways. However, no clear single mechanism has been defined which 
contributes to the killing of tumour cells by macrophages. Our results show that K7 
antigen markedly augmented the cytostatic activity of macrophages towards MBL-2 
lymphoma cells. It is possible that an increased secretion of TNF-a from 
macrophages may be, in part, responsible for destroying the tumour cells. 
Interestingly, Keller et al (1987) had shown that the tumouricidal activity elicited by 
lymphokines, such as m a c r o p h a g e - a c t i v a t i n g lymphokines and IFN-y, was short-
lived whereas that induced by heat-killed bacteria persisted for weeks through a T 
cell- and IFN-y- independent pathway, provided that the bacteria were continuously 
I 
present in the culture. In an in vivo study, the tumour-protective effect of bacteria 
was much more pronounced than that of the lymphokines (Keller et al" 1989). Thus, 
the use of bacteria for the induction of tumouricidal activity of macrophages seems 
to be more preferable than that of lymphokines. However, whether the purified 
bacterial components, such as K7 antigen, would act in the same way as heat-killed 
bacteria for the induction of tumouricidal activity of macrophages remains to be 
determined. 
It has been reported that P-glucans, such as SSG, lentinan and GRN, were 
capable of enhancing the phagocytic capacity of macrophages (Abel et al, 1989 & 
Sakurai et al, 1992b), and the production of inflammatory cytokines (Adachi et al, 
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1994). Recently, a receptor specific for (l->3)-p-glucans was suggested to be present 
on macrophages/ monocytes which might contribute to phagocytosis (Janusz et al" 
1986 & Abel et al" 1989) and secretion of various inflammatory mediators (Poutsiaka 
et al” 1993 & Elstad et al" 1994). In addition, Abel and Czop (1992) showed that this 
receptor was related to the production of TNF-a and IL-1 by monocytes stimulated 
by particulate (3-glucan. Until now, no report has been documented that the presence 
of similar receptors for bacterial polysaccharides which contribute to phagocytic 
function of macrophages and the secretion of inflammatory mediators. However, 
Athamna et al (1990) reported that macrophages express a mannose/N-
acetylglucosamine-specific lectin which serves as a receptor for non-opsonic 
phagocytosis of the bacteria Klebsiella pneumoniae. Interestingly, Klebsiella pneumoniae 
serotype 7 bacteria were found to bind poorly to the alveolar macrophages while the 
isolated capsular polysaccharide of Klebsiella pneumoniae serotype 7 could efficiently 
bind to the macrophages through this receptor (Athamna et al., 1990). Although no 
evidence supports that the binding of capsular polysaccharides to this receptor 
would enhance the phagocytosis of macrophages, it may be possible that the 
efficient binding of isolated K7 antigen to the mannose/N-acetylglucosamine-
specific lectin receptors on macrophage surface can facilitate its uptake into the 
macrophages which subsequently results in the activation of the macrophages. 
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CHAPTER 6 , 
ANTI-TUMOUR ACTIVITIES 
OF KLEBSIELLA 
K7 CAPSULAR ANTIGEN 
I 
6.1 INTRODUCTION 
There has been an increasing interest in the studies of polysaccharides as a 
BRM for tumour therapy (Clark, 1993 & Wong et al； 1994a). The interest in 
polysaccharides as anti-tumour substances came from the dissatisfaction with 
current cancer therapy. For example, most chemotherapeutic anti-tumour drugs 
have considerable side effects and /or poor efficacy. With the view of developing 
new anti-tumour drugs with low toxic potential, a number of polysaccharides 
derived from different biological sources, e.g., bacteria, fungi, yeast, algae, and 
higher plants, have been investigated for their anti-tumour and immunomodiilating 
activities. These bioactive polysaccharides have been shown to display anti-tumour 
effects against allogeneic (Suzuki et al" 1987 & Kraus et al., 1992), syngeneic (Suzuki 
et al., 1988 & Kado et al., 1991), as well as autologous tumours (Suga et al" 1984) 
Current evidence indicated that the anti-tumour activity of the immunostimulatiiig 
polysaccharide is not caused by direct cytotoxic effects, but is thought to be 
mediated through modulation of the host's immune system. Many bioactive 
polysaccharides have been found to be capable of stimulating the cell-mediated 
immunity, such as activation of helper T-cells, NK cells, LAK cells and cytotoxic 
macrophages as well as augmentation of cytotoxic T-cell activity, in addition to an 
enhanced production of some serum factors (Lien, 1990 & Lien and Gao, 1990). In 
previous chapters, the K7 antigen has been shown to be capable of modulating 
hematopoietic cell development and stimulating lymphocyte proliferation (Chapter 
4) as well as activating macrophages both in vitro and in vivo (Chapter 5). Therefore, 
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in this chapter, the in vivo and in vitro anti-tumour activities of K7 antigen were also 
examined. 
Differentiating agents are one kind of biological response modifiers that can 
reverse or suppress the phenotype of cancer cells by either induction of 
differentiation or by restoration of responses to normal growth control mechanisms 
(Lotan et al., 1990). It has been well documented that formation of some myeloid 
leukemia cells are due to the impairment of a certain stage of differentiation in the 
normal hematopoietic process. More recently, there are increasing evidences which 
suggest that different myeloid leukemia cells can be induced to differentiate into 
cells with normal characteristics of macrophages, granulocytes, or erythrocytes by a 
variety of differentiation inducers (Michaeli et al" 1993 & Warrell, 1995). The 
differentiated cells normally stop to proliferate and lose their transplantability in 
syngeneic animals (Leung et al" 1994). Therefore, the induction of terminal cell 
differentiation by certain inducers is a promising approach to the therapy of some 
forms of myeloid lexikemias. Since K7 antigen has shown to be capable of 
modulating the normal hematopoietic cell development (Chapter 4), thus, in this 
chapter, the differentiation-inducing activity of K7 antigen on a subcloned and well 
characterized leukemia cell model (WEHI-3B JCS) was examined. 
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6.2 RESULTS 
6.2.1 Effect of K7 Capsular Antigen on the In Vitro Growth of Various 
Tumour Cell Lines 
The anti-proliferative activity of K7 antigen on various cultured tumour cell 
lines was assessed by determining the % inhibition of [
3
H]-TdR incorporation in the 
K7 antigen-treated tumour cells. It was found that K7 antigen exerted a dose-
dependent suppressive effect on the proliferation of various myeloid leukemia cells, 
including M l cells (Fig. 6.1), WEHI-3B JCS (Fig. 6.2), and HL-60 cells (Fig. 6.3) with 
IC50 of 3.2 j ig/ml, 100 |ng/ml and >200 fxg/ml respectively. In contrast, K7 antigen 
exhibited little, if any, cytostatic effect on a variety of tumour cell lines, including 
fibroblast tumour such as L929 cells (Fig. 6.4), fibrosarcoma such as SC180 (Fig. 6.5), 
T lymphoma cells such as MBL-2 cells (Fig. 6.6) and YAC-1 cells (Fig. 6.7), 
macrophage-like tumour such as P388Di cells (Fig. 6.8) and carcinoma cells such as 
EAT cells (Fig. 6.9). 
6.2.2 Effect of K7 Capsular Antigen on the In Vivo Growth of EAT cells 
It has been reported that most polysaccharides did not show any direct 
inhibitory effect on tumour cells in vitro but they often display strong anti-tumour 
effect in vivo through modulation of the host immune defense mechanisms (Wong et 
al., 1994b). As shown in section 6.2.1, K7 antigen did not exhibit any anti-tumour 
activity on EAT cells in vitro. Therefore, the in vivo anti-tumour activity of K7 antigen 
on EAT cells was assessed. Results in Table 6.1 show that K7 antigen exerted strong 
anti-tumour activity in vivo on EAT cells. It inhibited the in vivo growth of EAT cells 
to about 37% of the control group. 
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Figure 6.1: Cytostatic effect of K7 capsular antigen on murine myeloblastic 
leukemia M l cells. Ml cells (5 x 10
3
 cells/0.2 ml) were incubated with different 
concentrations of K7 antigen (0-200 |ig/ml) at 37°C for 48 hr in a humidified 
atmosphere containing 5% C〇2-95% air. The cultures were then pulsed with [3H]_ 
TdR (0.5 |iCi/20|aI/well) for 6 hr before harvesting. Radioactivity in cpm was 
measured by liquid scintillation counting. Results were expressed as % inhibition of 
[
3
H]-TdR incorporation, using untreated Ml cells as a control. Each data point 
represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated Ml cells was 36,280 土 870 cpm. 
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Figure 6.2: Cytostatic effect of K7 capsular antigen on the murine 
myelomonocytic leukemia cells WEHI-3B JCS cell. JCS cells (1 x 1CP cells/0.2 ml) 
were incubated with different concentrations of K7 capsular antigen (0-200 |xg/ml) 
for 72 hr at 37°C in a humidified atmosphere containing 5% C〇2-95% air. The 
cultures were pulsed with [
3
H]-TdR (0.5|iCi/20(il/well) for 6 hr before harvesting. 
Radioactivity in cpm was measured using liquid scintillation counting. Results were 
expressed as % inhibition of [
3
H]-TdR incorporation, using untreated JCS cells as a 
control. Each data point represents the mean 士 S.E. of quadruplicate cultures. The 
basal [
3
H]-TdR incorporation of the untreated JCS cells was 46,320 土 181 cpm. 
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Figure 6.3: Cytostatic effect of K7 capsular antigen on the human 
promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10
4
 cells/0.2 ml) were 
incubated with different concentrations of K7 antigen (0-200 | ig/ml) at 37°C for 48 hr 
in a humidified atmosphere containing 5% C〇2-95% air. The cultures were then 
pulsed with [
3
H]-TdR (0.5 |iCi/20|Lil/well) for 6 hr before harvesting. Radioactivity in 
cpm was measured by liquid scintillation counting. Results were expressed as % 
inhibition of [
3
H]-TdR incorporation, using untreated HL-60 cells as a control. Each 
data point represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of untreated HL-60 cells was 83,827 士 1903 cpm. 
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Figure 6.4: Effect of K7 capsular antigen on the proliferation of L929 
fibroblast cells. L929 cells (1 x 10
4
 cells/0.2 ml) were incubated with different 
concentrations of K7 antigen (0-200 ng/ml) at 37°C for 48 hr in a humidified 
atmosphere containing 5% C〇2-95% air. The cultures were then pulsed with [3H]-
TdR (0.5 |j.Ci/20|j.l/well) for 6 hr before harvesting. Radioactivity in cpm was 
measured by liquid scintillation counting. Results were expressed as % inhibition of 
[
3
H]-TdR incorporation, using untreated L929 cells as a control. Each data point 
represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated L929 cells was 88,422 ± 1335 cpm. 
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Figure 6.5: Effect of K7 capsular antigen on the proliferation of 
fibrosarcoma SC180 cells. SC180 cells (5 x 10
3
 cells/0.2 ml) were incubated with 
different concentrations of K7 antigen (0-200 jig/ml) for 48 hr at 37°C in a 
humidified atmosphere containing 5% C〇2-95% air. The cultures were pulsed with 
[
3
H]-TdR (0.5|xCi/20nl/well) for 6 hr before harvesting. Radioactivity in cpm was 
measured using liquid scintillation counting. Results were expressed as % inhibition 
of [
3
H]-TdR incorporation, using untreated SC180 cells as a control. Each data point 
represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated SC180 cells was 46,320 土 181 cpm. 
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Figure 6.6: Effect of K7 capsular antigen on the proliferation of T 
lymphoma MBL-2 cells. MBL-2 cells (5 x 10
3
 cells/0.2 ml) were incubated with 
different concentrations of K7 antigen (0-200 jag/ml) at 37°C for 48 hr in a 
humidified atmosphere containing 5% C〇2-95% air. The cultures were then pulsed 
with [
3
H]-TdR (0.5 jiCi/20|il/well) for 6 hr before harvesting. Radioactivity in cpm 
was measured by liquid scintillation counting. Results were expressed as % 
inhibition of [
3
H]-TdR incorporation, using untreated MBL-2 cells as a control. Each 
data point represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated MBL-2 cells was 128,849 士 4828 cpm. 
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Figure 6.7: Effect of K7 capsular antigen on the proliferation of T-
lymphoma YAC-1 cells. YAC-1 cells (5 x 10
3
 cells/0.2 ml) were incubated with 
different concentrations of K7 capsular antigen (0-200 pg/ml) for 48 hr at 37°C in a 
humidified atmosphere containing 5% C〇2-95% air. The cultures were pulsed with 
[
3
H]-TdR (0.5piCi/ 20jul/well) for 6 hr before harvesting. Radioactivity in counts per 
minute (cpm) was measured using liquid scintillation counting. Results were 
expressed as % inhibition of [
3
H]-TdR incorporation, using untreated YAC-1 cells as 
control. Each data point represents the mean 土 S.E. of quadruplicate culture. The 
basal [
3
H]-TdR incorporation of the untreated YAC-1 cells was 46,320 土 181 cpm. 
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Figure 6.8: Effect of K7 capsular antigen on the proliferation of 
macrophage-like tumour P388Di cells. P388Di cells (1 x 10
3
 cells / 0.2 ml) were 
incubated with different concentrations of K7 antigen (0-200 |Lig/ml) for 48 hr at 37°C 
in a humidified atmosphere containing 5% C〇2-95% air. The cultures were pulsed 
with [
3
H]-TdR (0.5(iCi/ 20fil/ well) for 6 hr before harvesting. Radioactivity in cpm 
was measured using liquid scintillation counting. Results were expressed as % 
inhibition of [
3
H]-TdR incorporation, using untreated P388Di cells as control. Each 
data point represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated P388Di cells was 26,296 土 795 cpm. 
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Figure 6.9 : Effect of K7 capsular antigen on the proliferation of murine 
carcinoma EAT cells. EAT cells (5 x 10
3
 cells/0.2 ml) were incubated with different 
concentrations of K7 antigen (0-200 jug/ml) at 37°C for 48 hr in a humidified 
atmosphere containing 5% C〇2-95% air. The cultures were then pulsed with [3H]-
TdR (0.5 |iiCi/20|LLl/well) for 6 hr before harvesting. Radioactivity in cpm was 
measured by liquid scintillation counting. Results were expressed as % inhibition of 
[
3
H]-TdR incorporation, using untreated EAT cells as control. Each data point 
represents the mean 土 S.E. of quadruplicate cultures. The basal [3H]-TdR 
incorporation of the untreated EAT cells was 63,070 土 749 cpm. 
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Table 6.1: In Vivo Anti-Tumour Effect of K7 Capsular Antigen on EAT 
Cells 
EAT number 
(x 10-8 cells) Suppression (%) 
Treatment Mean 士 S.E. Mean 士 S.E. 
PBS 8.96 土 0.6 
K7 antigen 3.35 土 0.5 63.4 土 12.2* 
BALB/c mice in groups of five were injected i.p. with EAT cells 
(10
5
/mouse) on day 0. K7 antigen (25 |iig/ mouse/ day) was injected i.p. for 
4 consecutive days (on day 5 - 8 ) . Mice in control group were injected with 
an equal volume of PBS. The tumour cell number recoverable from the 
peritoneal cavity of each mouse was determined on day 9. The difference 
between the control and treatment group was determined by the Student's 
t-test. The results were expressed as mean 土 S.E. of EAT cell number of five 
mice. * P<0.0001. 
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6.2.3 Effect of K7 Capsular Antigen on the Activation of LAK cells 
In Chapter 5, K7 antigen had been shown to activate the various anti-tumour 
activities of macrophages. Apart from activating macrophages, the anti-tumour 
activity of K7 antigen might also be mediated through the activation of the host 
cytotoxic effector cells. Therefore, in the present study, the ability of K7 antigen to 
activate different types of non-specific cytotoxic effector cells such as NK and LAK 
cells was examined. It was found that incubation of normal mouse splenocytes with 
either rmIL-2 or K7 antigen for 3 days could generate significant LAK activity in vitro 
(Fig. 6.10). In addition, the in vivo injection of K7 antigen could augment the 
cytotoxic activity of splenic LAK cells as compared to those with the in vivo injection 
of PBS (Fig. 6.10). Moreover, the in vivo priming of mice with K7 antigen also 
enhanced the cytotoxic activity of IL-2-stimulated but not K7 antigen-stimulated 
splenic LAK cell activity as compared to those with the in vivo injection of PBS (Fig. 
6.10). 
6.2.4 Effect of K7 Capsular Antigen on the Activation of NK cells 
In addition to the cytotoxic activity of LAK cells, the cytotoxic activity of NK 
cells was also determined. Results in Fig. 6.11 show that K7 antigen could slightly 
augment the cytotoxic activity of splenic NK cells when injected at a dose of 125 jag 
per mouse. 
6.2.5 Effect of K7 Capsular Antigen on the Induction of Monocytic 
Differentiation of the Murine Myeloid Leukemia JCS Cells 
The results in Section 6.1 show that K7 antigen significantly inhibited the 
proliferation of JCS leukemic cells in a dose-dependent manner. It was found that 
the anti-proliferative effect of K7 antigen on the leukemia JCS cells could not be 
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Figure 6.10: Effect of K7 capsular antigen on the induction of LAK activity 
of murine splenocytes. Mice in groups of five were injected with PBS (0.2 
ml /mouse /day) or K7 antigen (50 jng/0.2 ml /mouse/day) for 7 consecutive days. 
Splenocytes obtained from these two groups of mice were incubated medium, IL-2 
(50 U/ml) , or K7 antigen (50 (ig/ml) for 3 days at 37°C. The viable splenocytes were 
then incubated with WEHI-164 cells at an effector to target ratio of 25:1 for 24 hr at 
37°C. LAK activity of different cultures were determined by measuring the % 
cytotoxicity on WEHI-164 cells using neutral red uptake assay. Results were 
expressed as mean % cytotoxicity 土 S.E. of quadruplicate cultures. ^Significantly 
different from the corresponding control group (normal splenocytes cultured with 
medium only), P<0.001. **Significantly different from the corresponding control 
group (splenocytes from mice injected with PBS only), P<0.0001. 
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Figure 6.11: Effect of K7 capsular antigen on the activation of NK cells. On 
day 0y different doses of K7 antigen (75,100 or 125 jug/mouse) were injected i.v. into 
groups of three BALB/c mice. On day 2, NK activity was assayed by a 6 hr cytotoxic 
assay using
 51
Cr-labelled YAC-1 cells as target at an effector to target ratio of 100 :1. 
Poly I:C (100 (ag/ml) was injected into mice and acted as a positive control. Results 
were expressed as mean % cytotoxicity 土 S.E. of quadruplicate cultures. The 
differences between PBS-injected group and treatment groups were determined by-
Student's t-test. *P<0.003 and #P<0.005. 
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attributed to its direct cytotoxicity on the leukemia cells, as the results in Table 6.2 
clearly show that K7 antigen exhibited little (<3%), if any, cytotoxicity towards JCS 
cells after 8 hr or 24 hr incubation, even up to a concentration of 200 jag/ml. In view 
of the potent anti-proliferative activity of K7 antigen on JCS cells, the ability of K7 
antigen to induce differentiation of the JCS cells was also examined. 
6.2.5.1 Effect of K7 Capsular Antigen on the Induction of Morphological 
Changes of JCS cells 
The dose-dependent induction of monocytic differentiation of the leukemia 
JCS cells by K7 antigen was confirmed by examining the cytocentrifuge preparations 
of K7 antigen-treated JCS cells. It was found that the untreated JCS cells were 
myeloblastic in morphology (Fig. 6.12A). Interestingly, JCS cells treated with K7 
antigen (12.5 and 100 jag/ml) demonstrated significant morphological changes, 
including increases in cell size, cytoplasm/ nucleus ratio and vacuolation as 
compared with the untreated control cells (Fig.6.12B & C). 
Cell morphology was analyzed on the modified Wright-Giemsa stained cell 
smear and differential cell counts were performed. JCS cells were scored as blast 
cells (myeloblasts and promyelocytes), intermediate stages cells (myelocytes and 
promonocyte-like cells) and mature cells (macrophage-like cells) (Table 6.3). It can be 
seen that when JCS cells were treated with a lower concentration of K7 antigen (12.5 
jug/ml),〜61% of the cells changed from the blast cell to morphology to the 
intermediate stage morphology and only 〜8% of the cells became macrophage-like. 
On the other hand, exposure of JCS cells to a higher concentration of K7 antigen (100 
jLig/ml) significantly induced the monocytic differentiation of the JCS cells, with ~ 
31% of the cell population showing macrophage-like morphology. 
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Table 6.2: Effect of K7 Capsular Antigen on the Viabili ty of 
Leukemia JCS Cells In Vitro 
Incubation time* K7 antigen % dead cellst 
(jug/ml) Mean 土 S.E) 
8 hr Nil 0.92 士 0.02 
12.5 0.59 士 0.30 
100 0.88 士 0.49 
200 2.65 土 0.46 
24 hr Nil 1.23 ± 0.24 
12.5 1.99 土 0.33 
100 2.76 ± 0.05 
200 4.07 土 0.19 
• Leukemia JCS cells were incubated with different concentrations 
of K7 antigen for 8 or 24 hr at 37°C. 
t Number of dead cells / 100 cells counted in a hemacytometer by 
the trypan blue exclusion method. 
t Results were expressed as arithmetic mean 士 S.E. of triplicate 
cultures. 
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Figure 6.12: Morphological changes of K7 antigen-treated leukemia JCS 
cells. JCS cells (5 x 10
3
 cells/ml) were incubated with two different concentrations of 
K7 antigen (12.5 & 100 ^ig/ml) at 37°C for 72 hr. Cytocentrifuge preparations were 
made and cells were stained with the modified Wright-Giemsa stain. JCS cells were 
incubated with [A] culture medium; [B] K7 antigen (12.5 jig/ml) and [C] K7 antigen 
(100 |xg/ml). (Magnification x 400) 
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Table 6.3: Morphological Differentiation of K7 Antigen-Treated Leukemia JCS 
Cells 
% of cells (mean 士 S.E.) 
K7 antigen Blast Intermediate Mature 
(jig/ml) cells stage cells macrophage-like cells 
Control 96.32 ±0.10 3.68 ±0.10 0 
1 2 . 5 3 0 . 7 2 土 1 . 5 3 6 0 . 8 6 土 2 . 0 1 8 . 4 2 土 0 . 5 1 
1 0 0 1 4 . 8 0 土 0 . 6 3 5 4 . 3 2 士 0 . 3 7 3 0 . 8 8 土 0 . 4 0 
JCS cells (5 x 10
3
 cells/ml) were incubated with two different concentrations of 
K7 antigen (12.5 & 100 lag/ml) at 37°C for 72 hr. Cytocentrifuge preparations 
were made and cells were stained with the modified Wright-Giemsa stain for 
morphological identifications of the cells. Differential counts were performed by 
counting at least 300 cells and the cells were scored as blast cells (myeloblasts 
and promyelocytes), intermediate stage cells (myelocytes and promonocyte-like 
cells) and mature cells (macrophage-like cells). 
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6.2.5.2 Effect of K7 Capsular Antigen on the Expression of Macrophage 
Differentiation Antigens on Leukemia JCS Cells 
During the differentiation and maturation of myeloid leukemia cells, the 
expression of a number of lineage-specific differentiation antigens may be 
augmented in the differentiated cells (Leung et al., 1994 & Mak et al., 1993). Thus, it is 
of great interest to study whether K7 antigen could increase the expression of 
macrophage differentiation antigens, such as Mac-1 and F4/80, on the JCS cells. 
Flow cytometric analysis showed that treatment of JCS cells with K7 antigen (12.5 
and 100 |a.g/ ml) induced phenotypic changes in the cells with the acquisition of 
characteristics of mature macrophages/ monocytes, as shown by the increased 
expression of the macrophage differentiation antigens, including Mac-1 (Fig 6.13) 
and F4/80 (Fig 6.14). 
5.2.5.3 Effect of K7 Capsular Antigen on the Induction of Non-specific 
Esterase Activity in Leukemia JCS cells 
Along with the increase in expression of macrophage differentiation 
antigens, flow cytometric analysis showed that K7 antigen induced the JCS cells to 
express non-specific esterase activity (Fig. 6.15), in which the degree of induction is 
known to be correlated with the stage of maturation along the monocytic 
differentiation pathway (Robinson et al., 1994). 
5.2.5.4 Effect of K7 Capsular Antigen on the Stimulation of Phagocytic 
Activity in Leukemia JCS cells 
The previous results showed that K7-treated JCS cells expressed most 
characteristics of macrophages such as morphological and phenotypic changes, 
increased expression of macrophage differentiation antigens and induction of non-
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Figure 6.13: FACS analysis of the expression of Mac-1 antigen on K7 
antigen-treated JCS cells. JCS cells (5 x 10
3
 cells/ml) were incubated with two 
different concentrations of K7 antigen (12.5 & 100 jmg/ml) at 37°C for 72 hr. Cells 
were stained with rat monoclonal antibody to Mac-1 antigen. Control cells were 
stained with relevant isotype-matched antibody. Paraformaldehyde-fixed cells (10
4 
cells) were analyzed for fluorescence intensity using the FACSort flow cytometer. 
JCS cells were incubated with [A] culture medium; [B] K7 antigen (12.5 jig/ml) and 
[C] K7 antigen (100 |ig/ml). The x-axis was plotted in logarithmic scale. 
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Figure 6.14: FACS analysis of the expression of F^SO antigen on K7 
antigen-treated JCS cells. JCS cells (5 x 10
3
 cells/ml) were incubated with two 
different concentrations of K7 antigen (0-100 \ig/ ml) at 37°C for 72 hr. Cells were 
stained with rat monoclonal antibody to F4/ 80 antigen. Control cells were stained 
with relevant isotype-matched antibody. Paraformaldehyde-fixed cells (10
4
 cells) 
were analyzed for fluorescence intensity using the FACSort flow cytometer. JCS cells 
were incubated with [A] culture medium; [B] K7 antigen (12.5 jug/ml) and [C] K7 
antigen (100 (j-g/ml). The x-axis was plotted in logarithmic scale. 
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Figure 6.15 : Induction of non-specific activity in K7 antigen-treated 
leukemia JCS cells. JCS cells (5 x 10
3
 cells/ml) were incubated with two different 
concentrations of K7 antigen (12.5 & 100 ^ig/ml) at 3 7 ( for 72 hr. Non-specific 
esterase activity was then determined by fluorescein diacetate staining using 
untreated JCS cells as a control. Paraformaldehyde-fixed cells (10
4
 cells) were 
analyzed for fluorescence intensity using the FACSort flow cytometer. The x-axis 
was plotted in logarithmic scale. 
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specific esterase activity. Thus, it would be of interest to examine whether the K7 
antigen-treated cells could exhibit the functional characteristics of macrophages such 
as acquisition of phagocytic activity. In the present study, treatment of JCS cells with 
K7 antigen (12.5 & 100 }ig/ml) had resulted in a dose-dependent induction of 
phagocytic activity in JCS cells after 3 days of incubation (Table 6.4). 
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Table 6.4: Stimulatory Effect of K7 Capsular Antigen on the Phagocytic 
Activity of the Leukemia JCS Cells 
K7 antigen 
(pg/ml) % phagocytic cells 
Control 0 
12.5 4.40 土 0.26 
100 22.13 土 0.16 
JCS cells (1 x 10
3
 cells/0.2 ml) were incubated with two different 
concentrations of K7 antigen (12.5 & 100 |ig/ml) at 37°C for 72 hr. 
Phagocytic activity was determined by the uptake of latex beads. The 
percentage of phagocytic cells (cells that had ingested three or more latex 
beads) was determined by counting at least 300 cells under light 
microscopy and the results were expressed as mean 土 S.E.. 
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6.3 DISCUSSION 
The anti-tumour activity of many bioactive polysaccharides derived from 
different sources is believed to be attributable to their effects on the host defense 
mechanisms rather than their direct damage to the tumour cells (Wong et al., 1994b). 
However, in the present study, K7 antigen was found to have a selective inhibitory 
effect on the proliferation of various cultured tumour cell lines. Our results show 
that K7 antigen exhibited significant anti-proliferative effect on two murine myeloid 
leukemia cell lines, including Ml cells (IC50 = 3.2 jag/ml) and WEHI-3B JCS (IC50 = 
100 jug/ml). On the other hand, the human myeloid leukemia HL-60 cells were 
found to be much less sensitive to the cytostatic effect of K7 antigen (IC50 > 200 
fig/ml). In contrast, K7 antigen exhibited little, if any, anti-proliferative activity on a 
wide variety of tumours, including fibroblast tumours, T cell lymphomas, 
macrophage-like tumour, a fibrosarcoma and a carcinoma. Previously, it had been 
reported that the protein-bound polysaccharides (SN-C) isolated from Cordyceps 
o-phioglossoides could decrease the permeability of glucose through the tumour cell 
membrane in vitro, resulting in the inhibition of DNA synthesis of tumour cells 
(Ohmori et al., 1988). However, the actual basis for the selective in vitro anti-tumour 
activity of K7 antigen on various tumour cells is not known, and whether the anti-
proliferative effect of K7 antigen was resulted from inhibition of glucose uptake 
remains to be determined. Interestingly, K7 antigen exhibited a selective suppressive 
effect on the myeloid leukemia cells which are immature or poorly differentiated 
cells. On the other hand, K7 antigen has no cytostatic activity on a wide variety of 
tumour cell lines, which express the more mature phenotype. Nevertheless, whether 
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the cytostatic activity of K7 antigen is related to the degree of differentiation of the 
tumour cells remains unclear and needs further investigation. Moreover, the activity 
of many natural anti-neoplastic compounds was found to relate to its chemical 
structures (Lou et al., 1988), therefore, the structure of K7 antigen and its anti-tumour 
activity in vitro will be clarified in the future. 
The exhibition of in vivo but not in vitro anti-tumour activity on EAT cells by 
K7 antigen suggested that the in vivo anti-tumour activity of K7 antigen on EAT 
carcinoma was mediated by the modulation of host defense mechanisms. Since 
cytotoxic effector cells such as cytotoxic macrophages, LAK cells and NK cells are 
usually the target cells for the action of anti-tumour polysaccharides (Chu et al, 1988; 
Tani et al" 1992; 1993 & Ren et al, 1995), therefore, in the present study, experiments 
were performed to investigate whether their anti-tumour activities were modulated 
by K7 antigen in vivo. 
Firstly, results in Chapter 5 show that K7 antigen could induce anti-tumour 
activity in murine peritoneal macrophages through enhancement of their cytostatic 
activity towards tumour cells and production of anti-tumour cytokine such as TNF-a 
and RNI such as NO. Similarly, Vacheron et al (1989) had demonstrated that RU-
41470, a glycoprotein complex extracted from Klebsiella pneumoniae, was capable of 
activating macrophages through induction of IL-1 and TNF-a production. Therefore, 
it is conceivable that one possible mechanism whereby K7 antigen may mediate its 
anti-tumour activity is through direct activation of macrophages' tumouricidal 
activity in vivo. 
Secondly, K7 antigen alone was capable of inducing LAK-like activity in 
normal splenocytes in vitro. Interestingly, in vivo priming of mice with K7 antigen 
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was found to enhance the LAK cell cytotoxicity of splenocytes incubated in vitro 
with low dose of rmIL-2 (50 U/ml) towards WEHI-164, a LAK cell-sensitive but NK 
cell-resistant cell line, as compared to mice treated with PBS only. The mechanism 
for enhancing the LAK cell cytotoxicity is still unclear, however, previously Tani et 
al. (1993) showed that the increased LAK cell cytotoxicity after the co-incubation of 
peripheral blood mononuclear cells with IL-2 and lentinan was due to the 
augmentation of expression of IL-2 receptors in these cells. Whether K7 antigen can 
augment LAK cell cytotoxicity through stimulation of IL-2 secretion or upregulation 
of IL-2 receptors in murine splenocytes remains to be established. 
Thirdly, the NK cell cytotoxicity against YAC-1, a NK-sensitive cell line, was 
also found to be augmented by K7 antigen in vivo. Early work by Wybran et al. (1989) 
had shown that bacterial extracts could markedly increase the NK activity of human 
peripheral blood mononuclear cells (PBMC), possibly through increased production 
of cytokines such as IFN-y, TNF-a and IL-2. Similarly, Kato et al (1975) had 
demonstrated that CPS-K could enhance the production of IFN in mice, which 
would in turn enhance the NK cell activity in vivo. However, whether K7 antigen 
acts in the same way as CPS-K in inducing the interferon production is still 
unknown and remains to be determined. 
In addition to the enhancement of anti-tumour activities of various cytotoxic 
effector cells, K7 antigen was found to have differentiation-inducing activity on a 
murine myeloid leukemia WEHI-3B JCS cells. Recently, Ji et al. (1994) has reported 
that polysaccharide from Pleurotus sajjidus (PPS) can inhibit the proliferation and 
induce the differentiation of human monoblast leukemia U937 cells. More recently, 
using an in vitro culture system, Chen et al. (1997) has shown that the conditioned 
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medium from Cordyceps sinesis polysaccharide (PSCS)-stimulated PBMC could 
inhibit the growth and induce the differentiation of the U937 cells. The tumouricidal 
and differentiating effects of the conditioned medium were attributed to the 
stimulation of cytokine production such as IFN-y and TNF-a by PSCS. In the present 
study, K7 antigen was shown to induce the appearance of mature macrophage-like 
cells in JCS cultures in a dose-dependent manner. The monocytic differentiation of 
JCS cells induced by K7 antigen was found to be associated with an increase in the 
expression of macrophage differentiation antigens, induction of non-specific esterase 
activity and stimulation of phagocytosis. Collectively, these findings suggest that 
JCS cells were induced to differentiate into phenotypically macrophage-like cells 
which possess normal functional properties of mature macrophages, such as 
phagocytic activity. Nevertheless, the mechanism(s) whereby K7 antigen can induce 
the differentiation of leukemia JCS cells is unclear and remains to be established. 
Moreover, the relationship between the anti-proliferative activity and 
differentiation-inducing ability of K7 antigen and the possible involvement of 
cytokines in K7 antigen-triggered leukemia cell differentiation are intriguing aspects 
that require further investigation. 
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CHAPTER 7 
CONCLUSIONS 
AND FUTURE PERSPECTIVES 
Bacterial capsular polysaccharides are a diverse range of biologically 
important molecules that may mediate direct interactions between the bacteria and 
their immediate environment and have been implicated as a crucial factor in the 
onset and development of many bacterial infections (Roberts, 1996). It has been 
reported that the polysaccharide capsule of Klebsiella pneumoniae is an important 
virulence factor that confers resistance to phagocytosis. Capsules contain K-specific 
antigens which are commonly used for serotyping purpose and which can also 
trigger the immune system to produce K-specific antibodies. Thus, vaccine 
development for Klebsiella pneumoniae infection was mainly emphasized on capsular 
(K-specific) antigens in the past (Cryz et al" 1984 & Cross et al" 1990). In spite of this, 
the effects of capsular polysaccharide antigens isolated from Klebsiella pneumoniae on 
the immune system are far from being understood. Therefore, the aims of this thesis 
project are to examine the hematopoietic, immunomodulatory and anti-tumour 
activities of a purified capsular antigen isolated from Klebsiella pneumoniae serotype 
7. 
In the past decade, there have been many studies on the effects of bioactive 
polysaccharides isolated from different natural sources in modulating hematopoietic 
proliferation and differentiation in myelosuppressed subjects, especially those that 
have received irradiation for cancer treatment (Patchen et al., 1984; Hofer et al, 1993 
& Egger et al., 1996). These polysaccharides may exhibit protective effects on the 
hematopoietic system by stimulating or enhancing the recovery of hematopoiesis in 
irradiated subjects. In the present study, K7 antigen alone was found to have a 
stimulatory effect on the proliferation of murine bone marrow cells in vitro (Chapter 
4). On the other hand, K7 antigen also exhibited significant inhibitory effect on the 
r m I L - 3 - s t i m u l a t e d proliferation of bone marrow cells in vitro. The precise 
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mechanism(s) by which K7 antigen stimulates the proliferation of bone marrow cells 
and inhibits the proliferation of rmIL-3-stimulated bone marrow cells remains 
obscure. Previous studies had shown that the combination of GM-CSF and LPS or 
IFN-y markedly suppressed the proliferation of murine bone marrow cells, which 
was considered to be mediated by the enhanced production of NO from bone 
marrow cells (Punjabi et al., 1992). On the other hand, using bone marrow-derived 
macrophages, IFN-y, TNF-a and LPS were found to be potent and reversible 
inhibitors of CSF-1, GM-CSF, or IL-3 induced bone marrow cell proliferation (Vairo 
et al., 1991). It has been shown that K7 antigen behaves like LPS in many aspects, 
including (1) mitogenic to B lymphocytes (Chapter 4) and (2) induction of pro-
inflairnnatory cytokines from macrophages (Chapter 5). Thus, it may be possible that 
K7 antigen acts like LPS in suppressing the rmIL-3-induced bone marrow cell 
proliferation by (1) directly enhancing the NO production of IL-3-stimulated bone 
marrow culture or (2) by inducing the production of IFN-y or TNF-a from the bone 
marrow cells which in turn increases the NO production of the IL-3-stimulated bone 
marrow culture. 
K7 antigen not only inhibited the rmIL-3-induced bone marrow cell 
proliferation, but also suppressed the number of colony in rmIL-3-stimulated bone 
marrow cell culture (Chapter 4). However, K7 antigen alone induced the 
differentiation of bone marrow cells to become macrophage-like cells (Chapter 4). 
The mechanism(s) whereby K7 antigen can induce the differentiation of bone 
marrow cells is unclear. Previous work in our laboratory had demonstrated that PH-
I Ba, a carbohydrate-rich fraction isolated from Pseudostellaria heterophylla, could 
induce the differentiation of bone marrow cells (Wong et al, 1994c). The 
d i f f e r e n t i a t i o n - i n d u c i n g capacity of PH-I Ba was found to be resulted from the 
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induction of GM-CSF production from bone marrow cell culture stimulated by PH-I 
Ba (Wong et al., 1994c). Whether the differentiation-inducing activity of K7 antigen is 
mediated through its ability to induce the production of CSFs requires further 
investigation. 
Apart from inducing the differentiation of bone marrow cells, K7 antigen can 
also effectively induce the differentiation of myeloid leukemia WEHI-3B JCS cells in 
vitro (Chapter 6). Since Leung et al. (1994) have shown that IL-4 can synergize with 
TNF-a in the induction of monocytic differentiation of JCS cells, therefore, it would 
be of great interest to examine whether K7 can synergize with other BRMs such as 
cytokines in the induction of JCS cell differentiation. In addition, the ability of K7 
antigen to stimulate the terminal differentiation of other types of tumour cells (e.g. 
erythroleukemia cells, neuroblastoma cells, eosinophilic leukemia cells, etc) has not 
yet been determined and requires further investigation. If the induction for the 
reversal of malignancy to normal and/or mature status is promising, the induction 
of cell differentiation by natural products such as bioactive polysaccharides will 
provide a new strategy in the treatment of certain cancers in the future and it may 
widen the potential therapeutic clinical applications of K7 antigen. 
Bacterial polysaccharides consist of repeating oligosaccharide units and are 
considered to be TI antigens, since T cells are not essential for the induction of 
antibody synthesis (Mond et al, 1995). In Chapter 4, K7 antigen was shown to be a 
potent in vitro mitogen for B murine lymphocytes as it could (1) enhance the DNA 
synthesis of splenocytes that were depleted of T cells and macrophages, and (2) 
increase the B cell population (LR-1
+
 cells) in K7-treated splenocytes. In addition, K7 
was shown to be a potent in vivo mitogen for B murine lymphocytes as injection of 
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K7 into mice could (1) increase the spleen weight and spleen cell number; (2) 
increase the B cell population (LR-1+ cells) in the splenocytes; and (3) augment the 
proliferative response of splenocytes. Although our results demonstrated that K7 
antigen is a TI antigen, it is still not possible to conclude to which type of TI antigen 
(TI-1 or TI-2) should the K7 antigen belong because other non-T cell population(s) 
besides macrophages, such as NK cells, may be essential for the triggering of 
antibody response by K7 antigen (Mond et al” 1995). As shown in Chapter 6, K7 
antigen was found to enhance splenic NK cell cytotoxicity in vivo, but it is not clear 
whether there is any correlation between NK activation and the triggering of 
antibody response induced by K7 antigen. Furthermore, previous findings have 
shown that bacterial polysaccharides, such as Streptococcus mutans polysaccharides 
(Taylor and Bright, 1989), capsular polysaccharides from Neisseria meningitidis 
(Miiller and Apicella, 1988) and Streptococcus pneumoniae (Taylor and Bright, 1989) all 
belong to TI-2 antigens. Therefore, further investigation is required to clarify which 
type of TI antigen that K7 antigen should be and whether NK cells or other accessory 
cells are essential for triggering of antibody response by K7 antigen, as these may 
have significant implications for the development of more effective vaccines against 
Klebsiella in fec t ion . 
As shown in Chapter 5, K7 antigen was found to enhance the functional 
activity of macrophages such as phagocytic activity in vitro as well as stimulating the 
in vivo migration of macrophages. In addition, K7 antigen was demonstrated to 
induce the tumouricidal activities of macrophages by enhancing their production of 
NO and TNF-a. Furthermore, K7 antigen was found to augment the cytostatic 
activity against tumour cells. Using RT-PCR, K7 antigen was also found to enhance 
the expression of certain proinflammatory cytokines, including IL-la, IL-1 (3, TNF-a, 
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TGF-P and IL-6. Collectively, these findings suggested that K7 antigen can activate 
the macrophages, especially the inflammatory macrophages, to acquire tumouricidal 
activities. Although the precise mechanism(s) by which the K7 antigen-activated 
macrophages can exert their anti-tumour activity has not yet been established, it may 
be possible that K7 antigen can stimulate the macrophages to produce NO (Hibbs et 
al., 1988) and TNF-a (Bonta et al., 1993), which are then cytotoxic/cytostatic to the 
tumour cells. Alternatively, since K7 antigen can upregulate the expression of certain 
pro-inflammatory cytokines in macrophages, it is conceivable that TNF-a produced 
can act synergistically with IL-1 and IL-6 in mediating the acute-phase response 
(Ramadori and Buschenfelde, 1990), or that IL-6 can act synergistically with TNF-a 
in promoting an anti-tumour response (Mule et al., 1990). Recently, Ben-Efraim et al. 
(1994) have found that human peritoneal macrophages activated in vitro are effective 
against a human tumour implanted in nude mice. In view of the fact that activated 
macrophages can react indiscriminately against "immunogenic", "weakly 
immunogenic", and "non-immunogenic" tumours (Fidler, 1985), K7 antigen may be 
a potential candidate of BRM in the macrophage-directed immunotherapy of cancer. 
Uronic acids are common components of LPS and extracellular 
polysaccharides from Gram-negative bacteria and are also found in the cell wall (as 
teichuronic acid) and extracellular polysaccharides of Gram-positive bacteria (Kenne 
and Lindberg, 1983). Recently, it has been reported that both uronic acid polymers 
and LPS can stimulate monocytes to produce TNF by binding to membrane CD14 
(Wright et al., 1990 & Espevik et al" 1993). Furthermore, there has been increasing 
evidence showing that CD14 may play a role in the induction of cytokine production 
(TNF, IL-1 and IL-6) from monocytes in response to a variety of different 
compounds, including soluble peptidoglycan fragments and protein-free phenol 
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extracts from Staphylococcus aureus (Weidemann et al., 1994 & Kusunoki et al" 1995), 
rhamnose-glucose polymers from Streptococcus mutans (Soell et al" 1995b), chitosans 
from arthropods (Otterlei et al., 1994), mycobacterial lipoarabinomannan (Pugin et 
al., 1994), and insoluble cell walls from different Gram-positive bacteria (Pugin et al., 
1994). It has been reported that serum factors like soluble CD14 (sCD14), LPS-
binding protein (LPB), and bactericidal/ permeability-increasing factor (BPI) are able 
to interact with LPS, mannuronic acid polymer and rhamnose-glucose polymer, and 
influence their responses, as measured by the production of cytokines from 
monocytes (Haumann et al., 1993; Soell et al； 1995b & Jahr et al., 1997). Since K7 
antigen prepared was found to contain 16% of uronic acid (Chapter 3) and has TNF-
inducing capacity in macrophages (Chapter 5), it is possible that the K7 antigen-
induced TNF production from murine macrophages may be mediated by CD14 or 
other accessory molecules such as sCD14, LBP, and BPI. Whether K7 antigen 
mediates the TNF production by binding directly to the macrophages or with the aid 
of CD14 remains unknown and needs further investigation. 
Biotherapeutic approaches aiming at the modulation of immunological 
functions frequently use biological response modifiers that affect the MHC-
unrestricted cytotoxic activity such as the functions of NK cells and LAK cells 
(Herberman, 1987 & Foon, 1989). As shown in Chapter 6, K7 antigen was found to 
enhance the splenic LAK and NK cell cytotoxicity and exerted its anti-tumour effect 
in vivo rather than in vitro against EAT cells. Taken together, our results suggest that 
K7 antigen may exert its anti-tumour effect by activation of the host's cytotoxic 
effector cells such as NK cells, LAK cells, and macrophages. Preclinical studies in 
murine tumour models have demonstrated that biological response modifiers, used 
in combination with adoptive immunotherapy, can induce significant anti-tumour 
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responses (Yokota et al., 1988 & Yamasaki et al., 1989). Recently, a clinical trial with 
Lycium barbarum polysaccharides (LP) in combination with LAK/IL-2 therapy 
yielded encouraging results in the treatment of advanced cancer patients (Cao et al., 
1994). Since in vivo priming with K7 antigen can enhance LAK cell activity generated 
in vitro with a low dose of rmIL-2 (50 U/ml), whether the K7 antigen-potentiated 
LAK cells would be useful for adoptive immunotherapy of cancer is an intriguing 
aspect that is worthy of future investigation. 
Accumulating evidence has demonstrated that there is an important 
structure-function relationship between the structure of polysaccharides and their 
immunomodulatory activities (Ohno et al" 1988 & Lien and Gao, 1990). From the 
studies of the structure and anti-tumour activity of the (l->6)-branched (1—3)-P>D-
glucans such as lentinan, schizophyllan, and grifolan, it was found that their 
molecular weight (Adachi et al, 1990), ratio of branching (Saito et al., 1992) and 
ultrastructure (Ohno et al" 1995) are important parameters for their anti-tumour 
activities. Furthermore, not only there is a relationship between structure and anti-
tumour activity, but also there exists a relationship between structure and 
differentiation-inducing ability of polysaccharides. Recently, Volpi et al (1994) have 
shown that only the glycosaminoglycans with high charge density and N-sulfate 
groups (heparin and derivatives) can effectively induce the terminal differentiation 
of U937 cells. Interestingly, not all the capsular polysaccharides can induce the 
cytokine production from monocytes/macrophages, e.g. Pasteurella haemolytica Al 
purified capsular polysaccharide does not stimulate bovine monocytes and alveolar 
macrophages to release IL-1 and TNF (Czuprynski et al., 1991), and some even 
downregulate the cytokine production, e.g. purified capsular polysaccharide of 
Cryptococcus neoformans downregulates the TNF-a and IL-1 (3 secretion from 
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monocytes (Vecchiarelli et al., 1995). Thus, further studies on the structure-function 
relationship of K7 antigen is required to increase our understanding of its action 
mechanisms on tumours and hematopoietic cells. 
Most chemotherapeutic drugs (e.g. MTX, 5-FU, CY, etc) act by their direct 
cytotoxic effect on tumour cells, but they also exhibit potent immunosuppressive 
activity at high dosages (Chabner et al., 1995). Recently, the combined treatment of 
tumour-bearing mice with 5-FU and OL-2, a branched fungal (l->3)-P-D-glucan, 
could prolong the survival time of treated mice as compared to the control group 
treated with 5-FU only (Ohno et al., 1992). Since the anti-tumour activity of 
iimnunostimulating polysaccharides from K7 antigen is mainly mediated through 
the enhancement of immune responses, thus, the combination of these two 
modalities, chemoimmunotherapy, will take advantage of their different 
mechanisms of action. Some tumours show a good initial response to chemotherapy, 
reducing the tumour burden, but they often recur in the form of drug-resistant 
variants. Therefore, the application of K7 antigen as BRM may produce an 
additive/ synergistic anti-tumour activity in vivo. Chemotherapy reduces the tumour 
size and allows the activated immune system, mediated by K7 antigen, to destroy 
the residual drug-resistant tumour cells. 
As summarized in Fig. 7.1, the Klebsiella K7 capsular antigen exhibits various 
hematopoietic, immunomodulatory and anti-tumour activities. The anti-tumour 
activities of K7 antigen has been found to be mediated primarily through activation 
of the host immune system such as enhancement of the activity of cytotoxic effector 
cells (e.g. macrophages, NK cells and LAK cells), the induction of tumour cytotoxic 
molecules (e.g. NO and TNF) and the up-regulation of pro-inflammatory cytokine 
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gene expression (e.g. IL-la, IL-ip, TNF-a and IL-6) in activated macrophages. It is 
conceivable that the combined effects of cell-mediated immunity and cytokine-
mediated immunity will result in greatly enhanced anti-tumour activity in vivo. 
Therefore, the application of purified Klebsiella K7 polysaccharide antigen may have 
therapeutic advantages over the conventional methods of cancer treatment. In 
addition, further investigation to clarify the major cell type(s) involved in mediating 
the in vivo anti-tumour activities of K7 antigen may provide a more rational scientific 
basis for the better utilization of K7 antigen in cancer treatment. 
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Figure 7.1: A schematic diagram showing the hypothetical mechanisms of 
immunostimulating and anti-tumour activities of Klebsiella K7 capsular antigen. 
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